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1 INTRODUCTION 
 
 
The concept of health has dynamically been changing by rise of new needs and diversity in 
human preferences. Also by improvement of life expectancy from the beginning of 20th 
century, the concept of health for the person and the society has evolved. Advancements in 
science and technology has made this possible and has changed human needs. For example, 
fear of dying has changed to dedication to survival and living healthier for a longer time. 
Longer life expectancy leads to larger population of elderly people with higher chance of 
chronic health problems. Economic evaluation is vital, to make value for money when 
utilizing resources and achieve higher efficiency and effectiveness in decision-making. In 
order to avoid unfeasible and suboptimal decisions, a careful analysis of all aspects including 
costs and consequences is needed. Decision-making that are based on preferences for health 
states, along with the economic analysis focused on the patient's and societal perspective, can 
improve the distribution of finite resources in the face of a growing and increasingly 
challenging demand. 
New innovative health technologies are developed, often very effective but rather costly. The 
fourth hurdle, i.e., requirement of effectiveness and cost-effectiveness data for drug coverage 
policy decisions, became highly relevant even in economically developed countries. (Gulacsi 
et al., 2004). 
Health technology assessment (HTA) is now an established input to healthcare decision-
making and has been introduced in many countries. HTA involves health economic 
evaluation that requires input data considering local aspects such as characteristics of the 
health care system, clinical practice, patients’ characteristics, individual and societal 
preferences in a given country. 
Transferability of international results is often limited due to differences between countries 
and regions (costs differ, health states might differ, cultural differences might affect people’s 
preferences), therefore economic evaluation conducted in one setting might not be applicable 
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to another and as a consequence, country-specific evaluations are needed that reflect the 
needs of the decision-makers in that country. 
HTA has been introduced in Iran, however country-specific input data both on health-related 
quality of life (HRQOL) and cost data for health economic evaluation are often missing. 
 
The main aims of the studies of this thesis are the following: 
- to explore notions of health among the general public as it may have implications for 
HRQOL assessments and decision making in healthcare, including both medical and resource 
allocation decisions 
- to investigate HRQOL and cost-of-illness in a specific patient population, namely psoriasis 
and analyse the inter-country differences. 
 
In the first part of the thesis followed this introduction (Chapter 1 Introduction), the key terms 
related to the empirical researches are described (Chapter 2 Key terms and definitions of the 
thesis). Afterwards, a description of the Iranian health care system is provided (Chapter 3 
Iranian health system) as well as a policy analysis of the development of the Iranian HTA 
based on extensive literature review (Chapter 4 Health policy and health technology 
assessment in Iran). 
The focus of the empirical research of this thesis is on HRQOL, i.e. how individuals or a 
group perceive physical and mental health and social well-being over time. This subjective 
perception can be influenced by several factors, including their beliefs, subjective 
expectations, previous experiences, cultural and religious attitudes, personality-related 
factors. Moreover, it can vary individually or regionally.  
The first empirical study of this thesis (Chapter 5: An empirical investigation into the concept 
of health) aimed to explore people’s perception on health, which aspects of health are the 
most relevant for the individuals. It can have implications on HRQOL research and 
preference measurement. 
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The second empirical study (Chapter 6: Health-related quality of life and cost-of-illness of 
psoriasis patients in Iran) involved a cross-sectional survey in Iran among patients with a 
chronic dermatological disease, namely psoriasis. This study was part of a psoriasis research 
project leaded by researchers at Corvinus University; most of it was conducted in Hungary. 
Psoriasis is of high interest due to its prevalence, impact on patients’ HRQOL and, from the 
economic point of view, due to the costly biological drugs. Biological drugs have speeded 
up HRQOL and cost-of-illness (COI) research in psoriasis in many countries – measure 
health outcomes considering patients’ preferences (HRQOL measurement), cost-
effectiveness, budget impact issues and affordability. The aims of the study were on the one 
hand, to assess patients HRQOL and to assess the relationship between disease-specific and 
generic HRQOL measures in order to provide local data for health economic analyses, to 
compare the results with other countries and thus provide a basis for transferability analyses. 
On the other hand, and I find it equally important, this experiment can serve also as useful 
test how brief cross-sectional surveys developed in a European country (namely in Hungary) 
can be applied in and adapted to Iran in terms of feasibility and applicability in order to obtain 
comparable data in the context of limited research resources and to strengthen international 
collaboration. 
The results of the thesis clearly show the usefulness and increasing importance of health 
economics in health policy and financial decision making.  
Finally, all the results and policy implications are discussed in the last chapter (Chapter 7 
Summary). 
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2 KEY TERMS AND DEFINITIONS OF THE THESIS 
 
 
In this section, I provide a brief introduction to the main terms used in the thesis. 
 
 Health technology assessment 
Health technology assessment (HTA) has been defined as “a form of policy research that 
systematically examines the short- and long-term consequences, in terms of health and 
resource use, of the application of a health technology, a set of related technologies or a 
technology related issue”. (Henshall et al., 1997) 
The focus of HTA is mostly on the medical, organizational, economic and societal 
consequences of implementing health technologies or interventions within the health system. 
Thus, HTA is a multidisciplinary activity. It systematically evaluates the effects of a 
technology on health. It also evaluates the effects of a technology on the availability and 
distribution of resources and on other aspects of health system performance such as equity 
and responsiveness. (Garrido et al., 2008) Goodman (2004) states that the goal of HTA is to 
notify policymaking for technology in health care, where policymaking is used in the broad 
sense to include decisions made at various levels. For example, , the individual or patient 
level, the level of the health care provider or institution, or the regional, national and 
international are the mentioned levels. (Goodman, 2004) 
 Quality of life 
Quality of Life according to World Health Organization’s (WHO) definition is an 
[“individual’s perception of their position in life in the context of the culture and value 
systems in which they live and in relation to their goals, expectations, standards and 
concerns”] (1995). Different factors can play a role in quality of life according to personal 
preferences. These factors are, for instance, financial security, job satisfaction, family life, 
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health and safety. When quality of life is considered in the context of health and disease, it is 
commonly referred to as health-related quality of life (HRQOL) to differentiate it from other 
aspects of quality of life. (Lipscomb et al., 2004) 
 Health-related quality of life 
Strategies and processes for the effective dissemination and diffusion of research findings on 
health-related quality of life (HRQOL) into practical applications were explored at a 
workshop held in Montreal in April, 1994 by Wilson and Cleary. Wilson and Cleary 
published their seminal conceptual model of HRQOL, which provides a causal pathway 
linking traditional clinical variables to HRQOL. (Till et al., 1994, Shiu et al., 2014, 
Wilson&Cleary, 1995) The Wilson & Cleary model of HRQOL was further revised by 
Ferrans et al. in 2005. (Ferrans et al., 2005) A conceptual model for dissemination and 
diffusion of evidence about HRQOL was used to identify five different target groups: 
HRQOL assessors, policy makers, planners of clinical trials, developers of clinical practice 
guidelines, and those at the level of patient-practitioner clinical decision making. (Till et al., 
1994) HRQOL is a multidimensional construct covering physical, psychological with social 
functioning and well-being that includes both negative and positive aspects. 
HRQOL has a focus on the effects of illness and specifically on the impact; treatment may 
have on Quality of life (QOL). QOL is therefore appears to be a broad and idiosyncratic 
construct affected only moderately by health. (Feldman et al., 2000) 
To select measures for evaluating HRQOL, seven issues can be addressed, as follow: 
2.3.1 Disease-specific versus global assessment 
Measures may concentrate on the symptoms, complaints, disabilities, and distributions in life 
that are specific to the clinical condition under study. The disease-specific approach has been 
recommended in the study of arthritis, heart disease, and the evaluation of chemotherapy. 
Instead, global assessment, evaluate the quality of life resulting from the overall 
consequences of disease and management on the functional capacities and patients’ 
perception of well-being. (Medicine&Technology, 1989) 
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2.3.2 Clinical endpoints versus long-term outcomes 
Clinical endpoints usually used for evaluating prognoses include evidence of improvement 
following intervention, remission of disease, and recurrence. Long-term outcomes can be 
viewed as crucial to patients as they live with their resulting states of health. 
(Medicine&Technology, 1989) 
2.3.3 Patient ratings versus proxy assessments 
Preferably quality of life is reported by the patients themselves. When patients are not able 
to provide information regarding their health status (e.g., children, patients with cognitive 
problems), proxies (which include close family members or health care professionals) can 
provide the needed information on behalf of the patient. (Punjabi, 2008) 
2.3.4 Objective versus subjective measures 
Objective measures include indicators of health and living conditions, socio-demographic 
items and role functioning. (Yamauchi et al., 2008) Objective measures can be observed and 
recorded by various testing procedures and assessors. Whereas, subjective indicators measure 
life satisfaction in general and within different life domains. Subjective measures provide 
opportunities for individuals to express their thoughts, knowledge, attitudes, moods, and 
feelings. (Yamauchi et al., 2008, Medicine&Technology, 1989) 
2.3.5 Cognitive Functioning 
Cognitive functions are detected by studying behavior in defined stimulus–response 
situations. (Daliento et al., 2006) 
 
2.3.6 Ratings and Utilities 
As Schuessler and Fisher (1985) indicate, quality of life measures provide ratings or rankings 
of health and life. Some assessments attempt to move from states of health to judgments of 
 18 
 
the worth or value of life with a given state of health. (Schuessler&Fisher, 1985, 
Medicine&Technology, 1989) 
Analyzers are designing measures of the utilities of health states, with the typical scores 
ranging from 0 to 1 (“Death" to "Normal Health"). By multiplying the utility values by the 
number of years individuals live with a given health state, survival time can be demonstrate 
in Quality-Adjusted Life Years (QALY). Health economists have used this approach to 
compare technologies in terms of costs per QALY gained. Utility measures move the 
measurement of quality of life from rankings to judgments of worth and value. 
(Medicine&Technology, 1989) 
2.3.7 Timing of the Assessments 
Measures like the linear analogue self-assessment scales or the Functional Living Index, are 
designed for repeated use before, during, and immediately after treatment. The purpose of 
the repeated measures is to evaluate patients' short-term responses during the course of 
therapy. (Medicine&Technology, 1989) 
 Quality-adjusted life year 
Three different approaches to measuring quality of life are global scales, multi-attribute 
utility scales and multidimensional scales. Each of these approaches provides different kinds 
of information about quality of life and each can be used to provide information to healthcare 
purchasers concerning the relative value-for-money of health interventions. The value-for-
money of health interventions, in terms of quality of life, can be demonstrated in 2 ways: a 
formula-driven approach based on cost-utility analysis, which uses scales generating the unit 
of a quality-adjusted life year (QALY); and a non-formula-driven approach, which uses 
scales generating multidimensional profiles of quality of life. (Hyland, 1997) 
The QALY is a widely used measure, which incorporates both quality and quantity of life. It 
is applicable to all individuals and diseases. (Whitehead&Shehzad, 2010) QALYs are 
designed to aggregate in a single summary measure the total health improvement for a group 
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of individuals, capturing improvements from impacts on both quantity of life and quality of 
life – with quality of life broadly defined. (Torrance&Feeny, 1989) 
QALYs are calculated by estimating the years of life remaining for a patient following a 
particular treatment or intervention and weighting each year with a quality of life score (on 
a 0 to 1 scale) that reflect the preference for the given health state, the so called utility. (Figure 
1) 
Figure 1 Quality adjusted life year 
 
 
Source: (Arnesen&Norheim, 2003) 
 
Utilities are measured on a cardinal scale of 0–1, where 0 indicates death and 1 indicates full 
health. Using the ‘anchors’ of 0 and 1, utility measurement is on an interval scale, where the 
same change means the same irrespective of the part of the scale being considered (e.g. a 
change in health from 0.2 to 0.3 is equivalent to a change from 0.8 to 0.9). States worse than 
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death can also be accounted for, with such states taking a negative value. 
(Whitehead&Shehzad, 2010) 
One form of cost-effectiveness analysis, cost-utility analysis, allows the comparison of 
different health outcomes (such as prolongation of life, prevention of blindness or relief of 
suffering) by measuring them all in terms of a single unit — the QALY. (Mcgregor, 2003) 
 Mapping from disease-specific measures to utilities 
The main purpose of mapping is to derive utility scores for non-preference-based measures 
to be used in economic evaluation. Therefore, to perform a mapping two data sets are 
necessary: first an estimation data set and second a study data set. The estimation data set 
includes information about both the target (preference-based) measure and the base (non-
preference-based) measure from the same population. In contrast, the study data set includes 
only the base measure. (Chuang&Whitehead, 2012) 
Mapping or cross-walking is a methodology used to estimate the relationship between a non-
preference-based measure and a generic preference-based measure (Brazier et al., 2010). In 
randomized controlled trials (RCTs), data on clinical effectiveness are typically collected on 
disease-specific measures, as these are more sensitive to changes in outcomes as a results of 
treatments. (Wiebe et al., 2003) Meanwhile, preference-based methods are rarely applied in 
RCTs; therefore, utilities for cost-effectiveness analyses are lacking. Mapping provides an 
alternative to translate scores of disease-specific measures into utility values. (Brazier et al., 
2010, Lu et al., 2013) 
Mapping process involves the following steps: 
1. Regression methods should be use to get a statistical relationship between two 
measures that we have gathered. Therefore, through regression method we get a 
formula or algorithm.  
2. The algorithm that we got from the regression result, then applied to the base measure 
in the study data set to obtain the predicted score of the target measure. 
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3. Then finally, the predicted utility values are now ready for the study data set to 
conduct the required cost–utility analysis. (Chuang&Whitehead, 2012) 
 Cost-of-illness 
Cost-of-illness (COI), also known as burden of disease (BOD), is a definition that 
encompasses various aspects of the disease impact on the health outcomes in a country, 
specific regions, communities, and even individuals. (Jo, 2014) The aim of a cost-of-illness 
study is to identify, and measure all the costs of a particular disease, including the direct, 
indirect, and intangible dimensions. The output, expressed in monetary terms, is an estimate 
of the total burden of a particular disease to society. (Byford et al., 2000, Rice, 1994) 
The quantifiable costs associated with human disease and illness are usually categorized into 
two unique components, including direct (medical and non-medical) and indirect costs. 
(Boccuzzi, 2003) 
2.6.1 Direct cost 
Direct costs consist of healthcare costs and non-healthcare costs (also called direct medical 
and non-medical costs). Direct health care costs refer to the healthcare expenditures for 
diagnosis, treatment, and rehabilitation, etc., while direct non-healthcare costs refer to the 
costs like transportation, household expenditures, relocating, property losses and informal 
costs of any kinds (Jo, 2014). 
2.6.2 Indirect cost 
Indirect cost in cost-of-illness studies refers to productivity losses due to morbidity and 
mortality, borne by the individual, family, society, or the employer. (Sherman et al., 2001, 
Jo, 2014). (Table 1) Indirect costs cannot be traced to a given cost object without resorting 
to some arbitrary method of assignment. (Cleverley&Cameron, 2007) 
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Table 1 Direct and indirect costs of chronic conditions – some examples 
 
Direct costs Indirect costs 
Direct healthcare costs Direct non-healthcare 
costs 
Doctor’s office visits Care provided by nonpaid 
caregivers 
Absenteeism of 
employees who care 
for family members 
Diagnostic testing Consumer health 
education 
Loss of productivity at 
work 
Durable and nondurable 
medical products 
Financial assistance to 
persons with chronic 
disease 
Cessation of work 
Hospital, nursing home and 
home care services 
Housekeeping assistance 
needed because of disease 
Restricted work 
activity days 
Medications, immunizations Research and 
construction of healthcare 
facilities 
 
Physicians and other 
professionals 
Transportation to and 
from healthcare visits 
 
Treatment of general medical 
conditions attributed to 
condition 
  
Source: (Cleverley&Cameron, 2007) 
 
2.6.3 Intangible cost 
Intangible costs are usually the costs of pain, grief and suffering and loss of quality of life 
and these kind of costs cannot be quantified directly in monetary terms. (Jefferson et al., 
2000) Intangible costs are often omitted because of the difficulty in accurately quantifying it 
in monetary terms. In such a case, the study should note that intangible costs have been 
omitted. (Joel E, 2006, Hodgson&Meiners, 1982, Cooper&Rice, 1976) 
2.6.4 Cost-of-illness studies and their use in decision making 
Health economic analyses are becoming increasingly important in healthcare systems due to 
the scarcity of resources in healthcare systems. Disease burden or cost-of-illness (COI) 
analysis was the first economic evaluation technique used in the field of health economics. 
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The COI study is considered to be an essential evaluation technique in health care. By 
measuring and comparing the economic burdens of diseases to society, such studies can help 
health-care decision-makers to set up and prioritize health-care policies and interventions. 
(Jo, 2014) 
COI studies serve a different purpose compared to other economic evaluations such as cost-
effectiveness analysis (CEA), and cost-benefit analysis (CBA) that mainly compare the costs 
and outcomes of an intervention. COI always presumes the hypothesis that the emerging cost 
is the expenditure that return as profit in case of a positive result, so it estimates the amount 
that could be saved if a disease were to be abolished. Additionally, COI findings offer a good 
basis for further CEA and CBA studies.  
The usefulness of cost-of-illness as a decision-making tool has however been questioned 
since its inception. The main criticism came from welfare economists who rejected COIs 
because they were not grounded in welfare economics theory. (Tarricone, 2006) Other 
attacks related to the use of the human capital approach (HCA) to evaluate morbidity and 
mortality costs since it was said that the HCA had nothing to do with the value people attach 
to their lives. Finally, objections were made that COI could not be of any help to decision 
makers and that other forms of economic evaluation (e.g. cost-effectiveness, cost-benefit 
analysis) would be much more useful to those taking decisions and ranking priorities. 
Conversely, it is here suggested that COI can be a good economic tool to inform decision 
makers if it is considered from another perspective. COI is a descriptive study that can 
provide information to support the political process as well as the management functions at 
different levels of the healthcare organizations. (Tarricone, 2006) To do that, the design of 
the study must be innovative, capable of measuring the true cost to society; to estimate the 
main cost components and their incidence over total costs; to envisage the different subjects 
who bear the costs; to identify the actual clinical management of illness; and to explain cost 
variability. In order to reach these goals, COI need to be designed as observational bottom-
up studies. (Tarricone, 2006) 
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Cost-of-illness studies may be conducted from different perspectives, which determine the 
types of cost included in the analysis. These perspectives may measure costs to society, the 
health care systems, participants and their families, and third party payers. (Table 2) 
Table 2 Costs included in cost-of-illness (COI) studies using different perspectives 
 
Perspective Medical cost Productivity 
(due to 
morbidity 
and 
mortality) 
Non-medical 
cost (time cost, 
informal care, 
transportation) 
Transfer 
payment 
Societal All All All Administration 
cost and 
excess burden 
of taxes 
Health care 
system 
All - - - 
Participants 
and their 
families 
Out of pocket costs Lost wages or 
household 
production 
Out of pocket 
costs amount 
received 
Amount 
received  
Third party 
payer 
Covered cost Covered cost - Amount paid 
by others + 
administration 
cost 
Source: (Weinstein et al., 1996, Joel E, 2006, Saha&Gerdtham, 2013) 
 
2.6.5 Costing approach 
Cost-of-illness studies can be based on three different combinations of costing approaches: 
incidence or prevalence-based approaches, top-down or bottom-up approaches and 
prospective or retrospective approaches. (Tarricone, 2006) 
2.6.5.1 Incidence or prevalence-based approaches 
Prevalence-based COI analysis includes the total costs of prevalent cases of an illness or 
disease within a specified time period, in most cases one year, no matter when the disease 
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first occurred. In other words, prevalence-based estimates are a cross-sectional view of costs 
associated with the illness. Prevalence-based estimates do not tell us how much can be saved 
by prevention. They only look at the annual costs of a disease, rather than costs of a disease 
over the course of a life. 
Incidence studies refer to the new number of cases arising in a predefined period of time. 
(Tarricone, 2006) Unlike prevalence-based COI analysis, incidence-based COI analysis 
calculates the value of lifetime costs for new cases of the disease or illness. Incidence-based 
analyses are essential for calculating the value of prevention. 
2.6.5.2 Top-down versus bottom-up approaches 
Two approaches that are commonly used for quantifying the resources are the top-down 
(population-based) and the bottom-up (person-based) approach.  
The top-down approach estimates economic costs by using aggregate data on mortality, 
morbidity, hospital admissions, general practice consultations, disease-related costs, and 
other health-related indicators. Various sources and types of data are used to calculate the 
fractions of resources used that can be attributed to each disease. Generally, this information 
is collected from national health care statistics, patient registers, insurance databases, etc. 
The bottom-up approach calculates the resources used and productivity loss in individuals 
with the health problem in question. The mean per-person costs are then extrapolated to the 
whole population with relevant epidemiological data. In this case, the patient sample size 
needs to be unbiased and representative of the national population. The bottom-up approach 
is more comprehensive and enables detection of the variability related to differences in 
important demographic characteristics between patients. (Tarricone, 2006, Larg&Moss, 
2011, Segel, 2006, Akobundu et al., 2006) 
Incidence approach requires that the analysis be performed “from the bottom-up”, totaling 
the lifetime costs of an illness. This, in turn, requires that input data be gathered at a level of 
detail much greater than that employed in the prevalence approach where, in general, the 
analysis is performed “from the top-down”, allocating portions of a known total expenditure 
to each of several broad disease category. 
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2.6.5.3 Prospective versus retrospective COI studies 
In a retrospective approach, all the relevant events have already happened when the study 
starts, in which we just collect the data that are previously recorded. Conversely, in a 
prospective approach the relevant events have not already occurred at the beginning of the 
study, which means that the data collection needs to be done by following-up the patients 
over time. The prevalence- and incidence-based COI studies can be both performed either in 
prospective or retrospective way. (Jo, 2014, Tarricone, 2006) 
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3 IRANIAN HEALTH SYSTEM 
 
 
 Demography and health status of the population in Iran 
 
In this chapter basic characteristics of the population of Iran are presented, with special focus 
on main health indicators and health status. Some comparisons with Hungary are made in 
order to offer a background for the empirical research in psoriasis (see Chapter 6) which was 
conducted in these two countries and involved inter-country comparisons. 
3.1.1 Demography 
The total population of the Islamic Republic of Iran is dynamically growing, as it increased 
by 10 million between 2000 and 2011 (2017i) and was 79,109,000 in 2015 (WHO, 2017a). 
Regarding the age-structure of the population, a dominance of age-group 25-54 years can be 
observed (0-14 years: 23.65%; 15-24 years: 16.57%; 25-54 years: 47.59%; 55-64 years: 
6.79%; 65 years and over: 5.4%). (Indexmundi, 2017a) The rate of inhabitants aged less than 
15 is about 4-5 times higher than the inhabitants aged 65 and older, indicating a typically 
young population.  
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Figure 2 Population of Iran, 2000-2011   
 
 
Source: Statistical Center for Iran (2017i)  
 
Figure 3 Population of Iran aged less than 15 and 65 and over, 2006-2011 
 
 
Source: Statistical Center for Iran (2017i)  
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However, the population is ageing the projected age tree can be seen in Figure 4. 
 Figure 4 Population of Iran: demographic trees 1950-2050  
 
 
 
 
Source: United Nations population prospects data, (Basakha et al., 2014) 
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Life expectancy at birth is increasing in Iran (GBD, 2016) and it was 72.1 years for males 
and 74.6 years for females in 2011. (2017i) The probability of dying between 15 and 60 years 
per 1000 population is 102 for males and 63 for females; the probability of dying under five 
per 1000 live birth is 17.53%. Infant mortality rate per 1000 live birth is 13 (year 2015) 
(Figure 2 and Figure 3). For comparison, the population of Hungary is about eight times 
smaller than of Iran (9 830 485, year 2016) and it is decreasing. It represents a different age 
pattern characterized by the dominance of two age-groups (35-40 and 60-65) (Figure 5 and 
Figure 6). 
 Life-expectancy at birth in Hungary is rather similar compared to Iran (72.1 and 78.6 years 
for males and females, respectively) but the infant mortality rate per 1000 live birth is much 
lower (Hungary: 5, year 2015). (The WorldBank, 2017) 
Figure 5 Male population age structure in Iran and Hungary, 2016 
 
 
Source: PopulationPyramid.net (2016b, 2016a)  
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Figure 6 Female population age structure in Iran and Hungary, 2016 
 
 
Source: PopulationPyramid.net (2016b, 2016a)  
 
3.1.2 Causes of death and disability 
The Institute of Health Metric and Evaluation (IHME) provides country reports on disease 
burden data based on over 80,000 different data sources . 
The leading causes of death are non-communicable diseases in Iran, namely ischaemic heart 
disease and cerebrovascular diseases, the same as in Hungary. (Table 3) However, in Iran 
road injuries continue to play significant role in deaths in 2015, whilst in Hungary lung and 
colorectal cancer are in 3rd and 4th place among the causes. Neonatal preterm birth and 
congenital defects were among the 10 leading causes of death in Iran, however these were 
ranked lower in 2015, whilst diabetes and stomach cancer came into front. 
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Table 3 Leading causes of death in Iran and Hungary, 2005 
 
IRAN HUNGARY 
Ischaemic heart disease Ischaemic heart disease 
Cerebrovascular disease Cerebrovascular disease 
Road injuries Lung cancer 
Hypertensive heart disease Colorectal cancer 
Alzheimer disease COPD 
Other cardiovascular Alzheimer disease 
Neonatal preterm birth Hypertensive heart disease 
Congenital defects Self-harm 
Lower respiratory infection Breast cancer 
COPD Diabetes 
Source: Institute for Health Metrics and Evaluation (2017e, 2017d)  
 
Table 4 Leading causes of death in Iran and Hungary, 2015 
 
IRAN HUNGARY 
Ischaemic heart disease Ischaemic heart disease 
Cerebrovascular disease Cerebrovascular disease 
Road injuries Lung cancer 
Hypertensive heart disease Colorectal cancer 
Alzheimer disease COPD 
Other cardiovascular Alzheimer disease 
COPD Hypertensive heart disease 
Diabetes Breast cancer 
Lower respiratory infection Self-harm 
Stomach cancer Diabetes 
Source: Institute for Health Metrics and Evaluation (2017e, 2017d) 
 
The most frequent health problems causing disability are very similar in both countries. In 
2015, the first four are: low back and neck pain, depressive disorders, sense organ diseases, 
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diabetes. Of note, anxiety disorders are in 8th place in both countries and their rate is stable 
between 2005 and 2015. (Table 4, Table 6) 
I find important to note, that skin disorders have similar importance in the ranking (5th and 
6th cause in Hungary and Iran, respectively). (Table 5) 
 According to a study in 2010 which involved all new cases of skin diseases referred to one 
hospital in Southern Iran over a 3-year period, infectious and parasitic diseases (including 
infections of the skin and subcutaneous tissues) were found to be the most common skin 
diseases (32.1%), followed by dermatitis and eczema (24.5%). (Baghestani et al., 2005) 
 Table 5 Leading causes of disability in Iran and in Hungary, 2005 
 
IRAN HUNGARY 
Low back & neck pain Low back & neck pain 
Depressive disorders Sense organ diseases 
Sense organ diseases Depressive disorders 
Skin diseases Diabetes 
Migraine Skin diseases 
Diabetes Migraine 
Other musculoskeletal diseases Oral disorders 
Anxiety disorders Anxiety 
Drug use disorders Osteoarthritis 
Other cardiovascular disorders Iron-deficiency anemia 
Source: Institute for Health Metrics and Evaluation (2017e, 2017d)  
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Table 6 Leading causes of disability in Iran and in Hungary, 2015 
 
IRAN HUNGARY 
Low back & neck pain Low back & neck pain 
Depressive disorders Sense organ diseases 
Sense organ diseases Depressive disorders 
Diabetes Diabetes 
Migraine Skin diseases 
Skin diseases Migraine 
Other musculoskeletal diseases Oral disorders 
Anxiety disorders Anxiety 
Drug use disorders Osteoarthritis 
Other cardiovascular disorders Iron-deficiency anemia 
Source: Institute for Health Metrics and Evaluation (2017e, 2017d)  
 
While the major burden of disease is non communicable diseases (NCDs) including 
cardiovascular disease (CVD), cancer and injuries, the country is still faced with the problem 
of infectious diseases, for instance Cholera epidemic in 2005 and 2007. (Lankarani et al., 
2013) 
3.1.3 Health status of the population 
Health status data of the general population (also called as health status population norm) is 
available with the Short-Form-36 (SF-36) questionnaire in Iran. This questionnaire has been 
applied also in Hungary hence it allows inter-country comparisons. (Montazeri et al., 2005) 
The SF-36 is a generic health status measure which consist of 36 questions and assesses the 
health status of the respondent in eight dimensions of health, namely Physical functioning, 
Role physical, Bodily pain, General health, Vitality, Social functioning, Role emotional, 
Mental health. A score between 0 and 100 is calculated based on the 36 questions for each 
dimension, the lower the score the more disability .  
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Results of the Iranian population survey confirm that, similarly to other countries, health 
status of the population worsens with age in Iran. Among the eight health dimensions of the 
SF-36 survey, Vitality is the most affected in general, but in age-group 65 and over, the 
highest disability is observed in Role physical dimension. 
Direct comparison with the Hungarian data is not feasible as results are available by different 
age-groups. In general, similar trends and scores can be observed with slightly better scores 
in the Role emotional dimension in Hungary than in Iran. (Figure 7 and Figure 8) 
 
Figure 7 Health status of the general population by age-groups in Iran 
 
 
Source: (Montazeri et al., 2005) 
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Figure 8 Health status of the general population by age-groups in Hungary 
 
 
Source: (Czimbalmos et al., 1999) 
 
3.1.4 Comparison with countries of the region 
The Global Burden of Diseases and Injuries, and Risk Factors Study (GBD) study allows 
some comparisons between Iran and other countries from the region. (Shahraz et al., 2014) 
Considering 20 countries (bordering Iran and others: namely Afghanistan, Armenia, 
Azerbaijan, Bahrain, Egypt, Iran, Iraq, Jordan, Kuwait, Lebanon, Libya, Oman, Pakistan, 
Qatar, Saudi Arabia, Syria, Tunisia, Turkey, Turkmenistan, United Arab Emirates), with a 
life-expectancy of 74.4 years (95% CI: 73.3 – 76), Iran ranked 14th among the 20 countries 
in 2010, and 12th by the age-standardized death rates. (Figure 9)  
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Figure 9 Health-adjusted life-expectancy in 20 countries of the region, 2010 
 
Source: (Shahraz et al., 2014) 
 
 History of medicine in Iran 
The history of medicine in Iran is as old as and as rich as its civilization. In the pre-Islamic 
Iran, the history of medicine dates back to four centuries before Christ and the primary 
principles of Iranian medicine were mentioned in Avesta (the holy Book of Merian – ancient 
Iranian religion). (Velayati, 1988) 
A great center of learning medicine was founded at Jundishapur (Gundeshapur) University 
in the 4th century AD, which had a large hospital and an academy, and the first international 
medical congress was held there. (Nikbakht&Kafi, 2008) 
Jundishapur University was a breeding ground for the union among great scientists from 
different civilizations. These centers successfully followed their predecessors' theories and 
greatly extended their scientific research through history. (Pourahmad, 2008) Some experts 
go so far as to claim that: "to a very large extent, the credit for the whole hospital system 
must be given to Persia". (Pandit, 2009) 
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The excellent clinical observations and physical examinations and writings of Iranian 
scientists such as Rhazes (Al-Razi, 865-925 AD), Haly Abbas (Ali ibn-al Abbas-al Majusi, 
died 994 AD), Avicenna (Abou Ali Sina, 980-1037) and Jurjan (Osmail ibn al-Husayn al-
Jurjani, 110 AD) influenced all fields of medicine. 
The new era of medicine in Iran begins with establishment of Dar-ul-funoon in 1851, which 
was the only center for modern medical education before the establishment of Tehran 
University. Following the establishment of the Tehran university school of medicine in 1934 
and the return of Iranian graduates from the medical schools in Europe, much progress was 
made in the development and availability of trained manpower and specialized faculties in 
medicine. (Pourahmad, 2008) 
 Health System in Iran 
Iran as a developing country is an upper middle-income country located in the southwest of 
Asia – the Middle East. Based on the latest reports of the World Bank, its population is 79.1 
million people (2015), its GDP (current US$) is 393.7 billion (2015), its Health expenditure, 
public (percent of total health expenditure) is 41.2 (2014) and its total expenditure on health 
is 6.9 percent of GDP (2014) (The WorldBank, 2015). Article 29 of the Constitution of the 
Islamic Republic of Iran emphasizes that every Iranian has the right to enjoy the highest 
attainable level of health. The Ministry of Health and Medical Education is mandated to 
fulfill this goal through designing and implementing a national-level health policy (1979). 
According to the law, government has the responsibility to provide services and financial 
protection for every individual citizen of the country therefore today the largest health care 
delivery network is owned and run by the Government through Ministry of Health and 
Medical Education (MoHME). (The WorldBank, 2008) 
Although the Iran health system consists of both public and private sectors, currently all 
Iranians have access to a government-supported health insurance system. However, due to 
the lack of sufficient resources in public health sectors and national health insurance schemes, 
in the past years and up to 2012, out of pocket payments of patients have substantially 
increased, it was 55% in 2008 - although the Iranian Development Plan set the goal for out-
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of-pocket payment to as low as 30% in 2008 - and has topped to over 81.3% of the costs of 
medical services. (Davari et al., 2012, Merhdad, 2009) 
Health care system in Iran vas compared to a group of high-income countries focusing on the 
service provider and payment method. In this comparison nine countries including Norway, 
Australia, United States of America, Germany, Italy, Canada, England, Denmark and Japan 
were selected. (Khangah et al., 2017) Primary care and hospital care were compared. The 
author concluded that “the implementation of the process of decentralization of the 
government in some sections and different levels of health care is the best option for the 
health care system of Iran”. 
 Iranian Health Financing System  
There are several ways of financing healthcare in Iran and the most important types include 
general revenue financing, social health care insurance, household out-of-pocket payments 
and also private actuarial health care insurance. 
Private actuarial health care insurance mostly gives secondary coverage to the people who 
have already social insurance. Private insurance market is small in Iran. 
Government pay for general revenue financing health care. General revenue financing of 
health care mostly gives primary health care (PHC) to the people and focus on several 
secondary care services such as expensive-to-manage diseases. In addition to that, public 
hospitals’ infrastructure mostly paid out of government general revenue. Medicine 
production benefits from significant government subsidies.  
Social health care insurance covers around 90% of the population and it focused on non-PHC 
'treatment' services, which includes most ambulatory, diagnostic and hospital services. The 
number of services that they provide varies depending on the service and setting, and to some 
extent on who is the insurer. However, an important share of health care bill is paid by people 
as out-of-pocket payments at the time of service utilization. 
Total health expenditure has increased very rapidly in the past decade. The per capita health 
expenditure has increased from $68 in 1995 to $229 in 2000 to $351 in 2014 (Table 7) (The 
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WorldBank, 2015). World Bank estimated the public health expenditure (% of government 
expenditure) 12.7 in 2010 and out-of-pocket expenditure is 81.3% in 2014.  
The Iranian health care financing system organized through a number of public and non-
public insurance schemes. Access to services and choice of provider is determined largely 
by the type of insurance coverage. 
Table 7 Expenditure on healthcare in Iran 
 
 GDP per 
capita 
(current 
US$) 
Total health 
expenditure 
per capita 
(current 
US$) 
Total health 
expenditure 
(% of GDP) 
Public health 
expenditure 
(% of GDP) 
Private 
health 
expenditure 
(% of GDP) 
Iran  
(1995) 
(2000) 
(2014) 
 
1,664.3  
1,598.5 
5,442.9 
 
68  
229  
351 
 
3.7  
4.5  
6.9  
 
1.7  
1.9  
2.8  
 
2.1  
2.7  
4.1  
Source: The World Bank DataBank (2015)  
 
The Gross Domestic Product per capita in Iran was last recorded at 5757.80 US dollars in 
2015. The GDP per Capita in Iran is equivalent to 46 percent of the world's average. 
(Tradingeconomics, 2017) Gross domestic product based on purchasing-power-parity (PPP) 
per capita GDP was US$ 16591.39 in 2013 and 17113.56 US dollars in Iran in 2014. 
(Indexmundi, 2017b) This figure is similar to the GDP/capita in of the lower income Central 
and Eastern European countries such as Bulgaria 17709.08 US dollars (2016), and Croatia 
21408.55 US dollars (2016). And comparable to other CEE countries for instance Hungary 
25381.29 US dollars in 2016 (PPP) and Czech Republic 31071 US dollars. The GDP/capita 
PPP is comparable to the GDP/capita of the lower income Western European countries such 
as Portugal 27006 US dollars, Greece 24263.88 US dollars. 
 
These figures show that Iran has a similar health care financing capacity as a group of EU 
countries and according to our assumption Iran is facing very similar resource allocation 
decision situation and dilemmas than the group of EU countries with similar or at least 
comparable GDP/capita.  
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Total health expenditure in Islamic Republic of Iran has increased rapidly in the past decade. 
The per capita health expenditure increased from US$ 65 in 2000 to US$ 259 in 2007. In the 
same period per capita government expenditure increased from US$ 24 to US$ 121. 
However, the share of out-of-pocket expenditure is still over 50%. (WHO, 2017b) 
 Health Insurance system 
The Iranian health system is primarily an insurance based system which represents an 
important influence on the Iranian healthcare system (Davari et al., 2012). There are two 
kinds of health packages, which are funded by the health systems and insurance 
organizations: basic and supplementary packages. First package is basic health services that 
governments finance the most part of the costs of this package. The second package includes 
medical services that are funded by insurance organizations. (Barati Marnani et al., 2012) 
There are several insurers each with different benefits package co-payments and referral-and 
counter-referral systems and 90% of the population are under the coverage of at least one 
kind of health insurance market. Different insurance systems provide different levels of 
service coverage, so enrollment in different plans makes it easier to shop for services at a 
lower cost. (Mehrdad, 2009)  
The main public health insurers are: 
1. The Social Security Insurance Organization covers more than 27 million people (36% 
of the Iranian population) across the country. (Davari et al., 2012) Almost all of its 
customers are workers and employees in the private sector where coverage is 
compulsory by law. (Mehrdad, 2009) The Social Security Insurance Organization 
owns and runs many out-patient and in-patient settings, mainly in urban areas. 
Medical services in these out-patient clinics and hospitals are offered either free of 
charge or at very low payments for the insured individuals. 
2. Imdad Imdad (Relief) Committee Health Insurance is a charity-based health 
insurance for the uninsured poor and destitute. About 20% of its revenue comes from 
charitable donations and the government provides the rest. It covers about 4.5 million 
disadvantage people. (Davari et al., 2012) 
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3. The Medical Services Insurance Organization (MSIO) covers governmental 
employees and all individuals of the community with various socioeconomic levels 
that were not eligible to be covered by other health insurance organizations. (Davari 
et al., 2012) The majority of the health care providers accept patients holding this 
insurance. (Mehrdad, 2009) Patients are paying co-payment at the point of the 
utilization of the service. 
4. The Armed Forces Medical Services Insurance Organization (AFMSIO) covers 
around 4.5 million people in the armed forces and their families. (Davari et al., 2012) 
 
Health policy, with regard to health insurance is developed by the Higher Insurance Council 
(HIC) and communicated to all health insurance organizations to implement. The council 
was established in 1994 to undertake policy planning, coordinating and conducting, 
monitoring and evaluating the quality and quantity of health insurance services. (Davari et 
al., 2012) 
Each health insurance companies have their own regulation for those who are covering. For 
example, the regulation provides for those who are covered by Iranian Social Security Law, 
medical aids shall be rendered by the Social Security Organization or its affiliated physicians, 
except in the following cases: 
1. The Social Security Organization’s physician considers that the patient’s referral to 
outside physicians or his treatment outside is mandatory, 
2. The patient has had no access to the Social Security Organization’s medical services, 
and 
3. If the patient notifies the Social Security Organization within 48 hours of his first 
referral to an outside physicians or hospitalization. 
In 2012, 8.04% of the Iranian population benefited from supplementary medical insurance. 
Demand for supplementary insurance is growing and peaks in middle-age when savings and 
income are highest.  
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To avoid catastrophic health expenditure1 insurance companies should adjust their insurance 
policy according to clients' needs, household characteristics, and their incomes. (Nouraei 
Motlagh et al., 2015) Determinants of the health care utilization is an important policy and 
financing issue. The most important factors affected on utilization were age, income level 
and deciles, job status, household dimension and insurance coverage. There was a negative 
relationship between health care utilization and education but it had a positive relationship 
with private health care utilization. Suffering from chronic disease was the most important 
variable in health care utilization- (Nouraei Motlagh et al., 2015) 
According to the empirical data asymmetric information and moral hazard is an important 
policy issue in the Iranian insurance market. The presence of such problems can lead to less 
coverage of health insurance provided by insurers, loss of contracts with health care 
institutions and service providers, and lower quality of health services. (Lotfi et al., 2015) 
 Health Reform in Iran  
Iran's health system has undergone several reforms in the past three decades with many 
challenges and successes. The most important reform was the establishment of the National 
Health Network in 1983, which aimed to reduce inequities and expand coverage and access 
to health care in deprived areas. (Nasseri et al., 1991) The 11th government, elected in June 
2013, launched series of reforms in May 2014 to respond to some of the known issues in the 
performance of health system. The changes, so-called Health Sector Evolution Plan (HSEP) 
or Health Transformation Plan, were designed by the Ministry of Health and Medical 
Education (MoHME) based on the fifth 5-year health development national strategies (2011-
2016) and the new President’s manifest in order to achieve the universal and comprehensive 
                                                 
1 Catastrophic health care expenditure is one of the approaches to assess the financial burden 
provoked by health expenditure. It refers to cases when out-of-pocket payments exceed a 
certain threshold share of either total or non-food expenditure of households 
(Wagstaff&Eozenou, 2016) 
The choice of threshold is somewhat arbitrary, but commonly used thresholds are 10-25% of 
total 
consumption expenditure or 25-40% of non-food expenditure (Smith&Nguyen, 2013) 
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health services coverage. (Moradi-Lakeh&Vosoogh-Moghaddam, 2015) The reforms are 
driven by concerns about increases in the overall costs of healthcare, the extent of 
government expenditure on healthcare, decreases in access to healthcare, and the lack of cost 
effective services. (Bahadori et al., 2015) Rapid population ageing is an important policy 
issue in Iran, health care reform tries to control the increasing health expenditure. (Basakha 
et al., 2014) 
Equity and sustainability are major concerns during the health care reform. (Moradi-
Lakeh&Vosoogh-Moghaddam, 2015) In 2013, the MoHME has developed the Health Equity 
Monitoring System to help formulate evidence based actions and plans to improve equity. 
(Beheshtian et al., 2015) 
As part of the health care reform in Iran the pay for performance (P4P) mechanisms is 
becoming increasingly popular in the health care sector as a tool for encouraging quality 
improvement. (Aryankhesal et al., 2013) P4P is a management tool to increase the hospital 
performance to the national quality standards. The autonomy and financing of the hospitals 
and other health care institutions including family medicine is an important policy issue 
nowadays. (Doshmangir et al., 2015, Esmaeili et al., 2014) 
 Health Sector Evolution Plan 
HSEP is a national plan, with two main phases: the first phase relating to improving fair 
access to healthcare and quality of inpatient and outpatient care in hospitals and the second 
to the public health care. (Moradi-Lakeh&Vosoogh-Moghaddam, 2015, Najafi et al., 2016) 
The reforms resulted in extensive social reaction and different professional feedback. The 
official monitoring program shows general public satisfaction. However, there are some 
concerns for sustainability of the programs and equity of financing. (Moradi-
Lakeh&Vosoogh-Moghaddam, 2015) 
One of the important policy issue is the percentage of people with catastrophic health 
expenditures has been increased from 2.3% to above 3.1% between 2003-2010. This 
tendency clearly shows that the fairness of financial contribution index is decreasing. Cost 
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control and fair distribution of the state financed reimbursement is an important public health 
issue in Iran today. (Fazaeli et al., 2014) 
Out-of-pocket expenditures in hospital care with increasing length of stay, lower household 
wealth index, and admission to a private hospital are major factors contributing to the 
increase in the probability of catastrophic expenditure. (Hajizadeh&Nghiem, 2011) Out-of-
pocket health expenditure can be an economic shock for household in Shiraz and through 
spending on health a household may fall into poverty. (Khammarnia et al., 2014) Health 
inequalities are increasing and reducing inequalities is an important health policy plan. (Zare 
et al., 2014) 
It seems necessary to apply new policies regarding the structure and management of financial 
resources in order to decrease paying directly from pockets. (Keshavarzian&Mofidian, 2014) 
Another health policy issue recently the increasing drug costs in Iran which accounts for 
about 30% of the total health care expenditure. The diffusion of the high-cost drugs has been 
rapidly increasing to the Iranian market, the share of the drug cost within the health care 
budget is increasing. (Yusefzadeh et al., 2015) 
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4 HEALTH POLICY AND HEATH TECHNOLOGY ASSESSMENT IN IRAN 
 
 
  Health technology assessment in Iran 
Iran has one of the first national Health Technology Assessment (HTA) program, established 
in 2007, in the Eastern Mediterranean Region. (WHO, 2013) 
The main aim of HTA is informing healthcare policymakers, managers and practitioners of 
the clinical consequences in terms of outcomes, and also the economic, ethical, and other 
social implications of the diffusion and use of a specific procedure or technique on medical 
practice. (Fournier, 2012, Facey, 2006) 
The mission of HTA office in Iran is: “systematic and rational assessment of health 
technologies with the purpose of improving the accessibility and productivity of the health 
system” and “The necessity of applying health technology assessment in health systems has 
been highlighted by scientific centers and international organizations such as the WHO and 
World Bank because not only this interdisciplinary knowledge facilitates response the 
unlimited needs of the population with the limited available resources through systematic 
assessment of the effects of technology on health, but also affects other aspects of health 
systems such as equality and responsiveness” . (Doaee et al., 2012) 
This assessment is performed by independent experts and evaluates short and long term 
effects of health technologies. Health technologies include drugs, interventions, medical 
equipment, drugs, biological substances, medical procedures, and interventions related to the 
support, organization, and management systems. HTA measures the effectiveness, clinical 
                                                 
This chapter draws upon the following journal article: 
 
MORADI, M., KOVÁCS, Á. (2017): Az egészségügyi forrás allokáció aktuális kérdései 
Iránban; egészségügyi technológiaelemzés. Köz-gazdaság. [accepted for publication] 
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efficiency, safety, cost-effectiveness, social effects like justice in access, and ethical and legal 
outcomes of these technologies as research projects. (Doaee et al., 2012) 
HTA began its activities as a secretariat in the Deputy of Health in 2007 in Iran and it 
continues as a Health Technology Assessment Office at the Management of Health 
Technology Assessment, Standardization, and Tariff at the Deputy of curative affairs of 
Ministry of Health and Medical Education (MoHME) in the beginning of 2010 with 
structurally enhanced objectives and goals to promote evidence based policy making. (Doaee 
et al., 2012) Between 2007-2010 altogether 22 HTA evaluations were conducted in Iran, 14 
HTAs focused on medical equipments and 8 pharmaceutical drug related HTA were 
completed (Doaee et al., 2012). These HTA assessments were funded through governmental 
budgets. Type of equipments and drugs were not specified by the authors.  
Priorities have a key importance in the health care sector. Priority setting related to the state 
reimbursement of technologies in Iran are based on the following key factors:  
-prevalence of the disease,  
-load of the disease,  
-cost and fluctuations in applying technologies,  
-political and ethical acceptance, and  
application of findings. (Doaee et al., 2012) 
According to our interpretation the “load of disease” is a ‘disease burden’ in health 
economics term. 
Like many developing countries, the process of priority setting and it's criteria in Iran's health 
care system is not so transparent and explicit. (Dehnavieh et al., 2015) HTA has been 
established in the healthcare system of Iran but what is needed is a clear political will to push 
forward the objectives of HTA in Iran. (Doaee et al., 2012) 
Mobinizadeh et al. (2016) conducted a questionnaire survey among HTA professionals Iran, 
the main aim was to create a model for MCDM (Multiple Criteria Decision Making) model 
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for priority setting of health technology assessment in Iran. (Mobinizadeh et al., 2016) The 
following nine priority criteria were identified: 
-efficiency/effectiveness,  
-safety,  
-population size,  
-vulnerable population size,  
-availability of alternative technologies,  
-cost effectiveness in other countries,  
-budget impact,  
-financial protection, and  
-quality of evidence. 
Priority setting and stakeholder analysis were conducted by other authors as well. (Arab-
Zozani et al., 2017) Attitude of health technology assessment students were assessed in their 
given field were conducted at 2015, the needs of the students, professor's attention to 
motivate and responding to student questions, and anticipated job categories and carriers in 
the relevant organizations were assessed. (Arab-Zozani et al., 2017)  
Ethics and bioethics is an important, country specific issue in HTA this was is also assessed 
by Iranian authors. (Abbasi, 2012) 
Olyaeemanesh et al. (2014) investigated the current challenges of Iran’s health technology 
assessment and provide strategies to establish and institutionalize HTA program. 
International databases were searched and seven HTA papers were identified from Iran. 
(Olyaeemanesh et al., 2014) Based on this literature search and analysis twenty-two HTA 
challenges were identified by the authors. Most of these challenges are policy, governance 
and management related, such as lack of integration, organization culture related factors, 
stewardship factors (lack of clear boundaries between private and public sector), lack of HTA 
institutions and experts, and lack of coordination between the HTA process and the policy-
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making level and insufficient resources. This clearly shows that HTA is an important tool of 
a well-established, managed and financed health care system with appropriate policy goals.  
Olyaeemanesh et al. (2016) stated that between 2010-2015: “More than 50 projects were 
conducted until the end of 2015; however, no evidence is available on the extent to which 
these projects have been effective.”. (Olyaeemanesh&Majdzadeh, 2016) Topics like cost-
effectiveness of the cervical cancer screening (Nahvijou et al., 2016) noninvasive 
intervention of weight loss (Nojomi et al., 2016) immunization against haemophilus 
influenzae type B (Moradi-Lakeh et al., 2012) and prosthodontics and restorative dentistry 
(Mobinizadeh et al., 2014) the whole list of HTAs were not specified by the authors. HTA 
assessments were ordered by National Institute of Health Research. These HTA assessments 
were used to inform Health Transformation Plan were mainly implemented in public 
hospitals since May 2014. Decision making reimbursement medicines and medical 
equipment by the Ministry of health is done by another Department, not by the HTA office. 
Reimbursement does not depend on the results of HTA. Increasing knowledge and of the 
policy makers of HTA results are necessary, but not enough for the effective use of HTA 
results in Iran for policy and financial decision making. The initiative of the Medical Journal 
of the Islamic Republic of Iran in publishing HTA results increase the awareness of the 
providers promote the utilization of HTA. 
The next step us establish policy-making process based on the HTA reports, aimed to develop 
a Decision Support System (DSS) in order to adopt evidence-informed policies regarding 
health technologies in Iran. (Yazdani&Jadidfard, 2017) This study was carried out to evaluate 
the opinions of stakeholders on their roles in health technology assessment (HTA) in Iran 
and to determine the barriers and facilitators existing in the organizations to help increase 
their involvement in the HTA program. Therefore, to prevent misunderstanding 
(inappropriate use and expectations not based by evidences) of stakeholders about HTA, it is 
essential to create opportunities in which their thoughts and ideas are taken into account. 
(Yazdizadeh et al., 2016) In Iran the importance of the Evidence Based Medicine is 
recognized. (Baradaran-Seyed&Majdzadeh, 2012) 
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Several authors are conducting research on how to increase the usefulness and efficacy as 
well as barriers and solutions of the HTA backed decision making in Iran. (Mohtasham et al., 
2016, Yazdani&Jadidfard, 2017) Competition of health care providers to utilize new 
technologies and increasing public demand created, and mass media are the key factors that 
lead to an increase in demand for new health technologies. Uncontrolled rapid diffusion of 
new health technologies without proper assessment and a full understanding of their side 
effects decreases public trust toward the health system. (Mohtasham et al., 2016) 
The importance of the BIA as practical policy tool was discussed by (Jamshidi et al., 2014). 
Budget impact analysis (BIA) estimates financial consequences of implementing a new 
health technology or intervention within a specific health care context. (Mauskopf et al., 
2007, Brodszky et al., 2014, Brodszky et al., 2016, Gulácsi et al., 2017, Orlewska&Gulacsi, 
2009) Nowadays, in most of the countries, reimbursement authorities increasingly require 
BIAs, along with a CEA, as part of reimbursement submissions of the pharmaceutical 
companies.  
4.1.1 Pharmaceutical market and drug reimbursement decisions 
Abidi was the first Iranian pharmaceutical company in 1946, followed by Tolid Darou and 
Darou Pakhsh in 1958 and 1963, respectively. (Kebriaeezadeh et al., 2013) 
Self-sufficiency and non-reliance became main goals of the government mostly after the 
Islamic revolution since 38 years ago. After Islamic revolution in 1979, two important 
motions caused fundamental changes: nationalization of the pharmaceutical industries, and 
generic scheme. Governmental industry privatization and transition to the semi-
governmental sector was one of the major actions taken by the government in the 1988 to 
1993 period. (Kebriaeezadeh et al., 2013) 
 Two years after the revolution Ministry of Health (MOH) adapted a full and compulsory 
generic medicine policy and based on this policy pharmaceutical companies which were 
already taken over by the government ask to produce only generic medicines using 
International Nonproperty Names (INN). In order to promote competition MOH encouraged 
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national pharmaceutical industry to manufacture branded generic medicines since 2011. 
(Cheraghali, 2017) 
National industry has manufactured copies of biopharmaceuticals in the past few years, but, 
none of these medicines has had comprehensive evaluation according to Food and Drug 
Administration (FDA) or European Medicines Agency (EMA) guidelines. The lower cost of 
these copied biopharmaceuticals could improve the affordability of these clinically important 
medicines, but authorities need to perform close vigilance of these biopharmaceuticals in 
order to evaluate their safety and efficacy. (Cheraghali, 2013) 
Even after the implementation of national scheme for privatization of the industry we can see 
that the majority of the local pharmaceutical market is manage by semi-governmental 
organizations. (Cheraghali, 2017) 
All aspects of medicines policy including production, importation and distributions of 
medicines in Iran are under strict control of Iran Food and Drug Administration (IFDA) 
(Cheraghali, 2017). IFDA has the mission to regulate all aspects of pharmaceutical market 
including registration of the new medicines. Iran Drug Selection Committee has the 
responsibility to maintain and revise Iran Medicine List (IML). The National law has banned 
production, importation, distribution, and prescription of medicines which they are not 
included in Iran Medicine List. Although, IFDA policy makers have created a mechanism to 
provide those medicines that are not included in the medicine list but it might be essential for 
the treatment of particular patients. (Zargaran et al., 2016) 
Entry of any biological product, such as serum and vaccine, and laboratory products, and any 
pharmaceuticals and pharmaceutical raw materials and pharmaceutical packaging from 
abroad, by the private or public sector, clearance of customs, and also manufacturing of any 
kind of medicinal product or biological product and Selling them inside the country or 
exporting them abroad requires a prior authorization from the Ministry of Health and Medical 
Education and need licensing (The Law on Medical Pharmaceutical and Food and Drug 
Affairs Regulations). 
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Distributors of various medical and biological products, whether governmental or non-
governmental, and private, must obtain a certificate from the Ministry of Health and Medical 
Education. By introducing a qualified technical officer whose eligibility is approved by the 
relevant legal authority (Article 20 of the law), he/she is eligible regarding the distribution of 
medicines and biological substances throughout the country (The Law on Medical 
Pharmaceutical and Food and Drug Affairs Regulations). The qualifying terms of the 
technical authority are: 1) Ph.D. in Pharmacy; 2) no criminal record; 3) no corruption record 
(The Law on Medical Pharmaceutical and Food and Drug Affairs Regulations). 
Iran national pharmaceutical industry is a non-innovative industry which mostly produces 
generic medicines. Therefore, until recently Iran national pharmaceutical industry never feel 
to use tools such as pharmacoeconomics in a non-competitive pharmaceutical market of Iran. 
(Cheraghali, 2006, Cheraghali, 2013) Due to the lack of in the health sectors, in the past years 
till 2012, out of pocket payments of patients have substantially increased and reached 60% 
of the costs of medical services (3). In 2013, the Iran government implemented a national 
health reform program mostly targeted at reduction of out of pocket payment by the patients. 
The program was successful to reduce out of pocket spending share in total health care 
spending to about 20% and to about 10% for medicines for inpatient services. In 2014, the 
Iran pharmaceutical market was valued at about 4.2 billion USD. (Cheraghali, 2016) 
4.1.2 Current pharmaceutical market 
Total expenditure on health is increasing, because private sector expenditure as out-of-pocket 
payment is significantly high in Iran, whereas the public sector’s share is decreasing. 
Iranian Pharmaceuticals Industry Analysis Report (2016) conducted that: 
 Pharmaceutical spending is close to 20% of total treatment costs in Iran.  
 Ten largest companies hold close to 50% market share and ten importing drugs 
companies hold more than 73% of the importing drug market.  
 Antibiotics consumption is nearly a quarter of all drug consumption in Iran, in terms 
of value. 
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 Nearly a third of market sales is linked to sales of brand medicines. The WHO 
predicted 15 percent increase in the pharmaceutical industry's sales. (Novin, 2016) 
 
SWOT analysis of Iranian pharmaceutical industry was done by Iran Pharmaceuticals & 
Healthcare Report Q4 2016 as can be find in the Table 8 (Iran Pharmaceutical and healthcare 
Report, 2016b).  Iran has a large pharmaceutical market in the region and it has a popular 
destination for medical tourism mostly from the neighboring countries. One of the important 
threats is the dependency of the industry on the imports of raw materials and government 
mostly prefer the domestic product rather than imported products and the price of domestic 
products are much cheaper than the imported ones.  However, taxes are low on the foreign-
made drugs that are not manufactured locally and expanding public health insurance 
coverage can boost demand for generic medicines.  An exchange rate fluctuation is one of 
the barriers to attract foreign investment to the country.  
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Table 8 Iran Pharmaceutical Industry's SWOT Analysis 
Strengths: 
 Large pharmaceutical market in regional 
terms, supported by large population.  
 Popular regional destination for medical 
tourism.  
 Wide-ranging public healthcare 
coverage, including in most rural areas.  
 Requirement for registration of drugs 
under their brand names.  
 Local manufacturing sector output 
comprising mostly inexpensive, basic 
medicines resulting in a market that is 
reliant on imports for hi-tech treatments.  
 Acquisition of advanced medicine 
production capability.  
 Fast-growing alliance of international 
trading partners. 
Weakness: 
 Low per capita spending on 
healthcare and pharmaceuticals 
results in a focus on basic 
treatments. 
 International investors are reluctant 
to get involved in Iran, especially 
given the economic sanctions.  
 Relatively poor intellectual 
property standards.  
 Strict government controls on the 
price of pharmaceuticals.  
 Strict import regime favoring 
domestic companies.  
 Around half of raw materials used 
by the local industry are imported.  
 Government's strategy for self-
sufficiency with regards to 
pharmaceutical needs.  
 Government corruption and 
underinvestment has left healthcare 
infrastructure weak. 
 Lack of anti-money laundering 
legislation and banking regulations. 
Opportunities: 
 Low taxes on foreign-made drugs that are 
not manufactured locally.  
 Expanding public health insurance 
coverage boosting demand for generic 
medicines.   
 Improved intellectual property and 
regulatory conditions to attract some 
investment in local facilities.  
 Plans to improve drug registration times. 
 Improved international relations may 
increase confidence of multinational drug 
makers to invest in the market. 
 Increased investment in local 
pharmaceutical capacities.  
 Rising interest in collaborative 
agreements with partners in select foreign 
markets.  
 Removal of almost all economic 
sanctions.  
 Construction of private pharmaceutical 
city to house 100 companies.  
 Growing swing towards reformist and 
moderate political camp. 
Threats: 
 Counterfeiting remains a serious 
issue.  
 Exchange rate fluctuations, rising 
energy costs and inflation 
negatively impacting on 
profitability of drug production and 
also on final consumer prices. 
 Underperforming economy to have 
a negative impact on government 
spending.  
 Potential removal of OTC 
medicines from the reimbursement 
list.  
 Trade in parallel imports 
threatening companies' 
performance. 
 Regional instability linked to the 
proclamation of the Islamic State 
creating political and economic 
instability. 
 
Source: Iran Pharmaceuticals & Healthcare Report Q4 (2016b) 
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Iran remains a challenging market for foreign pharmaceutical companies. The difficult 
political situation will continue to discourage foreign direct investment into the country, in 
general, while the developed local generic manufacturing industry continues to satisfy most 
of the domestic demand, because it cost much less than the similar imported one. Truly, 
governments prefer to increase local manufacturing capacities, and recently they have a great 
focus on covering biological medicines. High inflation and local currency devaluation are 
two reasons that might stop the foreign companies to enter the market. 
The value of Iran's pharmaceutical market in 2015 was IRR69,545bn (USD1.93bn) and it 
forecast to increase to a market size of IRR125,142bn (USD2.72bn) by year 2020, 
corresponding to a local currency compound annual growth rate (CAGR) of +12.5% (7.1% 
in US dollar terms, highlighting the severe impact of the depreciating rial). By year 2025, the 
pharmaceutical market in Iran will be worth IRR202,891bn (USD3.59bn), corresponding to 
a local currency CAGR of 11.3% (6.4% in US dollar terms) (Table 9). (BMI Research, 2016) 
Table 9 Headline Pharmaceuticals & Healthcare Forecasts (Iran 2014-2020) 
 
 2014 2015 2016f 2017f 2018f 2019f 2020f 
Pharmaceutical sales, 
USDbn 
1.910 1.930 1.990 2.360 2.460 2.680 2.910 
Pharmaceutical sales, 
% of GDP 
0.45 0.44 0.60 0.59 0.58 0.57 0.57 
Pharmaceutical sales, 
% of health 
expenditure 
8.5 8.7 8.8 9.0 9.1 9.3 9.4 
Health spending, 
USDbn 
22.360 22.240 22.520 26.280 27.020 28.890 30.910 
Source: (BMI Pharmaceuticals and Healthcare Report, 2016a) 
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BMI highlighted that, after Iran rejoins world economy with sanctions relief on 2016, Iran’s 
economy will herald a new era for the country and we will see pharmaceuticals and healthcare 
markets benefit from greater multinational interest as foreign drug-makers look to expand 
their business operations for the long term. However, some issues in the country such as 
rampant corruption and years of underinvestment may prevent an immediate boom (BMI 
Report, 2016a) 
BMI Research mentioned two examples, in May 2016, Novo Nordisk declared the plans to 
locally produce Insulin in Iran, and also in May 2016, Iran and India made an agreement to 
conclude within the year a preferential trade agreement to boost bilateral trade with the aim 
of lifting sagging exports (Figure 10). The trade pact will be finalized early due to the lifting 
of international sanctions on Iran and will encompass trade, investment and services for 
pharmaceuticals as well as auto components, steel and jewelry. (BMI Report, 2016a) 
Figure 10 Pharmaceutical Market Forecast (2011-2025) 
 
Source: (BMI Pharmaceuticals and Healthcare Report, 2016a) 
Dinarvand, indicated that, since 2001 the pharma market, according to Ministry Of Health 
statistics, has expanded from $ 690 million to $ 2250 million in 2008. The annual growth 
rate from year 2001 to year 2008 for locally produced items has been 16.6% while the sale 
of imported items has annually increased 26.7% since 2001as can be seen in Figure 12. 
However, when the number of items sold in the market is taken into consideration, the total 
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sale of pharmaceuticals only shows a moderate 6.8% annual growth. The sale of locally 
produced and imported items has annually increased 6.7% and 9.4% since 2001. (Figure 11).  
 
Figure 11 The volume market size of pharmaceutical products in Iran 
 
 
Source: (Dinarvand, 2009) 
Figure 12 The volume market size of pharmaceutical products in Iran 
 
 
Source: (Dinarvand, 2009) 
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4.1.3 Drug reimbursement in Iran 
Reimbursed drugs account for about 53.5% of all available drugs and 77.3% of drug 
expenditures (Ansaripour et al., 2014). The Supreme Council of Health Insurance (SCoHI) 
deals with drug reimbursement decisions and the Drug Benefit Package Review Committee 
(DBPRC) as part of the SCoHI and is responsible for assessment. According to the health 
law all health technologies and services covered by of Health Insurance Organi11111zations 
(HIOs) must complete the reimbursement process. Pharmaceutical companies and other 
health care providers have to submit a dossier to the SCoHI. These documents contain general 
information about the drug, the proposed price, the cost of the treatment, a list of alternative 
drug therapies and detailed description of their advantages and disadvantages, and the clinical 
efficacy, safety, budget impact and cost-effectiveness of the drug. This information 
contributes to a certain number of points. The maximum possible score is 100 points. If the 
total score is less than 50 points the application is rejected. If the total score is 50 points or 
more, the application is send to the DBPRC, and members are asked to comment. If a drug 
application receives more than 80 points and no significant objections from the DBPRC, it is 
sent to the SCoHI with a suggestion to reimbursement. If the total score is in between 50 and 
80 BBPRC decides whether their vote is positive or negative. Final decision is made by 
SCoHI. No further information is available about the scoring system and the weights and the 
process as well as the results of the HTA process in peer reviewed English literature in 
Medline.  
4.1.4 Impact of HTA 
In Iran HTA activities have been developed and have become internalized in the decision 
making processes on technologies over the past decade. The most important characteristics 
of this development are the following: 
- formalization and institutionalization (legislation, official institutes with HTA tasks): HTA 
has been embedded in the law, no national HTA institution has been created yet, 
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- standardization (HTA guidelines, standard methodology, national criteria for decision-
making): no HTA country specific guideline were established yet, however national criteria 
for decision making has been already established, 
- execution (number and types of decisions made): the number of decisions has been 
published, but information about the types of decisions are not publicly available, 
- professionalization (capacity building): Iran has academics who are getting knowledgeable 
and have been trained in the field of HTA, the overall capacity is still limited. 
HTA method and the structure of the HTA report is very similar to other countries, such as: 
include at least data related to the following topics:  
1. Introduction, 2. Medicine characterization, 3. Target population, 4. Perspective, 5. 
Methods, 6. Comparator, 7. Outcomes (EQ-5D, SF-36), 8. Costs (indirect costs is not being 
considered), 9. Models: 10. Time horizon: 12. Sensitivity analysis, 13. Threshold: based on 
current national guidelines, IFDA considers drugs with cost/QALY of less than one national 
GDP per capita as “cost effective”, 14. Presenting the results. (Cheraghali, 2017) 
Cost Utility Analysis is the preferred analytical method. Therefore, the results of the study 
can be measured and expressed in different units such as quality-adjusted-life-year (QALY), 
life years gained/saved, disability averted or utility. 
A framework of clinical policy making was established and the following three principles of 
the framework are as follows: 
1. The principle of determining the indications: The indications must be specified according 
to: 
effectiveness; cost-effectiveness; complications of the intervention.  
2. Principle of explaining the recommendation: developing the guidelines.  
3. Principle of evaluation and supervision on the performance: Ultimately, the patients' 
identification and determining the outcomes and costs are important in monitoring the system 
performance. (Shirvani et al., 2014) 
 60 
 
Technology Acceptance Model was set, the main aim was to better maintain the technology 
adoption of the new technologies in Iran. A qualitative study was conducted involving 
physicians, nurses and managers who work at cardiac specialty hospitals in Tehran. Results 
showed that more attention must be paid on senior hospital managers they are key 
professionals of the new technology adoption process. (Safdari et al., 2017) Promoting 
knowledge level of HTA for all audience groups and raising awareness about the importance 
of HTA studies is effective tool. (Ghassemi&Dehnavieh, 2016)  
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5 AN EMPIRICAL INVESTIGATION INTO THE CONCEPT OF HEALTH 
* 
 
Health and illness were originally concepts of medical science. These concepts are very 
important. As far as the method of our study is concerned, the specification comes into 
existence or being by surpassing the limitations of the enormous number of particular 
definitions. The limitations in our special case can be as follows: positive or negative, well-
being or freedom from illness, serious or mild sickness, professional definition of health 
versus laymen’s opinions, and so on. (Blaxter, 2010) Let’s make a preliminary order among 
these cases! 
Figure 13 Possible degrees of health 
 
 
 
  
                                                 
This chapter draws upon:  
MAGYARI-BECK I., MORADI M. (2014): An empirical investigation into the concept of 
health. [Гигиена Культуры.Здоровье культуры – культура здоровья]. Working paper 
presented at the Russian Conference. Budapest, 2014. 10. 14 – 19. Location: Russian Cultural 
Centre.  
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The figure above shows the possible degrees of health. These concepts can be found in 
Blaxter’s book, but this two-dimensional “pyramid” and its interpretations are ours (Figure 
13). (Blaxter, 2010)  
 The closer to the top a notion is, the narrower both its empirical and logical scope. It would 
also be not only possible but important as well – via serious empirical and theoretical studies 
– to construct a bipolar scale having a central “zero” point of indifferent state on the margin 
of health and illness. However, the conditions of living systems usually are not in a clear, 
clean and transparent state of health or illness. “The suggestion is, therefore, that ‘none of us 
can be categorized as being either healthy or diseased, (instead) we are all located somewhere 
along a continuum’ (Sidell, 2010: 27)”.  (Blaxter, 2010) Perhaps the best subjective 
psychological indicator of health – although not totally accurate – can be the lack of 
subjective symptoms, e.g. the absence of pain. (Illyés, 1976) 
5.1 Hypotheses  
First of all, we immediately have to eliminate a conception widely held in the past and 
popular among laymen, according to which health is nothing other than a machine-like 
functioning of living systems. To deal with this mistaken view, we have to define the concept 
of machine. However, this is now an extremely difficult task. For a long time – thousands of 
years – a machine was a system of smooth process by an artificial mechanism, which itself 
could multiply men’s efforts mostly in work and art (e.g. musical instruments). This feature 
was expressed most clearly by the simple machines (Archimedean lever, pulley, and screw) 
in a transparent way. “Reuleaux’s definition of a machine has remained a classic “A machine 
is a combination of resistant bodies so arranged that by their means the mechanical forces of 
nature can be compelled to do work accompanied by certain determinant motions.” 
(Mumford&Winner, 2010) Mumford added to this definition the non-organic nature of 
classical machine. 
However, these sorts of definitions are now outdated. Mumford recognized this: “Instead of 
simplifying the organic, to make it intelligibly mechanical, as was necessary for the great 
eotechnic and paleotechnic inventions, we have begun to complicate the mechanical, in order 
to make it more organic; therefore more effective, more harmonious with our living 
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environment.” (Mumford&Winner, 2010) Informatics – as one of the greatest, newest 
revolutions of mankind – has gone radically beyond the mechanical, non-organic approach 
concerning machines. Today’s machines are very anthropological or humanoid and have little 
to do with the principle of mere mechanics. Now, what is the difference between mechanical 
and organic? Our preliminary hypothesis is as follows: the mechanical is a system of linear 
causalities, whereas the organic is a system of circular causalities.    
The problem is that while radically new mechanisms were created, the theory of machines 
failed to enlarge its basic concepts. The new machines can imitate thinking and – soon – also 
creating. Moreover, the general notion of machine can rather be as follows. For us machines 
are the imitations of living systems by engineering using inanimate matter in the service of 
mankind. The part of the definition “in the service of mankind” is the key point of our 
approach. Before continuing this train of thought, we must emphasize that the nature of the 
main determination of human beings is not mechanical. People are determined by their 
problems: they have a problem structure. 
Well. Let us see what health is. It is that kind of self-reproduction by which any living system 
contributes to the self-reproduction of its meta-systems. The function of the meta system – 
for the living system – is its preservation. There are basically three cases of health. At first: 
the health of the emerging living systems (young) is: reproduction of itself by exceeding its 
original “it”, and thereby extending and improving its meta-system as well. This is what we 
call development. This is an offensive way or strategy. Secondly: the health of the living 
system in its mid-ages is: reproduction of itself and thereby of its meta-system on the same 
level. This is rather a simple repetition, which can be called sustainability. This is the 
Midfensive case (I coined this terrible – but useful – notion: I.M.B.). Thirdly: the health of 
the so-called generation X – that is the old – is: reproduction of itself by increasing input 
under the circumstances of lawfully decreasing output. The strategy of the old is defensive. 
The price of life becomes higher and higher. Death comes when no effort produces the 
smallest output. The three phases of life are: Development (up), Plateau (horizontal), Decline 
(descent). It is better to measure people on the basis of their achievements and not on the 
basis merely of their biological age. And now let us see the applications of these definitions. 
Without successful applications no valid science can exist. 
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5.1.1 Applications 
Briefly speaking, the health of physiological organs: a semi-mechanical process. The health 
of the personality: a constructive private drama. The health of the family: mutual physical 
and psychological support. By the way, we make a distinction between the family and 
marriage. The family loves, supports, takes care of and develops its members, while marriage 
is mostly a formal act, which may or may not be good and bad from the point of view of the 
above. The health of society: some conflicts and balances between horizontal and vertical 
power. The health of culture: conflicts and balance between contradictory ideas and 
identification. The health of ethnic groups: balance between intolerance and tolerance. The 
health of nations: wealth of nations (Smith, 1776) and European concert. (Polanyi, 1944) 
The health of continents: war and peace. The health of mankind: vertical contra horizontal 
globalization. Today’s Western globalization has the philosophy of phenomenology as its 
ideology. This sort of philosophy denies the so-called “abstraction ladder” and prefers a 
picture of the world where there are no differences between the concrete and the abstract. 
That is, phenomenology is a – mutatis mutandis – Renaissance of a pre-Columbian flat world. 
Western globalization is not above nations, but instead of them. The above politics and its 
ideology need considerable improvement in the future. 
5.1.2 Definition of health  
The WHO defined health in its broader sense in 1946 as “a state of complete physical, mental 
and social well-being and not merely the absence of disease or infirmity”. (Grad, 2002) 
 Merriam-Webster dictionary gives three definitions of Health (2014b): 
1- a: the condition of being sound in body, mind, or spirit; especially: freedom from 
physical disease or pain 
b: the general condition of the body ‘in poor health’ ‘enjoys good health’ 
2- a: flourishing condition: well-being ‘defending the health of the beloved oceans 
— Peter Wilkinson’ 
b: general condition or state ‘poor economic health 
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3- a: a toast to someone’s health or prosperity 
 The Oxford Dictionary’s definition of health is: the state of being free from illness or 
injury and a person’s mental or physical condition (Oxfrod, 2010). 
 Medilexicon’s medical dictionary has three definitions for health (Medilexicon, 
2014a): 
1. The state of the organism when it functions optimally without evidence of disease 
or abnormality.  
2. A state of dynamic balance in which an individual’s or a group’s capacity to cope 
with all the circumstances of living is at an optimal level. 
3. A state characterized by anatomic, physiologic, and psychological integrity, ability 
to perform personally valued family, work, and community roles; ability to deal with 
physical, biologic, psychological, and social stress; a feeling of well-being, and 
freedom from the risk of disease and untimely death. 
 Boon How Chew (2011), family physician and lecturer in family medicine defined 
health as “Health is defined as the ability to adapt and self-manage in the face of 
social, physical, and emotional challenges.” (Huber et al., 2011) 
 Franklin P. Adams defined health as “the thing that makes you feel that now is the 
best time of year”. 
 In 1986, the WHO, in the Ottawa Charter for Health Promotion, said that health is “a 
resource for everyday life, not the objective of living. Health is a positive concept 
emphasizing social and personal resources, as well as physical capacities.” (WHO, 
1986) 
 Maloof (1991) argued that a perception of health or mental health is not only defined 
within the medical context, but it is also defined by the patient within a sociocultural 
context that includes family and social network as well as a wide selection of 
potiential providers. Such definitions may vary from one culture to another. Research 
among ethnic groups in the U.S. demonstrates the complexity in a non-clinical 
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definition of health and illness (2017b).  
 Earle (2007) mentioned that health has been called “an abstract concept” that people 
can find difficult to define. (Warwick-Booth et al., 2012) 
 Johnson (2007) argued that health is one of those things that most people assume they 
understand. But if we just stop and consider it for a moment and try to focus on it, it 
starts to float about in our minds. (Warwick-Booth et al., 2012) 
 Tones and Green (2004) refer to health as dichotomous differences in approaches to 
defining health. On the one hand there are positive approaches to defining health 
(health as well-being or as an asset) and on the other hand there are more negative 
definitions of health – those that are illness- or disease-oriented. When health is 
viewed in a negative way, then definitions will tend to focus on health as absence of 
disease. When health is viewed in a positive way definitions tend to be broader and 
take into account concepts such as ‘well-being’. (Warwick-Booth et al., 2012) 
 Aggleton (1990) argues that health is something that can be bought (by investment in 
private health care) or sold (through disease or injury). (Warwick-Booth et al., 2012)  
 Seedhouse (2001) describes health as the ‘foundations for achievement’. Health is a 
complex and contested concept. Seedhouse views health as the means by which we 
achieve our potential, both as individuals and as groups. Seedhouse (1986:61) 
therefore describes a person’s optimum state of health as being ‘equivalent to the set 
of conditions that enable a person to work to fulfill her realistic chosen and biological 
potentials’. (Warwick-Booth et al., 2012) 
 Dorland's Medical Dictionary defines health as “a state of optimal physical, mental, 
and social well-being, not merely the absence of disease. (Ratson, 2003) 
 According to a nurse aged fifty-two from Moscow, “Health is both your inner and 
your outer state – the state of soul – being more optimistic, not giving in to any kind 
of difficulties, trying to find some kind of compromise....and also, probably, being 
needed by society too, however old you are”. (Blaxter, 2010) 
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 “Complete physical, mental, social and spiritual well-being for individuals and 
populations.”  (Edlund, 2012) 
 Health is defined as the ability to adapt and self-manage in the face of social, physical, 
and emotional challenges. (Godlee, 2011) 
 What is health? For most people, it is a state of “perfection”, thus excluding most of 
us; but health is a social right, therefore it should be a possibility for all. This makes 
us wonder what health really is, and in this aim centering our attention on people with 
disabilities as a paradigm is really useful. (Bellieni, 2014) 
5.2.1.1 Classification of the Definitions 
Investigating the short but valuable set of health definitions, we regard it as important to 
classify them merely on a level of plausibility. This method of classification is an age-old 
means of reasoning, created by Aristotle. Without it not only the means of definitions is 
impossible, but the whole rationality, moreover rationalism as well (rationality being an 
instance of the preconscious, while rationalism being an instance of the conscious). It is true 
that today’s scientific life and the whole intellectual climate prefer such terms and directions 
as metaphor, phenomenology and postmodern; we will remain old-fashioned, conservative 
thinkers. Constructive conservatism is not a kind of backwardness. It is rather the 
preservation of successfully tested results. For us science and intellect are not the tools of 
omniscience. We accept Kant’s view that reason has its limitations. However, what is beyond 
our actual reason cannot be understood by us at all. In our “philosophy” the only way of 
understanding reality is the enlargement of reason and not cowardly flight from it. (Gross et 
al., 1996) The brick of the building of classification is definition, and the building of 
classification is made of the bricks of definitions. Without classification rational models and 
constructs cannot be built, or they collapse. However, it is also true that to give here and now 
a correct and final classification is impossible. So, we tried to arrange the cited classification 
on appropriate levels of the ladder of abstraction. This would be a door to the second step – 
after the first one of collecting– towards further – but also preliminary – classifications. This 
venture will be performed by us only in a rudimentary way.  
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5.1.2.2 On the Ladder of Abstractions 
Working with the above definitions, we identified a number of aspects. Namely: capacities, 
resources, assets, well-being, absence of disease, physical, psychological, mental, social, 
state of perfection, social right, ability to adapt, cope with challenges, emotional, self-
manage, relative, spiritual, subjective, longevity, optimism, fitness, compromise, 
achievement, realism, biological, balance, integrity, identity, coping with stress, freedom, 
stress, risk. The number of aspects shows the complexity of the notion of health. However, 
we were also able to reduce this complexity. Counting the number of occurrences of these 
aspects in these definitions, we found the winner. This was “well-being”, a psychological, 
economic, subjective and so on term. “Well-being” in general got 7 points. Physical well-
being has 8 points, mental well-being – 5 points, social well-being – 3 points, spiritual well-
being – 2 points. That is, special cases of well-being have altogether 18 points. If we add the 
general and special points, which is not an entirely correct method, the result will be 25 
points. In second place we find “asset”, “absence of disease” and finally “ability to adapt”. 
These aspects scored only 4 points each. All the other aspects lagged far behind the winner.  
What can we add to this overall picture? There are wide gaps between the complexity of the 
phenomenon of health and the simplicity of theoretical considerations in this domain. No 
wonder that not only laymen but also medical doctors, politicians, sociologists, 
psychologists, managers, artists, philosophers and scholars are ignorant concerning the issue 
of health. Just a further remark: health and sickness can be detected in both vertical and 
horizontal dimensions. As far as the horizontal dimension is concerned, we can speak of the 
health or illness of every profession, whereas on the vertical dimension it is possible to study 
the issue of health and illness on the levels of individuals, family, groups, social layers, 
cultures and so on. Moreover, the aspects of health and illness on the transcendental level are 
also absent. Thus, we are far from solving all the problems in this area. Well-being itself was 
more general in practice and not theoretically. We did not find even the shadow of either a 
horizontal or a vertical approach to the matter to be studied. Well-being seems to be only one 
of the stereotypes and remnants of the wealthy society that has already collapsed.  
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 Research Design 
The main aim of our study was to conduct a survey of laymen’s opinions concerning the 
everyday notions of health. The non-professional participants were – as a rule – asked to 
indicate their sex, age, level of education, profession, and ethnic group. We gathered thirty-
four factors (Table 10) – usually associated with the domain of health according to the 
literature– and asked the participants to rate the importance of each factor in respect of health 
in general and also asked them to add factors which they think are important in these respects. 
In our questionnaire, the degree of importance was measured on a Likert-type scale from 0 
to 6 as follows: most irrelevant, irrelevant, not at all relevant, neutral, less relevant, relevant, 
and most relevant. (Sullivan&Artino, 2013) 
Table 10 List of factors the authors could choose to ask the participants to find the most 
relevant to the most irrelevant factor which contribute to health in general 
 
1 Self-reproduction 13 Attractiveness 25 Lack of Illness 
2 Reproduction of 
Society 
14 Fitness 26 Engagement 
3 Sociability 15 Workability 27 Inner Freedom 
4 Well-balanced 16 Ability to 
Relax 
28 Productivity 
5 Machine-like 17 Sport 29 Innovativeness 
6 Flow 18 Goals, 
Harmony 
30 Positive 
Emotional 
Feeling 
7 Constructive Programs 
of Personality 
19 Religiousness 
and Belief 
31 Constructive 
Hobby 
8 Normal Genes 20 Optimism 32 Morality 
9 Identity or Rooted in 
one’s Culture 
21 Realism 33 Love  
10 Creativity  22 Maturity 34 Responsibility 
11 Longevity 23 Playfulness   
12 Beauty 24 Discipline   
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5.2.1 Instructions for scoring each factor 
We calculated how many participants answered to each degree for each factor. The maximum 
total score can be 735 and the minimum 7 for each factor. The higher the score, the more 
important the factor is to the overall health of a person. 
5.2.2 Scoring 
The scoring of each factor is as follows:  
0. Most Irrelevant   scored 1 
1. Irrelevant    scored 2 
2. Not at all Relevant   scored 3 
3. Neutral    scored 4 
4. Less Relevant   scored 5 
5. Relevant    scored 6 
6. Most Relevant   scored 7 
 
Scoring of each factor is calculated by counting how many times participants answered most 
irrelevant, irrelevant, not at all relevant, neutral, less relevant, relevant and most relevant to 
each factor, then the total number of each factor was multiplied by the score we gave to each 
degree and finally we add up all the numbers. The formula is: (Numbers choosing most 
irrelevant x 1) + (numbers choosing irrelevant x 2) + (numbers choosing not at all relevant x 
3) + (numbers choosing neutral x 4) + (numbers choosing less relevant x 5) + (numbers 
choosing relevant x 6) + (numbers choosing most relevant x 7). For example, 105 participants 
answered the factor of Ability to relax, the numbers of participants who chose most irrelevant, 
irrelevant, not at all relevant, neutral, less relevant, relevant, and most relevant, for the factor 
of ability to relax were 0, 0, 1, 8, 14, 29, 53, respectively. One participant did not answer for 
this factor. The total value for the factor of ability to relax was calculated in this way: 
 (0 x 1) + (0 x 2) + (1 x 3) + (8 x 4) + (14 x 5) + (29 x 6) + (53 x 7) = 530
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Table 11 Calculation of factors based on the participants’ answers 1-9. 
 
 1. 
Self-report 
2. 
Report of 
society 
3. 
Sociability 
4. 
Well-
balanced 
5. 
Machine-
like 
6. 
Flow 
7. 
Constructiv
e 
programs 
of 
personality 
8. 
Normal 
Genes 
9. 
Identity 
rooted in 
one’s 
culture 
F * S V F*S V F*S V F*S V F*S V F*S V F*S V F*S V F*S V 
I do not know 3 - 3 - 1  2 - 1 - 12 - 3 - 3 - 6 - 
Most Irrelevant 8*1 8 5*1 5 1*1 1 0*1 0 23*1 23 3*1 3 3*1 3 5*1 5 6*1 6 
Irrelevant 5*2 10 11*2 22 0*2 0 0*2 0 14*2 28 4*2 8 3*2 6 5*2 10 7*2 14 
 Not at all 10*3 30 8*3 24 4*3 12 1*3 3 23*3 69 14*3 42 10*3 30 8*3 24 12*3 36 
Neutral 18*4 72 23*4 92 14*4 56 12*4 48 24*4 96 27*4 68 16*4 64 21*4 84 19*4 76 
Less Relevant 26*5 130 30*5 150 27*5 135 15*5 75 11*5 55 20*5 100 22*5 110 22*5 11
0 
31*5 155 
Relevant 21*6 126 18*6 108 38*6 228 37*6 222 7*6 42 14*6 84 32*6 192 21*6 12
6 
24*6 144 
Most Relevant 14*7 98 7*7 14 20*7 140 38*7 266 2*7 14 11*7 77 16*7 112 20*7 14
0 
6*7 42 
Total 474 415 572 614 327 382 517 499 473 
* Frequency * score of each degree (Most Irrelevant: scored 1, irrelevant: scored 2, not at all relevant: scored 3, neutral: scored 4, less relevant: 
scored 5, relevant: scored 6, most relevant: scored 7) 
**Value 
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Table 12 Calculation of factors based on the participants’ answers 10-18. 
 
 10. 
Creativity 
11. 
Longevity 
12. 
Beauty  
13. 
Attractiveness 
14. 
Fitness 
15. 
Workability 
16. 
Ability to 
relax 
17. 
Sport 
18. 
Goals, 
Harmony 
F *S V F*S V F*S V F*S V F*S V F*S V F*S V F*S V F*S V 
I do not 
know 
0 - 4 - 0 - 0 - 0 - 1 - 0 - 0 - 0 - 
0 Most 
Irrelevant 
2*1 2 1*1 1 5*1 5 4*1 4 0*1 0 0*1 0 0*1 0 1*1 1 0*1 0 
1 
Irrelevant 
3*2 6 6*2 12 11*2 22 7*2 14 0*2 0 1*2 2 0*2 0 0*2 0 0*2 0 
2 Not at all 4*3 12 6*3 18 13*3 39 10*3 30 1*3 3 3*3 9 1*3 3 3*3 9 1*3 3 
3 Neutral 15*4 60 24*4 96 25*4 100 24*4 96 5*4 20 12*4 48 8*4 32 14*4 56 5*4 20 
4 Less 
Relevant 
22*5 110 32*5 160 34*5 170 34*5 170 25*5 125 38*5 190 14*5 70 22*5 110 25*5 125 
5 Relevant 33*6 198 23*6 138 15*6 90 23*6 138 36*6 216 29*6 174 29*6 54 43*6 258 36*6 216 
6 Most 
Relevant 
26*7 182 9*7 63 2*7 14 3*7 21 38*7 266 21*7 147 53*7 371 22*7 154 38*7 266 
Total 570 488 440 473 630 570 530 588 630 
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Table 13 Calculation of factors based on the participants’ answers 19-27. 
 
 
 
 
19. 
Religiousness 
& belief 
20. 
Optimism 
21. 
Realism 
22. 
Maturity 
23. 
Playfulness 
24. 
Discipline 
25. 
Lack of 
Illness 
26. 
Engagement 
27. 
Inner 
Freedom 
F*S V F*S V F*S V F*S V F*S V F*S  F*S  F *S V F*S V 
I do not 
know 
0 - 1 - 4 - 1 - 3 - 0 - 0 - 4 - 0 - 
0 Most 
Irrelevant 
19*1 19 0*1 0 1*1 1 4*1 4 0*1 0 0*1 0 0*1 0 6*1 6 0*1 0 
1 
Irrelevant 
16*2 32 1*2 2 0*2 0 1*2 2 3*2 6 3*2 6 2*2 4 2*2 4 0*2 0 
2 Not at 
all 
14*3 42 0*3 0 3*3 9 10*3 30 6*3 18 4*3 12 3*3 9 7*3 21 4*3 12 
3 Neutral 22*4 88 5*4 20 17*4 68 17*4 68 18*4 72 23*4 92 15*4 60 25*4 100 8*4 32 
4 Less 
Relevant 
12*5 60 16*5 80 28*5 140 24*5 120 16*5 80 33*5 165 17*5 85 25*5 125 26*5 130 
5 
Relevant 
15*6 90 43*6 258 40*6 240 38*6 228 33*6 98 30*6 180 32*6 192 27*6 162 35*6 210 
6 Most 
Relevant 
7*7 49 39*7 273 12*7 84 10*7 70 26*7 182 12*7 84 36*7 252 9*7 63 32*7 224 
Total 380 633 542 522 456 539 602 481 608 
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Table 14 Calculation of factors based on the participants’ answers 28-34. 
 
 28. 
Productivity 
29. 
Innovativeness 
30. 
Positive emotional 
feeling 
31. 
Constructive 
hobby 
32. 
Morality 
33. 
Love 
34. 
Responsibility  
F*S V F*S V F*S V F*S V F*S V F*S V F*S V 
I do not know 0 - 0 - 0 - 2 - 2 - 1 - 1 - 
0 Most 
Irrelevant 
1*1 1 1*1 1 1*1 1 1*1 1 2*1 2 0*1 0 1*1 1 
1 Irrelevant 0*2 0 3*2 6 0*2 0 1*2 2 3*2 6 0*2 0 1*2 2 
2 Not at all 6*3 18 9*3 27 1*3 3 7*3 21 12*3 36 5*3 15 7*3 21 
3 Neutral 12*4 48 18*4 72 3*4 12 13*4 52 21*4 84 7*4 28 15*4 60 
4 Less 
Relevant 
32*5 160 37*5 185 12*5 60 28*5 140 30*5 150 14*5 70 30*5 150 
5 Relevant 33*6 198 23*6 138 33*6 198 35*6 210 20*6 120 32*6 192 24*6 144 
6 Most 
Relevant 
21*7 147 14*7 98 55*7 385 18*7 126 15*7 105 46*7 322 26*7 182 
Total 572 527 659 553 503 627 560 
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Finally, factors were sorted in descending order in the basis of the sums explained above. We 
present it in more visible form: 
 
1. Positive emotional feeling 659 
2. Optimism 633 
3. Fitness or Goal, Harmony 630 
4. Love 627 
5. Well-balanced 614 
6. Inner freedom 608 
7. Lack of illness 602 
8. Sport 588 
9. Productivity or sociability 572  
10. Workability or creativity 570 
11. Responsibility 560 
12. Constructive hobby 553 
13. Realism 542  
14. Discipline 539 
15. Ability to relax 530 
16. Innovativeness 527 
17. Maturity 522  
18. Constructive program of personality 517 
19. Morality 503  
20. Normal genes 499 
21. Longevity 488 
22. Engagement 481 
23. Self-reproduction 474 
24. Identity rooted in one's Culture or Attractiveness 473  
25. Playfulness 456 
26. Beauty 440 
27. Reproduction of society 415 
28. Flow 382 
29. Religiousness and belief 380 
30. Machine-like 327 
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5.2.3 Results 
Survey questionnaires distributed to 105 participants aged 19 to 63 years. The mean age was 
31 (SD 9.1), 66.7 % (n=70) of the participants were female and 33.3 % (n=35) male. 2 % had 
completed secondary school, 45.7 % had a Bachelor’s degree, 35.2% a Master’s degree, 
13.3% a PhD and 3.8% others. 
Table 11, Table 12, Table 13 and Table 14 show the factors from the point of view of 
evaluation expressed in numbers given by the members of the population studied. The first 
five most relevant factors are Positive emotional feeling, Optimism, Fitness, Goal and 
harmony, and Love, respectively, and the five most irrelevant factors are Machine-like, 
Religiousness and beliefs, Flow, Reproduction of society, and beauty. Some of the most 
important aspects of health, such as – Discipline, Ability to relax, Innovativeness and 
Maturity – were placed by participants in the mid part of our rank order. Not to speak of 
Creativity. It occupies the 10th place in the rank order of aspects of health. Participants were 
asked to add factors which they thought were important and they were as follows: no stress, 
patience, security, proper partner relations, education, healthy diet, social responsibility, 
motivation, loving animals, spiritual well-being, internal and external balance, faithful and 
reliable friends.  
 Discussion 
The “Positive emotional feeling” is a dubious criterion, especially if we do not know why a 
person experiences “positive emotional feeling”. If, for example, somebody is a sadist, they 
will have a positive emotional feeling when they torture the victim. A dictator enjoys acting 
without any moral and/or practical limitation. An idle person is happy even avoiding work 
that is necessary for him or her. As far as the aspect of “Optimism” is concerned, this is a 
very important but by no means an omnipotent feature of health. An optimist can also be a 
heavy drinker who harms himself and the life of his or her family. The same can be said about 
the drinker’s style of life and social relationships. “Fitness or Goal and Harmony” are again, 
beyond doubt, very important factors of soundness. However, they have to be understood 
correctly. Fitness in its classical conceptions spoke of a person’s good adaptation to the 
 78 
 
conditions of niches of his bio-cultural environment, and not simply to be smart and strong. 
Similar statements can be made for goal and harmony. Without goals we live in psycho-
physical entropy, whereas harmony is essential for all animate and inanimate matter. “Love” 
is again a notion applicable on both the transcendental and worldly levels. The famous Greek 
philosopher Empedocles applied it to the solar system, while Jesus Christ applied it to human 
relationships. It was Newton who first coined from it a secular term. What is in fact the 
concept of “Well-balanced”? This qualification is appropriate for the large systems which 
can be characterized by three properties, namely: being complex, contradictory and random. 
These properties are obligatory because both beyond and beneath the human being and 
including also the latter, we have not found a unique feature of living systems. 
Likewise the items in the middle of the scale present very important aspects from the point 
of view of health. They are as follows: “Discipline”, “Ability to relax”, “Innovativeness”, 
“Maturity”. These features are even more important than the first five winners of this unusual 
race. All of them contribute much more and better to private and public health than the first 
five. There are a lot of average people and medical practitioners who have many things to do 
with public health questions. Now, let’s see the most “inferior” aspects of our scale! They 
are: “Machine-like”, “Religiousness and beliefs”, “Flow”, “Reproduction of society” and 
“Beauty”. To our great surprise these aspects have the most importance as regards human 
soundness. “Machine-like” – if it is identified with strict and strong determination – is 
unacceptable. But if the term machine includes new techniques like the Internet, the matter 
seems different: strict determination immediately evaporates and the notion of human-like 
becomes acceptable, important and appropriate. Now, “Religiousness and belief” are the 
most important values in history. Without them no enlightenment and progress are possible. 
Mutatis mutandis, the same can be said of humanity and health. “Flow” – the term coined by 
Csíkszentmihályi – is one of the best characteristics of healthy functioning of man and 
mankind. (Csíkszentmihályi, 1990) 
This proto-psychological type of psychological concept expresses the lack of obstacles in 
living systems’ functioning, without which health is impossible. Finally: “Reproduction of 
society” and “Beauty” mean, on the one hand, sustainability and on the other hand signal a 
biological, psychological and mental excellence.  
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5.3.1 Limitations 
The first results of our 34 dimensions 7 levels wellbeing score is presented here. The 34 
dimensions were derived from the literature, the 7 levels were defined by the researches who 
conducted this study. Further studies are needed to validate the design, the Like-type scale 
used and the results. 
 Summary 
In summary our first remark is: that the laymen’s concepts of health are usually upside down 
notions. What is health and soundness for a layman is the opposite of logic and good sense. 
Can we illuminate the background of these approaches? We all know that our historical age 
is the age of liberalism. But what is liberalism? Is it a possibility or is it a necessity? For us 
liberalism is first all a necessity. Why? Because we, in the Euro-Atlantic culture, have 
developed our culture to such an extent that it is impossible for the average man to keep up 
with the changes. The balance between the general and particular values vanishes to the 
benefit of particularities. As a result, poor man confronts a huge amount of problems in his 
mental helplessness. Under these circumstances freedom is not a gift, it is a compulsion. Busy 
with solving their particular problems, people’s minds are occupied by particular opinions. 
The only and useful issue in liberalism is that its practice is similar to the diversity in 
psychological studies. It can considerably contribute to the growing number of ideas and 
conceptions and subsequently to selecting and finding the best solution for the time and place. 
It is no wonder that we found such a distorted picture not only in the health question but in 
almost all domains of thinking and acting. The only way out of liberalism – a historical phase 
between the past and the future – lies in the substantial elaboration of a new set of integrative 
principles which make the culture again simpler, more collective, transparent and helpful. 
We have to enter a new period of history as soon as possible.      
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6 HEALTH-RELATED QUALITY OF LIFE AND COST-OF-ILLNESS OF 
PSORIASIS PATIENTS IN IRAN 
 
Psoriasis represents a social and financial burden for patients and the healthcare system (See 
Chapter 2). Patients often suffer from disfigurement and from social stigmatization. Because 
the disease is usually persistent, patients with a diagnosis of psoriasis usually need lifelong 
care, which also means a lifetime of expenses. Raho et al. performed a systematic literature 
search to review the evidence available concerning the social burden and costs of psoriasis 
(the search included 'quality of life', 'burden' or 'stigmatization', 'psychological factors' in 
PubMed up to January 2010). (Raho et al., 2012) Results suggest that quality of life was 
affected by psoriasis to a degree comparable with diabetes or cancer.  
 Description of the discussed health problem – psoriasis  
 
6.1.1 Epidemiology and definition 
Psoriasis is a chronic inflammatory disease affecting approximately 2% of the population 
globally. (Michalek et al., 2017) In Europe, the prevalence of psoriasis varies largely across 
countries, it ranges between 0.73% in the United Kingdom to 2.90% in Italy. In Iran, the 
prevalence of psoriasis is estimated to be around 1 %. (Baghestani et al., 2005, 
Noorbala&Kafaie, 2010) In the US, the estimated prevalence of diagnosed psoriasis is 
3.15%. However, it is reported to be less prevalent in Asia than in Europe. 
                                                 
HRQOL results of this chapter draw upon the following journal article:  
 
MORADI, M., RENCZ, F.: GULÁCSI, L., MORADI, A., BROSZKY, V. (2015): Health 
status and quality of life in patients with psoriasis: Iranian cross-sectional survey. Arch Iran 
Med. 18(3), pp. 153-9. IF 0.931 
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(Chandran&Raychaudhuri, 2010) A quarter of patients develop the disease before the age of 
20 years. A further peak in incidence is recorded in the fifth and sixth decades. 
(Leman&Burden, 2008) 
6.1.2 Diagnosis of psoriasis 
Psoriasis is a chronic dermatological condition with multiple phenotypical variations and 
degrees of severity. 
Diagnosis is primarily based on the clinical symptoms. The most common clinical subtype 
is chronic plaque psoriasis, which is also called psoriasis vulgaris, and it is characterised by 
well-demarcated bright red plaques covered by adherent silvery white scales. 
(Boehncke&Schon, 2015) These may appear in any localisation, most often symmetrically, 
especially the scalp and extensor surfaces of extremities. The differential diagnosis includes 
other dermatological conditions, such as eczema, lichen planus and systemic lupus 
erythematosus. (Boehncke&Schon, 2015) Another clinical subtype, guttate psoriasis is 
characterized by the rapid development of multiple small papules over wide areas of the 
body. Generalised pustular psoriasis is a rather rare form, presenting as multiple non-
follicular pustules within plaques of psoriasis. If occurs acutely, it is often associated with 
fever. There are many genetic and environmental factors described to determine the induction 
and/or exacerbation of psoriasis (Zeng et al., 2017), for example, stress is a well-known 
trigger factor playing a role in acute exacerbation of psoriasis (Ferreira et al., 2016). 
Psychological stress or an abnormal response to stressors were reported to modify the 
evolution of skin disorders. (Basavaraj et al., 2011) 
6.1.3 Characteristics of the disease 
Psoriasis has a variety of different presentations. The classic presentation is of well-defined 
red plaques with silver scale. The characteristic scale makes the disorder highly visible and 
intrusive on the patient's lifestyle. The visible nature of the disease ensures that psoriasis has 
both physical and psychosocial effects. In normal skin, epidermal cell reproduction and 
proliferation takes 28 days. In psoriasis this process is considerably accelerated to 
approximately 4 days, resulting in the deposit of immature cells on the skin. (Ryan, 2008)  
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Up to 50% of patients with psoriasis have concurrent nail psoriasis, with a lifetime incidence 
of 80% to 90% in psoriasis patients. (Reich, 2009) Clinical manifestations of nail psoriasis 
are pitting, discolouration, onycholysis and subungual hyperkeratosis as well as nail plate 
crumbling and splinter haemorrhages. Nail psoriasis is associated with discomfort in many 
patients and leads to significant functional impairment and psychological stress. The often 
distressing appearance of affected nails impacts the patient tremendously in both work and 
social activities. Importantly, 80% of patients with psoriatic arthritis have nail psoriasis. 
(Baran, 2010) 
 The physical symptoms of psoriasis include itching, irritation, burning/stinging, sensitivity, 
and pain. Patients also suffer psychological distress, especially as a result of stigmatization, 
self-consciousness, and embarrassment, which can in turn affect employment and social 
activities. (van Voorhees&Fried, 2009) Disease management will be dependent on disease 
severity, psychosocial effects and the patient's lifestyle. (Ryan, 2008) 
Psoriasis is often associated with a number of comorbid conditions. (Takeshita et al., 2017a, 
Takeshita et al., 2017b) Psoriatic arthritis (PsA) is the inflammation of the joints, which is 
present in 20-40 % of individuals with psoriasis and has an estimated prevalence of 0.1–
1.0 % in the general population. (Gladman et al., 2005, Mease&Armstrong, 2014) Obesity, 
type 2 diabetes, metabolic syndrome (Takeshita et al., 2017a), depression and suicide, 
smoking, and alcohol consumption are also more common in patients with psoriasis. (Menter 
et al., 2011, Gupta et al., 1987, Ginsburg&Link, 1989) Patients with psoriasis demonstrate a 
higher prevalence of cardiovascular risk factors and may have an increased risk for coronary 
heart disease, cerebrovascular disease or peripheral arterial disease. (Patel et al., 2011) 
Epidemiology studies found that psoriasis and Crohn’s disease (CD) share common genetic 
background, with a 3.8 to 7.5-fold incidence of Crohn’s disease among psoriasis patients 
compared with the general population. (Najarian&Gottlieb, 2003, Menter et al., 2011) 
6.1.4 Disease severity in psoriasis 
According to the European consensus, the severity of psoriasis is defined based on the extent 
of body surface area (BSA) affected, Psoriasis Area and Severity Index (PASI) and 
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Dermatology Life Quality Index (DLQI). (Mrowietz et al., 2011) Mild disease is defined as 
(BSA ≤10 or PASI ≤10) and DLQI ≤10, while moderate to severe psoriasis is defined as 
(BSA > 10 or PASI > 10) and DLQI > 10. (Finlay, 2005) (BSA, PASI and DLQI measures 
are introduced in detail in Chapter 5) The literature suggests that four-fifth of patients present 
with mild disease, whereas 20% have moderate to severe disease. (Menter et al., 2011) 
6.1.5 Health-related quality of life 
Psoriasis may interfere significantly with patients’ health-related quality of life (HRQOL). 
(Bhosle et al., 2006, De Korte et al., 2004, Gonzalez et al., 2016) Despite being a non-life-
threatening disease, it poses a great deal of social and financial burden to the patients and the 
societies. (Raho et al., 2012) 
The literature suggest that even if the disease involves small BSA, it can have a substantial 
psychological impact on one’s personal well-being, especially when it affects face, 
décolletage, handnails or the genital area. (Menter et al., 2011) For example, psoriatic lesions 
on the face or scalp may be associated with considerable embarrassment and may 
considerably impair quality of life. (De Korte et al., 2004) Involvement of the genital skin 
occurs in 29–40% of patients with psoriasis, which may interfere with psychosocial well-
being of patients. (Meeuwis et al., 2011)  
It has been estimated that patients with moderate to severe psoriasis suffer from a significant 
(15–20%) decrease in working ability. (Mustonen et al., 2015, Chan et al., 2009, Pearce et 
al., 2006, Meyer et al., 2010) In recent years, introduction of biological agents opened up 
new horizons in the treatment of the patients. Compared to standard treatment, they proved 
clinical efficacy, but at a higher cost. (Iskandar et al., 2017) 
Measurement of HRQOL in psoriasis has a growing literature. A large number of generic as 
well as disease-specific questionnaires have been used is psoriasis patients so far (e.g. EQ-
5D, Medical Outcomes Study 36-Item Short Form (SF-36), Dermatology Life Quality Index 
(DLQI), Skindex-29, Skindex-17, Skindex-16, The Psoriasis Index of Quality of Life 
(PSORIQOL), Dermatology Quality of Life Scales (DQOLS). (Ali&Cueva, 2017) Using 
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valid HRQOL questionnaires both routine practice and clinical research is crucial. (Bronsard 
et al., 2010) 
In randomized controlled trials (RCTs) of psoriasis treatments, DLQI is the most commonly 
used HRQOL instrument (83%), followed by the SF-36 (31%), EQ-5D) (15%), and Psoriasis 
Disability Index (14%) and Skindex (5%). (Ali&Cueva, 2017) The EQ-5D is the most 
commonly applied HRQOL measure in cost-effectiveness analyses of psoriasis interventions. 
(Gutknecht et al., 2016) 
The DLQI plays a particularly important role in the management of psoriasis patients, it is 
not only recommended to use the DLQI to assess the burden of plaque-type psoriasis on the 
HRQOL in adult patients before the initiation of a systemic treatment and during follow-up 
to evaluate the therapeutic effect, but it is among eligibility criteria to receive biological 
therapy in many countries. (Wakkee et al., 2008, Rencz et al., 2015) 
6.1.6 Treatments of psoriasis 
The goals of psoriasis treatment are to gain initial and rapid control of the disease process, 
decrease the percentage of body surface area involved, decrease plaque lesions, achieve and 
maintain long-term remission, minimize adverse events, and improve patient HRQOL. 
(Lebwohl, 2005)   
Treatment modalities are chosen on the basis of disease severity, relevant comorbidities, 
patient preference (including cost and convenience), efficacy, and evaluation of individual 
patient response. (Menter&Griffiths, 2007) Therapy varies depending on disease severity and 
spread and will shift from control of acute flares to long-term maintenance. For patients with 
less than 20% body surface involvement, topical therapy is the most appropriate choice for 
initial treatment. (Tristani-Firouzi&Krueger, 1998) Primary treatment options for localized 
psoriasis include tar preparations, corticosteroids, calcipotriene, tazarotene and anthralin. Tar 
has reported to show limited effectiveness and may be used at night with more appealing 
topical corticosteroid preparations during the day. Topical calcipotriene may be the safest 
treatment for long-term control of face or genital disease because there is no risk of atrophy. 
Topical tazarotene is more effective with less irritation when used in combination with 
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topical corticosteroids. (Feldman, 2000) For lesions that are difficult to control with initial 
therapy, anthralin or tazarotene may be tried. (Pardasani et al., 2000) 
The use of the various forms of phototherapy remains an essential treatment option for 
moderate to severe forms of psoriasis vulgaris and represents a safe and very effective 
treatment. (Zanolli, 2003) 
Systemic therapy is suggested primarily for patients with moderate to severe psoriasis who 
cannot be sufficiently treated with topical therapy and/or phototherapy. Treatment of 
moderate to severe psoriasis includes systemic therapies, such as methotrexate, acitretin, 
cyclosporine, and biologic agents. (Sukarovska et al., 2007, Lebwohl, 2005) Methotrexate 
(MTX) is used most frequently for the treatment of moderate to severe plaque-type psoriasis, 
especially in cases with joint involvement or in pustular or erythrodermic forms. (Smith, 
2000, Haider et al., 2014) Ciclosporin is indicated in patients with the most resistant forms 
of psoriasis, especially with plaque-type disease. Ciclosporin is used as a short-term therapy 
for 2 to 4 months; courses of treatment can be repeated at intervals. (Pathirana et al., 2009) 
Ciclosporin can be considered for long-term therapy only in individual cases, with frequent 
monitoring, particularly for kidney toxicity. 
For decades, topical and oral retinoids have been used as antipsoriatic treatments. Etretinate, 
acitretin, and isotretinoin have been used in the treatment of psoriasis. Approved indications 
for acitretin are severe psoriasis that cannot be managed by topical treatments or 
phototherapy, as well as erythrodermic or pustular psoriasis. The acitretin treatment of 
women of reproductive age is discouraged due to the teratogenic potential of the drug. 
(Pathirana et al., 2009) 
Over the past two decades, the treatment of psoriasis has undergone a revolution with the 
advent of biologic therapies including adalimumab, etanercept, infliximab, ixekizumab, 
secukinumab and ustekinumab and they are designed to target specific components of the 
immune system and are a major technological advancement over traditional 
immunosuppressive medications. (Sivamani et al., 2013) In Iran, only adalimumab and 
infliximab are available. (MoHME, 2017) Also, there are further new biologic substances 
under investigation (eg. brodalumab, risankizumab, guselkumab, tildrakizumab, targeting the 
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interleukin-17 and interleukin 23 signaling pathway), which are very promising for the 
treatment of psoriasis. (Lønnberg et al., 2014, Dong&Goldenberg, 2017) Efficacy and safety 
of the interleukin-17 inhibitor ixekizumab have been established and became a registered 
drug, and brodalumab has been approved by the US Food and Drug Administration in 
February 2017 and the European Medicines Agency adopted a positive opinion in May 2017. 
It is also important to mention that an increasing number of biosimilar drugs are available to 
treat psoriasis (e.g. biosimilar infliximab, etanercept and adalimumab). Biosimilars are 
biotechnologically processed protein substances whose amino acid sequence is identical to 
the reference product. (Radtke&Augustin, 2014, Nast et al., 2015) 
6.1.7 Assessment of treatment response in psoriasis 
The measures recommended to be used for the assessment of response to treatment by the 
European Medicines Agency (EMA) (2004) are summarized in Table 15. 
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Table 15 Outcome measures suggested to be used in psoriasis by the EMA 
 
Outcome measure Description 
Visual assessment of 
index lesions 
Measurements of at least 2 index lesions 
representative of the disease (one from refractory area - 
elbow or knee, and one from trunk) for separate variables 
including erythema, scale and elevation on a 3-point scales. 
Among skin signs, elevation is considered the most critical, 
scale the least. 
Body Surface Area 
(BSA) 
Estimation of BSA affected by psoriasis may be done by 
using hand area, which represents approximately 1% of total 
body surface. 
Clinical signs score - 
Total severity sign score 
(TSS) 
Sum of signs (redness/erythema, scale/crusting, 
thickening/elevation) and symptoms (pruritus) using 3-point 
scales (e.g. 0=none, some=1, extensive=2). Score varies 
from 0 to 12. Each level of severity (clear, mild, moderate) is 
defined in a standardised fashion. 
Physician’s global 
assessment of 
improvement (PGA) 
Global assessment of the patient’s overall severity of the 
disease on 6 or 7-point scale, scored from « severe » to « 
clear » 
Lattice System 
Physicians Global 
Assessment (LS-PGA) 
LS-PGA incorporates ranges of the percent of BSA involved 
and the overall plaque morphology. 
Source: Guideline on clinical investigation of medicinal products indicated for the treatment 
of psoriasis (EMA) (2004) 
 
Health-related quality of life (HRQOL) may be a secondary or tertiary endpoint in pivotal 
clinical trials. Only validated HRQOL measures are recommended to measure the impact of 
a treatment, such as the dermatology-specific DLQI or Dermatology Quality Life Scales 
(DQOLS) or Skindex, or the psoriasis-specific Psoriasis Disability Index (PDI) and Psoriasis 
Life Stress Inventory (PLSI). However, these HRQOL measures have the drawback that they 
are not able to generate health utility values for economic evaluations. 
6.1.8 Costs of psoriasis 
In this chapter a brief summary is provided on the costs of psoriasis in various countries from 
data published after 2010. 
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6.1.8.1 Economic burden of psoriasis in European countries 
In Denmark and Norway, Larsen et al. conducted a prospective, non-interventional study in 
a private dermatologist care setting, before and after the initiation of biological therapy. 
(Larsen et al., 2013) Overall, 163 psoriasis patients were enrolled to the study, who all 
received biological therapy. Total annual costs before and after the biological therapy were 
DKK 78,000 and DKK 286,000, respectively (year of costs 2010).  
In France, a retrospective COI study based on health insurance database was performed by 
Le Moigne et al. from the third-party payer perspective. (Le Moigne et al., 2014) The mean 
annual total direct medical costs with and without biological therapy were €16,214 and 
€3,356 per patient, respectively (year of costs 2011). Cost of hospitalizations and biological 
drugs were responsible for the majority of between-group differences. 
In Finland, Mustonen et al. assessed the direct and indirect costs of psoriasis a societal 
perspective. (Mustonen et al., 2013) According to data of 232 patients, total annual 
medication costs were €1,083 per patient.  Costs of physician visits amounted to €673 and 
€359 in mild and severe psoriasis patients respectively. Biological therapy was associated 
with very high costs. 
Three studies evaluated costs of psoriasis in Germany. In a multicentre, cross-sectional, 
retrospective study, Berger et al. measured the direct and indirect costs from patient’s, third-
party payer and societal perspectives in German departments and hospitals (year of costs 
2002). (Berger et al., 2005) Altogether 192 patients were included. From a third-party payer 
perspective, per patient costs of psoriasis were €864 annually. Main cost drivers were 
prescribed medications (60%) and inpatient stays (22%). Complementary and alternative 
medications cost €596 to the patients per annum. Annual average cost of patients treated by 
systemic and photo therapy were €4,985 and €1,173, respectively. Indirect costs were as 
much as €1,440 per year.  
Schöffski et. al. conducted a retrospective analysis, based on data of 184 patients from 
dermatological practices and hospital outpatient departments. (Schöffski et al., 2007) Total 
costs of psoriasis per patient was €6,709 on average (year of costs 2004). Higher costs were 
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associated with more severe disease, higher hospitalization rate and larger number of sick 
leaves.  
Steinke et al. compared costs of inpatient and outpatient care in psoriasis, and according to 
different treatment modalities from a societal perspective in a retrospective study with 120 
patients between 2005 and 2006. (Steinke et al., 2013) They found that mean total annual 
costs per patient added up to €7,092 in Germany. Annual per patient costs of in- and 
outpatients were €13,042 and €2,984, respectively. Costs of patients treated by systemic 
biological therapy were €30,200 (inpatient) and €11,601 (outpatient).  
In Hungary, Balogh et al. conducted a non-interventional, cross-sectional questionnaire 
survey involving 200 moderate-to-severe psoriasis patients from two academic dermatology 
departments. (Balogh et al., 2014) Cost calculation was performed from a societal 
perspective. The majority of the patients (52 %) were treated by biologics at the time of the 
survey. The mean annual total cost per patient was €9,254 (SD €8,502), with direct costs 
accounting for 86% (year of costs 2012). The mean total cost of patients treated by biologics 
was €15,790.  
In Italy, Colombo et al. evaluated the COI associated with moderate to severe psoriasis based 
on data from 150 patients in multicenter, prospective study. (Colombo et al., 2008) The total 
costs, including direct and indirect items were measured from the patient’s, societal and third-
party payer’s perspectives. Mean annual total costs of psoriasis amounted to €8,371 per 
patient (year of costs 2004). Moderate disease was associated with half the costs of the severe 
disease (€5,226 vs. €11,434). Hospitalization was identified as the main driver of costs. 
In the Netherlands, Driessen et al. collected health care resource utilization data 12 months 
before and after starting biologic therapy including 67 patients. (Driessen et al., 2010) Direct 
costs before and after biological therapy were €10,146 and €17,712 per patient per year, 
respectively.  
In Spain, Carrascosa et al. performed a 12-month, multicentre, prospective longitudinal and 
observational study enrolling 797 psoriasis patients from a third party payer as well as a 
societal perspective. (Carrascosa et al., 2006) The mean total cost per patient was €1,079/year 
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including direct and indirect costs. Prescription drugs accounted for the majority of costs 
(46.6%).  
In Sweden, a prevalence-based prospective study was carried out by Ghatnekar et al. 
including 164 psoriasis patients. (Ghatnekar et al., 2012) The mean total cost was €994 per 
patient per month, which results in a mean annual cost of €11,928/patient (year of costs 
2009). Outpatient visits and phototherapy (49%), biological drugs (20%) and productivity 
loss (22%) were accounted for the majority of costs.  
Navarini et al. analysed resource utilisation data of 383 psoriasis patients in Switzerland. The 
analysis adopted a societal perspective. (Navarini et al., 2010) Annual total costs per patient 
were CHF1,800, 3,600 and 17,000-20,000 in mild, moderate and severe psoriasis, 
respectively (year of costs 2005). 
In the UK, Fonia et al. conducted a retrospective observational study with 76 patients. Only 
direct medical costs were included from a third party payer perspective. (Fonia et al., 2010) 
Total cost of psoriasis care prior to biological treatment were £4,207 per patient annually, 
while after the initiation of biological treatment total costs increased significantly to £11,981 
per patient (year of costs 2004). 
6.1.8.2 Economic burden of psoriasis outside of Europe 
In the US, Yu et al. conducted a COI study enrolling 56,528 psoriatic patients from societal 
perspective. (Yu et al., 2009) Compared with controls, psoriatic patients had significantly 
greater total healthcare costs ($US5,529 vs $US3,509) (year of costs 2010). In the line with 
the literature, patients with more severe psoriasis had greater total healthcare costs than 
patients with mild psoriasis ($US10,593 vs $US5,011), including higher drug costs 
($US4,738 vs $US1,283).  
Another study in the US by Beyer and Wolverton assessed the current total cost of systemic 
therapy for psoriasis. (Beyer&Wolverton, 2010) Authors examined the annual trends in 
psoriasis drug spendings between 2000 to 2008 from a third party payer perspective. Overall, 
costs for systemic treatment of psoriasis ranged from $US1,197 for methotrexate to 
$US27,577 for alefacept.  
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In a large study, based on the IMPACT database Kimball et al. estimated the incremental 
economic burden associated with psoriasis. (Kimball et al., 2011) The sample consisted of 
114,512 psoriasis patients with and without comorbidities. The mean costs were $1,980 and 
$4,992 per patient per 6 months in patients with and without comorbidities, respectively (year 
of costs 2011). 
In Canada, a COI study conducted by Levy et al. analysed 90 psoriasis patients’ resource 
utilisation in three Canadian dermatology clinics from societal perspective. (Levy et al., 
2012) The estimated mean annual cost of psoriasis was $7,999 per patient (year of costs 
2008). Direct costs accounted for more than half of the total costs (57%) The mean lost 
productivity costs were $3442 per patient.  
In Malaysia, Tang and his colleagues conducted a retrospective study including 250 psoriasis 
patients from eight dermatology clinics. (Tang et al., 2013) The total annual per patient cost 
of psoriasis was RM 1,307 (year of costs 2008).  
6.1.8.3  Comparison of studies 
Cost-of-illness analysis is a well-recognized tool to demonstrate the financial burden of a 
disease. A better understanding of the psoriasis economic literature can help inform health 
policy decision-makers regarding the burden of the disease. The literature suggests that 
psoriasis poses a considerable economic burden on societies. Main costs generated by 
biological drugs. The selected studies cover the period between 2002 and 2014. The studies 
outlined above cannot be directly compared because of the different countries, currencies, 
patient populations, health systems and unit costs. It seems that the annual health care 
spending on psoriasis patients has increased a lot by the introduction of biological drugs. 
While before the era of biologics, hospitalisation was the main driver of costs, now 
biologicals are. (Raho et al., 2012) In studies by Larsen, Driessen and Fonia 100% of the 
patients received biological therapy, while Balogh examined a sample where 52% of the 
patients received biological drugs. (Larsen et al., 2013, Driessen et al., 2010, Fonia et al., 
2010, Balogh et al., 2014) All these studies revealed significant increase in costs following 
the initiation of biologic therapy. Fonia found approximately £9,500 rise in drug costs, 
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Driessen €7,566 PPPY in the direct costs mainly due to biological drugs, while Larsen 
observed DKK 208,000 mainly due to the cost of etanercept treatment. (Fonia et al., 2010, 
Driessen et al., 2010, Larsen et al., 2013) Besides, they found that inpatient admissions were 
significantly less frequent in patients treated with biologicals. Driessen reported that the 
number of day-care and hospital admission days per year was reduced by 94% and 64%, 
respectively, after the introduction of biologics. (Driessen et al., 2010) (Table 16) 
Other significant cost drivers are productivity loss and physician visits. The presence of 
comorbidities may also increase the costs, for example, in the study by Kimball et al., where 
incremental costs of comorbidities associated with psoriasis were investigated (Kimball et 
al., 2011), the presence of cardiovascular diseases increased mostly the costs related to 
psoriasis.  
Disease severity was observed as an important predictor of costs in psoriasis. In the study by 
Yu et. al. patients with moderate to severe psoriasis had greater total health care costs 
compared with patients with mild psoriasis ($10,593 vs. $5,011). (Yu et al., 2009) Navarini 
et al. made a comparison regarding out-of-pocket payments in different disease severity, they 
found a considerable increase in total average out-of-pocket expenses depending on the 
severity of disease from CHF 630 per patient per year in mild psoriasis to CHF 2,400 in 
severe psoriasis. (Navarini et al., 2010) 
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Table 16 Cost-of-illness studies in psoriasis 
 
Author Country 
Year 
of 
costs 
Perspective of the analysis N 
Time 
horizon of 
the 
analysis 
Rate of 
biological 
therapy 
Cost drivers  
(Levy et al., 2012) Canada 2008 Societal 90 1 year 13% 43% - productivity loss 
(Larsen et al., 2013) 
Denmark and 
Norway 
2010 Societal/hospital point of view 163 4 years 100% 89% - medication costs 
(Mustonen et al., 
2015) 
Finland 2010 Societal 236 1 year 5% 
18% - medication and 
phototherapy 
(Le Moigne et al., 
2014) 
France 2012 Third party payer 1924 9 years 0.30% Biological therapy 
(Berger et al., 2005) Germany 2002 Third-party payer, societal, patient 192 1 year 0% 
46% - early retirement; 
18% - medication 
(Schöffski et al., 
2007) 
Germany 2004 Third-party payer, societal 184 1 year 0% 
46% - medication, 30% 
indirect costs 
(Steinke et al., 2013) Germany 2006 Societal 120 1 year 6% 
32% - inpatient treatment; 
28% - outpatient 
medication 
(Balogh et al., 2014) Hungary 2012 Societal 200 1 year 52% 79% - biological therapy 
(Colombo et al., 
2008) 
Italy 2004 Third-party payer, societal, patient 150 1 year 0% 
32% - productivity loss; 
30% - hospitalization 
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Author Country 
Year 
of 
costs 
Perspective of the analysis N 
Time 
horizon of 
the 
analysis 
Rate of 
biological 
therapy 
Cost drivers 
(Driessen et al., 
2010) 
The 
Netherlands 
2009 Societal 67 1 year 100% biological therapy 
(Carrascosa et al., 
2006) 
Spain 2003 Third-party payer, societal 797 1 year N/A 
47% - treatment costs; 
19% - hospitalization 
(Ghatnekar et al., 
2012) 
Sweden 2009 Societal 164 1 month 16% 
49% - outpatient visits and 
light therapy;20% - 
biological drugs 
(Navarini et al., 
2010) 
Switzerland 2005 Societal 3,596  1 year N/A ambulatory costs 
(Fonia et al., 2010) UK 2008 Societal 76 1 year 100% intensive care 
(Yu et al., 2009) US 2003 Societal 56,528 1 year 0% 29 % - drug costs 
(Beyer&Wolverton, 
2010) 
US 2008 Third-party payer N/A 9 years N/A alefacept treatment 
(Kimball et al., 
2011) 
US 2011 Third party payer 114,512 6 months N/A 
Treatment of 
cardiovascular 
comorbidities 
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6.1.9 Health-related quality of life and disease burden studies of psoriasis in 
Middle Eastern countries 
We performed a PubMed search in July 2017 to identify publications on health-related 
quality of life and cost-of-illness studies in psoriasis, focusing on Middle Eastern countries. 
Our primary aim was to provide a broad review on HRQOL studies in psoriasis from Iran 
and the region. Secondarily, our objective was to complement the previous COI review 
(presented above) which involved publications only after 2010, with special focus on Iran 
and further 19 selected countries from the region, namely Afghanistan, Armenia, Azerbaijan, 
Bahrain, Egypt, Iran, Iraq, Jordan, Kuwait, Lebanon, Libya, Oman, Pakistan, Qatar, Saudi 
Arabia, Syria, Tunisia, Turkey, Turkmenistan, United Arab Emirates. The detailed search 
strategy is presented in the figure below (Figure 14).  
 
Figure 14 Search strategy used in PubMed for quality of life and cost-of-illness studies 
in psoriasis in 20 selected countries in the Middle Eastern region 
 
 
 
("Psoriasis"[Mesh] AND ("Cost of Illness"[Mesh] OR "Quality of Life"[Mesh])) AND 
(("afghanistan"[MeSH Terms] OR "afghanistan"[All Fields]) OR ("armenia"[MeSH Terms] 
OR "armenia"[All Fields]) OR ("azerbaijan"[MeSH Terms] OR "azerbaijan"[All Fields]) OR 
("bahrain"[MeSH Terms] OR "bahrain"[All Fields]) OR ("egypt"[MeSH Terms] OR 
"egypt"[All Fields]) OR ("iran"[MeSH Terms] OR "iran"[All Fields]) OR ("iraq"[MeSH 
Terms] OR "iraq"[All Fields]) OR ("jordan"[MeSH Terms] OR "jordan"[All Fields]) OR 
("kuwait"[MeSH Terms] OR "kuwait"[All Fields]) OR ("lebanon"[MeSH Terms] OR 
"lebanon"[All Fields]) OR ("libya"[MeSH Terms] OR "libya"[All Fields]) OR ("oman"[MeSH 
Terms] OR "oman"[All Fields]) OR ("pakistan"[MeSH Terms] OR "pakistan"[All Fields]) OR 
("qatar"[MeSH Terms] OR "qatar"[All Fields]) OR "Saudi Arabia"[All Fields] OR 
("syria"[MeSH Terms] OR "syria"[All Fields]) OR ("tunisia"[MeSH Terms] OR "tunisia"[All 
Fields]) OR ("turkey"[MeSH Terms] OR "turkey"[All Fields]) OR ("turkmenistan"[MeSH 
Terms] OR "turkmenistan"[All Fields]) OR "United Arab Emirates"[All Fields]) 
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The search resulted 39 hits, however 15 studies were excluded as these did not focus on 
psoriasis (N=8) (Borman et al., 2007, Esmail et al., 2015, Guler et al., 2015, Nas et al., 2017, 
Saad et al., 2011, Talli et al., 2016, Turan et al., 2009, Ullbro et al., 2003), were neither 
HRQOL nor cost-of-illness studies (N=4) (Ammar-Khodja et al., 2015, Demirel et al., 2013, 
El-Darouti et al., 2015, Gokdemir et al., 2008), did not report original studies (N=2) or were 
not from the selected 20 countries (N=1). (Mork et al., 2004) 
None of the studies reported COI results in psoriasis.  
HRQOL studies in psoriasis were available from Iran (N=4) (including our publication, see 
Chapter 6) (Moradi et al., 2015), Kuwait (N=2), Lebanon (N=1), Saudi Arabia (N=1), Tunisia 
(N=1) and Turkey (N=15), these are briefly summarized below. 
Iran 
In Iran, validity of the Persian version of the Psoriasis Disability Index (PDI) questionnaire 
was tested in a sample of psoriasis patients (N=125). (Aghaei et al., 2009) 
 HRQOL in skin diseases was analysed in a sample of 300 patients (psoriasis N=100, alopecia 
areata N=100, vitiligo N=100) from one outpatient clinic. HRQOL was assessed by the Beck 
Depression Inventory (BDI), SF-36 and DLQI questionnaires. Significantly worse DLQI 
scores were detected in psoriasis cases than others and SF-36 score were significantly lower 
as well, BDI scores were the highest in psoriasis group indicating the importance of 
psychological effects of autoimmune skin diseases. (Ghajarzadeh et al., 2012) 
The efficacy of methotrexate plus pioglitazone vs. methotrexate alone in the treatment of 
plaque-type psoriasis (N=44) was studied in a single-blinded randomized controlled trial. 
HRQOL as measured by the DLQI did not differ significantly between the two study arms. 
(Lajevardi et al., 2015) 
Our publication on HRQOL in psoriasis in Iran was identified by the search, results are 
described in detail in Chapter 6. (Moradi et al., 2015) 
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Kuwait 
In Kuwait, the impact of different severity levels in psoriasis on HRQOL was assessed using 
the DQOLS involving a sample of 330 out-patients with psoriasis. Physical activities were 
affected in greater than 50% of cases and it increased significantly with the severity of 
psoriasis. Social relationships were affected in more than half of the patients. (Al-Mazeedi et 
al., 2006) 
Similar impairment of HRQOL has been demonstrated by the dermatology-specific DLQI 
instrument in patients with kloids and hypertrophic scars (N=48) and psoriasis (N=48) and 
their scores were higher (worse HRQOL) than of the sex- and age-matched healthy controls 
(N=48). (Balci et al., 2009) 
Lebanon 
A study in Lebanon assessing the preferences of patients with psoriasis (N=87) using vertical 
rating scale, time trade-off, and standard gamble methods. (Zug et al., 1995)  
Saudi Arabia 
The effect of Narrowband ultraviolet B phototherapy on HRQOL in psoriasis (N=72) was 
evaluated before and after treatment and significant improvement was detected both on DLQI 
and PASI scores. (Al Robaee&Alzolibani, 2011) 
Tunisia 
In Tunisia, the Tunisian version of the Skindex-29 measure was evaluated involving 60 
patients (psoriasis N=20, vitiligo N=20, onychomycosis N=20). (Zghal et al., 2003) 
Turkey  
The most studies were performed in Turkey, the first was published in 2000, in which 
depression, anxiety, life satisfaction and affective expression levels were assessed in 
psoriasis patients (N=50). The outcomes applied were Beck Depression Inventory (BDI), 
Spielberger State-Trait Anxiety Scale (STAI I-II), Life Satisfaction Scale (LSS), Courtauld 
Emotional Control Scale (CECS), Body Image Satisfaction Scale (BIS) and PASI. Compared 
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to controls, psoriasis patients reported significantly higher degrees of depression and more 
body cathexis problems. (Devrimci-Ozguven et al., 2000) 
A cross-sectional survey involving subjects with psoriasis vulgaris (N=50), with lichen 
planus (N=30) and healthy control subjects (N=40) revealed significantly higher Beck 
depression scores among the patients than in healthy controls, and PASI correlated with the 
Beck depression score. (Akay et al., 2002) 
Another paper reported the development and testing of a HRQOL instrument, namely the 
Psoriasis Quality of Life Questionnaire (PQLQ) questionnaire involving 75 patients with 
psoriasis, their relatives and physicians in the development (construct) of the questionnaire, 
and 156 psoriasis patients in the testing of its reliability and validity. (Inanir et al., 2006) 
 A study involving 66 female participants (psoriasis N=39, healthy volunteers N=27) and 70 
male participants (psoriasis N=39, healthy volunteers N=31) highlighted that patients with 
psoriasis, especially females have distinct sexual dysfunction compared with healthy controls 
regardless of the coexistent depression. (Turel Ermertcan et al., 2006) Similar findings were 
reported from a smaller study (psoriasis N=24). (Mercan et al., 2008) 
Symptoms among psoriasis patients was evaluated in a study involving psoriasis patients 
(N=87), the outcome measures used were the PASI, DLQI and the Hamilton Anxiety-
Depression Scale (HAD). Authors found that pruritus was a very common symptom in 
psoriasis, as well as burning, exudation and bleeding, hence these should be considered in 
further scoring systems of the disease. (Bilac et al., 2009) 
A study involving children and adolescents aged 8 to 18 years (N=48) with psoriasis 
confirmed that psoriasis is related to depression and impaired quality of life also in children. 
(Bilgic et al., 2010) 
Indicators of HRQOL in psoriasis was analysed in a follow-up study involving psoriasis 
patients (N=154) aged 16 or older. (Aksoy et al., 2011) 
Relationship between sleep apnoe and psoriasis was analysed (N=33) and results suggest that 
sleep apnoe occurs more frequently in psoriasis patients than in the general population. 
(Karaca et al., 2013) 
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A comparison of psoriasis patients (N=51) and healthy controls (N=51) highlighted that 
psoriasis patients have higher negative problem orientation and impulsive-careless problem-
solving style scores than the controls, as well as avoidant problem-solving style and lower 
life satisfaction. (Eskin et al., 2014) 
HRQOL of patients with psoriatic arthritis (PsA, N=80) and psoriasis (N=40) patients and of 
healthy subjects (N=40) was compared and patients with psoriasis and PsA had worse 
HRQOL and patients with PsA had worse functional status than healthy individuals. (Tezel 
et al., 2015)  
Impact of functional pruritus compared with mild psoriasis on HRQOL was assessed in total 
of 73 patients (psoriasis N=40, functional pruritus N=33) and similar negative impact was 
detected in the two diagnoses. (Altunay et al., 2014) 
The relationship between HRQOL and the severity of psoriasis was analysed (N=127) in a 
cross-sectional survey. HRQOL of was strongly reduced and significant relationship was 
confirmed for DLQI with nail psoriasis and smoking and a linear, positive correlation was 
detected between the DLQI and BSA but not between the DLQI and PASI. (Cakmur&Dervis, 
2015) 
Coping strategies of psoriasis patients were compared to control subjects (psoriasis vulgaris 
N=37, control subjects N=42) and in contrast to previous results in the literature, no 
significant differences in general psychiatric symptoms and coping strategies between the 
psoriasis patients and the control group. (Balta et al., 2016) 
The TUR-PSO cross-sectional observational study involved 3971 psoriasis from 40 centers 
in Turkey. The DLQI and EQ-5D questionnaires were applied to assess patient’s HRQOL. 
Mean DLQI was 7.03 ± 6.02, and the Anxiety/depression health dimension of the EQ-5D 
was the most frequently affected. Only 4.1% were on a biologic treatment, and only 30.5% 
of moderate to severe psoriasis patients were treated with systemic therapy. (Atakan et al., 
2016)  
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6.1.10 Summary 
According to our best knowledge there is no COI study in psoriasis available in Iran or the 
Middle East region published in PubMed.  
HRQOL studies in psoriasis in the Middle Eastern region (considering 20 selected countries) 
is increasing. Most studies are from Turkey, however, there are still many countries with no 
publication activity in the field. Patient samples are typically under 100, the highest sample 
was in Kuwait (N=330), only a recently published multicentric study from Turkey involved 
a large sample (N=3971). The majority were cross-sectional surveys. DLQI was the most 
often used HRQOL assessment tool.  
 Research questions and hypotheses  
Several questionnaires have been used to measure health-related quality of life (HRQOL) in 
patients with psoriasis in Iran, including generic (e.g., SF-36) and disease-specific 
questionnaires (e.g., Psoriasis Disability Index - PDI, Dermatology Life Quality Index - 
DLQI, Psoriasis Area and Severity Index - PASI) but to our knowledge there cannot be found 
any studies in the literature that assessed HRQOL of psoriasis patients with EQ-5D in Iran. 
(Ghajarzadeh et al., 2012, Ansar et al., 2013, Aghaei et al., 2009, Zandi et al., 2011) 
Over the past decade, the literature on mapping the generic preference-based measure, EQ-
5D in different diseases has rapidly grown. Heredi et al. mentioned that  “According to the 
University of Oxford HERC online database of mapping studies (Dakin, 2013) only two 
papers and a conference abstract have been published about mapping EQ-5D in psoriasis, 
so far”. (Blome et al., 2013, Currie&Conway, 2007, Norlin et al., 2012, Heredi et al., 2014) 
Therefore, four papers have been published about mapping EQ-5D in psoriasis.   
All these researches investigated the relationship between the dermatology-specific DLQI 
questionnaire and the EQ-5D index or EQ VAS. These models could explain only 27.0-
48.8% of the variance of EQ-5D. 
To our knowledge, no research has been published about cost-of-illness in psoriasis from 
Iran until now. 
The objectives of this cross-sectional study were:  
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1. To measure HRQOL of psoriasis patients in Iran with the general measure of EQ-5D 
and several disease-specific instruments, and analyze the relationship between these 
outcome measures. Additionally, we compare HRQOL differences between 
subgroups of patients regarding treatment, clinical subtypes and localization of 
psoriatic lesions. 
2. To compare HRQOL of psoriasis patients to the age-matched general population in 
Iran 
3. Mapping EQ-5D index scores and EQ VAS scores from DLQI to provide utility 
values for economic evaluations. 
4. To estimate annual per patient direct and indirect costs associated with psoriasis in 
Iran from a societal perspective. 
5. To compare HRQOL and cost-of-illness in patients with psoriasis between Iran and 
Hungary. 
 
 Methods 
 
6.3.1 Study design 
A cross-sectional questionnaire survey including 262 patients has been carried out. 200 
patients from Hungary and 62 from Iran enrolled to the study. The Iranian study was 
performed from May to August 2013 was conducted at Moradi Skin Laser Clinic in Shiraz, 
Iran. We used a questionnaire that incorporated self-designed items and validated HRQOL 
and disease severity measures. (Balogh et al., 2014, Heredi et al., 2014) The questionnaire 
consisted of two parts; the first was filled out by the patients and the second by their 
dermatologist. Patients were asked about demographic data (age, sex, marital status, weight, 
and height) and medical history (disease duration, family history, affected body sites). 
HRQOL was assessed by EQ-5D, EQ VAS, DLQI, and self-assessed disease severity visual 
analogue scale. All the patients were managed by a single dermatologist who provided data 
on clinical type of psoriasis, psoriasis treatment in the last 12 months, and moreover, he 
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completed PASI, and physician’s global assessment of disease activity visual analogue scale 
(PGA VAS) regarding each patient. 
In the Hungarian questionnaire, patient could choose among these areas: face, neck, hands 
and palms, forearm, fingers and finger nails, legs and thigh in order to state in which part of 
their body they have the problem. In the Iranian Questionnaire some other parts were added 
into the questionnaire as follows: knee, ankle, chin, groin, elbow, armpit, finger and toenails 
according to the talk we had with two dermatologists in Iran. In Iran, usually patients with 
psoriasis do not use a travel coupon and ambulance mostly used for emergency reasons. So, 
this part was deleted from the Iranian version of questionnaire compared to that by Balogh 
et al. 
Patients were asked to respond questions about their socio-economic background and 
demographics. In the Iranian questionnaire, salary categories were as follows: none to 
2,500,000 Rials, 2,500,000 to 5,500,000 Rials, 5,500,000 to 7,500,000 Rials, 15,000,000 to 
25,000,000 Rials and 25,000,000 to 35,000,000 Rials and more than 35,000,000 Rials. (1 
Euro= 40400 Rial; (17 March 2017)  
6.3.2 EQ-5D 
In many countries, utility measures are required for allocation decisions. The EQ-5D is a 
standardised instrument for use as a measure of health outcome which was introduced in 
1990. Applicable to a wide range of health conditions and treatments, it provides a simple 
descriptive profile and a single index value for health status. (Shaw et al., 2005, Wu et al., 
2007) 
The EQ-5D is one of the generic HRQOL instruments which has been extensively validated 
and been shown to be sensitive, internally consistent, and reliable in the general population 
and other patient groups including psoriasis. (Hurst et al., 1994, Dorman et al., 1997, Schrag 
et al., 2000) The conceptual basis of the EQ-5D is the holistic view of health, which includes 
the medical definition, as well as the fundamental importance of independent physical, 
emotional and social functioning. The concept of health in EQ-5D also encompasses both 
positive aspects (well-being) and negative aspects (illness). (Gusi et al., 2010) Yaling and his 
colleagues indicated (2014) that the validity and responsiveness of the EQ-5D was found to 
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be good in people with skin diseases, especially plaque psoriasis or psoriatic arthritis. (Yang 
et al., 2015) 
The EQ-5D consists of 2 pages - the EQ-5D descriptive system and the EQ visual analogue 
scale (EQ VAS). The EQ-5D descriptive system comprises the following 5 dimensions: 
mobility, self-care, usual activities, pain/discomfort and anxiety/depression). (Euroqolgroup, 
1990) Each of these dimensions can be rated as 1 (no problem), 2 (some problem) or 3 (major 
problem) – this is the so called EQ-5D-3L version of the EQ-5D questionnaire. (Schrag et 
al., 2000) A new version has been launched recently with 5 levels, named as EQ-5D-5L. An 
EQ-5D health state may be converted to a single summary index by applying a formula that 
essentially attaches weights to each of the levels in each dimension. (Golicki et al., 2014, 
Herdman et al., 2011) This formula is based on the valuation of EQ-5D health states from 
general population samples thus EQ-5D index reflects the utility of a health status from the 
societal point of view.  
While the general health status measure SF-36 has been used in previous studies comparing 
psoriasis treatments, there have been few applications of the EQ-5D in clinical trials of 
patients with moderate to severe plaque psoriasis. In a recent study, Blome et al. aimed to 
develop and test an algorithm for the transformation of DLQI scores into utilities. Both EQ-
5D global score and EQ VAS were used as utility measures. Correlations were computed to 
identify predictors of EQ-5D utilities. Linear stepwise regressions were conducted using 
DLQI and further possible predictors to find the optimal mapping algorithm. According to 
the findings, mapping of DLQI on EQ-5D in psoriasis patients currently has severe 
limitations in validity and clinical relevance. (Blome et al., 2013) 
In our study, the validated Farsi version of the EQ-5D was administered in this study. Due to 
absence of local value set in Iran, the UK weights were applied to calculate EQ-5D scores 
(i.e. utilities) that can range from -0.594 to +1, with higher scores referring to better quality 
of life (Dolan, 1997). EQ-5D is accompanied by a visual analogue scale (EQ VAS) on which 
patients are asked to provide a self-assessment of their own health in a range from 0 (worst 
imaginable health state) to 100 (best imaginable health state). 
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6.3.3 Dermatology Life Quality Index (DLQI) 
Dermatology Life Quality Index (DLQI) is the most commonly used dermatology-specific 
HRQOL questionnaire. (Finlay&Khan, 1994, Lewis&Finlay, 2004) It consists of 10 
questions covering symptoms, feelings, daily activities, leisure, work and school, personal 
relationships and treatment side effects that assess patients’ perception of the impact of skin 
condition of their HRQOL last week. Each question is scored on a 4-point Likert scale (0, 
not at all/not relevant; 1, a little; 2, a lot; 3, very much). DLQI score is calculated by summing 
up the score of each question and therefore, total scores range between 0 (least impact on 
HRQOL) and 30 (maximum impact on HRQOL). 
The Dermatology Life Quality Index (DLQI), developed in 1994, was the first dermatology-
specific Quality of Life instrument. It is a simple 10-question validated questionnaire which 
has been used in over 30 different skin conditions in over 33 countries and is available in 85 
languages. (Basra et al., 2008). Its use has been described in over 800 publications including 
many multinational studies. The DLQI is the most frequently used instrument in studies of 
randomised controlled trials in dermatology. (Ali&Cueva, 2017) 
The DLQI questionnaire is designed for use in adults, i.e. patients over the age of 16. It is 
self-explanatory and can be simply handed to the patient who is asked to fill it in without the 
need for detailed explanation. It is usually completed in one to two minutes. Each question 
is answered by a tick box: “not at all”, “a little”, “a lot” or “very much”. (Lewis&Finlay, 
2004) Each question refers to the impact of the skin disease on the patient’s life over the 
previous week. The scoring of each question is described in Table 17. 
The Dermatology Life Quality Index consists of 10 questions concerning symptoms and 
feelings, daily activities, leisure, work, and school, personal relationships and treatment 
(Table 18).  
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Table 17 Scoring of DLQI questions 
 
Answer Score 
Very much 3 
A lot 2 
A little 1 
Not at all 0 
Not relevant 0 
Question unanswered 0 
Question 7: "prevented work or studying" 3 
Source: (Finlay&Khan, 1994)  
The DLQI is calculated by summing the score of each question resulting in a maximum of 
30 and a minimum of 0. The higher the score, the more QOL is impaired. The DLQI can also 
be expressed as a percentage of the maximum possible score of 30 (Power et al., 2009). The 
possible score range is from 0 (meaning no impact of skin disease on quality of life) to 30 
(meaning maximum impact on quality of life) (Table 18 and Table 19).  
Score 0 or 1 mean s that psoriasis has no effect on patient’s life. Score 2 to 5 mean that 
psoriasis has a small effect on patient’s life, score 6 to 10 means that psoriasis has a moderate 
effect on patient’s life, score 11 to 20 means psoriasis has a very large effect on patient’s life 
and score 21 to 30 means psoriasis has an extremely large effect on patient’s life. 
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Table 18 Meaning of DLQI scores 
Score Meaning 
0-1 no effect at all on patient's life 
2-5 small effect on patient's life 
6-10 moderate effect on patient's life 
11-20 very large effect on patient's life 
21-30 extremely large effect on patient's life 
Source: (Hongbo et al., 2005)  
 
Table 19 The six dimensions of the DLQI 
 
Dimension Number of question Maximum total score 
Symptoms and feelings Questions 1 and 2 6 
Daily activities Questions 3 and 4 6 
Leisure   Questions 5 and 6 6 
Work and School Question 7 3 
Personal relationships Questions 8 and 9 6 
Treatment Question 10 3 
Source: (Finlay&Khan, 1994, Hongbo et al., 2005) 
6.3.4 Psoriasis Area and Severity Index (PASI) 
A wide variety of scoring system has been proposed to assess severity of psoriasis. More than 
44 different scoring systems were used in 171 randomized clinical trials of psoriasis therapies 
reviewed by Naldi et al. between 1997 and 2000. (Puzenat et al., 2010) 
According to the literature, the Psoriasis Area and Severity Index (PASI) seems to be the 
most valid and reproducible clinical severity score in the management of adult patients with 
plaque-type psoriasis. Other scores (Lattice System Physician’s Global Assessment - LS-
PGA, Self-Administered Psoriasis Area Severity Index - SAPASI and Salford Psoriasis Index 
SPI), however, appear to be interesting and require better evaluation. (Puzenat et al., 2010) 
The PASI can be used in everyday clinical practice in the management of adult patients with 
plaque-type psoriasis, in particular, if a systemic treatment is considered. To assess the 
severity of plaque-type psoriasis in adult patients, it is recommended to assess during the 
examination the following symptoms: pruritus, cutaneous pain, burning sensations, bleeding, 
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desquamation, sexual-life impairment and functional disability secondary to specific 
localisations of skin lesions (face, hands, nails, genital areas). (Paul et al., 2010) 
PASI is a gold standard to measure the severity of psoriasis (Puzenat et al., 2010, 
Fredriksson&Pettersson, 1978). PASI-72 (hereinafter PASI) combines the assessment of 
severity of lesions and the area affected into a single score in a range of 0 and 72 where 
highest score refers to worse disease severity. To make up the score, the three features of 
erythema, induration and desquamation are each assigned a number from 0 to 4 with 4 being 
the worst; and the extent of involvement of each body region is scored from 0 to 6. 
A patient’s PASI is a measure of overall psoriasis severity and coverage. PASI consists of 
two major steps, for each body section (head, arms, trunk and legs) specify: 
1. BSA (Body Surface Area): The body is divided into four regions comprising the head 
(h), upper extremities (u), trunk (t), and lower extremities (l). In each of these areas, 
the fraction of total surface area affected is graded on a 0-6 scale (0 for no 
involvement; up to 6 for greater than 90 % involvement). The various body regions 
are weighted to reflect their respective proportion of body surface area (BSA) 
(Louden et al., 2004). 
2. Severity of lesions 
When using the PASI, psoriatic plaques are graded based on three criteria: redness 
(R), thickness (T), and scaliness (S). Severity is rated for each index on a 0-4 scale 
(0 for no involvement up to 4 for severe involvement).  
The composite PASI score can then be calculated by multiplying the sum of the 
individual-severity scores for each region by the weighted area-of-involvement score 
for that respective region, and then summing the four resulting quantities; 
mathematically this evaluation is as follows:  
PASI = 0.1(Rh +Th +Sh )Ah + 0.2(Ru +Tu +Su )Au + 0.3(Rt +Tt +St )At + 0.4(Rl +Tl +Sl 
)Al  
Where Rh, Ru, Rt, Rl = redness score of plaques on the head, upper extremities, trunk, 
and lower extremities, respectively (0-4) Th, Tu, Tt, Tl = thickness score of plaques on 
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the head, upper extremities, trunk, and lower extremities, respectively (0-4); Sh, Su, 
St, Sl = scaliness score of plaques on the head, upper extremities, trunk, and lower 
extremities, respectively (0-4); and Ah, Au, At, Al = area of psoriatic involvement score 
for the head, upper extremities, trunk, and lower extremities, respectively (0-6). 
(Louden et al., 2004) 
 
All calculations are combined into a single score (PASI score) in the range of 0 (no psoriasis 
on the body) and up to 72 (the most severe case of psoriasis). 
Typically, the PASI would be calculated before, during and after a treatment period in order 
to determine how well psoriasis responds to the treatment. 
6.3.5 Physician’s global assessment visual analogue scale 
Physician’s global assessment visual analogue scale (PGA VAS) is a 100-mm-long visual 
instrument that allows dermatologists to evaluate easily the current disease activity of the 
patient. Self-assessed disease severity visual analogue scale is basically similar to PGA VAS 
but it is scored by the patients themselves.  
6.3.6 Costing 
The costing was performed from societal perspective based on data on resource utilizations 
provided by the patients and their dermatologist in the questionnaire. Data were collected 
about direct medical costs, direct non-medical costs and indirect costs (absenteeism and 
presenteeism). Copayments were considered as a part of direct medical costs. Official unit 
costs of the Iranian Ministry of Health were applied, where available. Timeframe of the cost 
analysis was 12 months, and the year of costs was 2016. All the costs were converted to 
Euros on an exchange rate of EUR 1 = IRR 42,000. 
6.3.6.1 Direct medical costs 
Data were collected from patients on the number of GP visits in the past one month, the 
number of dermatologist visits in the past three months and the number of hospitalizations 
over the past 12 months. According to the Iranian General Physicians’ Association cost of a 
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GP visit and a dermatologist outpatient visit are €5.34 and €8.21, respectively (2017h) (Table 
20). The daily average cost of hospitalization may vary according to the type of hospital in 
Iran. The daily rate is the lowest in governmental hospitals (€31.71/day), followed by public 
hospitals (€45.95/day), whereas the cost may be as high as €85.71/day in private hospitals. 
In this study, all hospitalizations were considered at a public hospital rate. On average 
fourteen days of inpatient stays were calculated for each hospitalization. 
Cost of ambulance transportation may again vary across different cities (2017a). For the 
capital, Tehran it is estimated to €23.81 per occasion (one-way trip). In comparison the price 
is about €19.05 n other larger cities, whereas €14.29 in smaller towns. As no data were 
collected regarding transportation to physician visits or to hospital, this cost item was not 
included in the cost calculation. 
The patients’ dermatologist provided data on the treatments applied in the past 12 months. 
Costs of drugs and topical treatments (i.e. ointments) were based on official pharmacy list 
prices. Where multiple generic products were available, the drug with lowest price was 
considered. Furthermore, patients answered questions about spa or a neuropath visits or any 
other treatments/services used, and also indicated the monthly amount payed for these. 
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Table 20 Unit healthcare costs in Iran (2016) 
 
  Unit cost in 
IRR (2016) 
Unit cost in 
EUR 
(2016)* 
Direct medical costs     
Cost of a GP visit 220,000 5.24 
Cost of an outpatient dermatologist visit 345,000 8.21 
Cost of hospitalization per day   
Governmental 1,332,000 31.71 
Public 1,930,000 45.95 
Private 3,600,000 85.71 
Cost of ambulance transportation per occasion   
Tehran 1,000,000 23.81 
Large cities  800,000 19.05 
Other cities  600,000 14.29 
Direct non-medical costs   
Cost of informal care per hour 143,571 3.42 
Transportation costs   
Cost of traveling 1 km by car 6,000-12,000  0.14-0.29 
Cost of public transportation (return ticket) 5,000-14,000 0.12-0.33 
Cost of traveling 1 km by train 500 0.01 
Indirect costs (productivity loss)   
Average hourly gross wage 157,143 3.74 
*EUR 1 = IRR 42,000 as of 01/02/2017 Source: http://www.ircurrency.com/, (2017f) 
6.3.6.2 Direct non-medical costs 
Direct non-medical costs may include costs of informal caregivers and transportations other 
than ambulance. To estimate costs of informal care, patients were asked to indicate how many 
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hours of help they receive from informal caregivers such as family members or friends on a 
weekly average. Cost of informal care per hour was calculated at a rate of €3.42/hour. 
Unit costs for transportation are provided in Table 20. Traveling 1 km by car in Iran costs 
approximately €0.14 to €0.29 depending on various factors, such as the type of car and fuel 
used. Price of a return bus ticket using public transportation amounts to €0.12 to €0.33 
depending on the distance and the city. Traveling 1 km by train costs approximately €0.01 in 
Iran. In this study, only cost of informal care represents the direct non-medical costs, due to 
the lack of resource utilization data of transportation.  
6.3.6.3 Indirect costs 
The costs of productivity loss due to psoriasis were estimated by employing the Human 
Capital Approach based on patients’ responses on the Work Productivity and Activity 
Impairment questionnaire. (Braakman-Jansen et al., 2012) 
The WPAI (Work Productivity and Activity Impairment) questionnaire is used to assess the 
impact of diseases on work productivity. (Reilly et al., 1993) Psoriasis patients indicated the 
hours actually worked in the past week, the hours missed by cause of psoriasis and other 
reasons, and indicated the degree to which psoriasis affected productivity while working on 
an 11-point rating scale. 
Both costs of absenteeism (working hours missed due to psoriasis) and presenteeism (reduced 
productivity while at work due to psoriasis) were calculated. The average gross hourly wage 
(€3.74/hour) was applied for the cost calculation. 
6.3.7 Data analysis 
Data analysis and cost calculation were performed using SPSS version 20.0 (SPSS Inc., 
Chicago, IL, USA). At first, descriptive statistics were implemented. Data were not normally 
distributed and therefore, the nonparametric Mann-Whitney U-test or Kruskal-Wallis test 
were used to test for differences in EQ-5D, EQ VAS, DLQI and PASI within subgroups of 
patients. Spearman’s correlation was applied to evaluate the relationship between the 
outcome measures. Also, bivariate linear regression was formulated to analyze the 
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relationship between the general HRQOL measures EQ-5D and EQ VAS, and the disease 
specific instrument DLQI (mapping). 
 Results 
 
6.4.1 Patient characteristics 
Altogether 62 patients and their dermatologist completed the questionnaire. Mean age was 
40.40 (SD 17.53, range 16-86), with 75.8 % males (Table 21). The mean disease duration 
was 13.60 (SD 11.37) years. Twenty-four (38.7%) participants were normal weight, 25 
(40.3%) were overweight, 5 (8.1%) were indicated obese based on their Body Mass Index 
(BMI) score. Regarding the number of affected body sites, 27 (43.5%), 20 (32.3%) and 14 
(22.6%) patients reported involvement of 1-2, 3-4 and 5-7 regions, respectively. Most 
common localizations were ankles (38.7%), elbows (38.7%), knees (33.9%), forearms 
(33.9%), feet/legs (32.3%), face (27.4%), hands/palms (24.2 %), and neck/décolletage (22.6 
%).  
In total, 66.1% of the patients were diagnosed with chronic plaque psoriasis followed by 
scalp psoriasis 35.5%, palmoplantar involvement 27.4%, inverse psoriasis 25.8%, guttate 
psoriasis 19.4%, and nail psoriasis 19.4 %. Overall, 30 (48.4%) patients used only topical 
therapy in the last 12 months and 24 (38.7%) patients received systemic non-biological 
therapy, of whom 16 also applied topicals (Table 21). 
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Table 21 Characteristics of the psoriasis patient population (n=62) 
 N, % or mean, SD 
Males (n, %) 47 (75.8%) 
Age, years (mean, SD) 40.40 (17.53) 
Medical history  
Psoriasis duration, years (mean, SD) 13.60 (11.37) 
Body mass index - BMI, kg/m2 (mean, SD) 25.66 (3.29) 
Localization of psoriatic lesions (n, %)  
Ankles 24 (38.7%) 
Armpits 11 (17.7%) 
Elbows 24 (38.7%) 
Face/forehead 17 (27.4%) 
Forearms 21 (33.9%) 
Feet/legs 20 (32.3%) 
Groin 11 (17.7%) 
Hand/palm 15 (24.2%) 
Inframammary fold 3 (4.8%) 
Knees 21 (33.9%) 
Neck/décolletage  17 (22.6%) 
Number of body sites affected (n, %)  
1-2 27 (43.5%) 
3-4 20 (32.3%) 
5-7 14 (22.6%) 
Clinical types (n, %)  
Chronic plaque psoriasis 41 (66.1%) 
Erythrodermic psoriasis 3 (4.8%) 
Inverse psoriasis  16 (25.8%) 
Guttate psoriasis 12 (19.4%) 
Nail psoriasis 12 (19.4%) 
Palmoplantar psoriasis 17 (27.4%) 
Psoriatic arthritis 3 (4.8%) 
Pustular psoriasis 2 (3.2%) 
Scalp psoriasis 22 (35.5%) 
Treatment in the last 12 months (n, %)  
Systemic non-biological* 24 (38.7%) 
Methotrexate 21 (33.9%) 
Retinoid 4 (6.5%) 
Only topical* 30 (48.4%) 
Corticosteroid 30 (48.4%) 
Calcipotriol  8 (12.9%) 
Salicylic acid 1 (1.6%) 
None 6 (9.7%) 
* Combinations may have occurred. 
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6.4.2 Health-related quality of life and disease severity 
Mean EQ-5D, EQ VAS, DLQI and PASI scores were 0.62 (SD 0.37), 60.18 (27.26), 10.19 
(SD 6.46) and 12.94 (SD 8.28), respectively (Table 22). Average PGA VAS was found 
significantly lower than self-assessed disease severity VAS (34.66 vs 53.60, p<0.001). In 
terms of the five underlying dimensions of EQ-5D, 17.7%, 25.8%, 27.5%, 62.9%, and 62.9% 
marked having some or severe problem in mobility, self-care, usual activities, 
pain/discomfort and anxiety/depression, respectively (Figure 15).  
Table 22 Quality of life and disease severity of the Iranian psoriasis patients 
 
 N, % or mean, SD 
EQ-5D score (–0.594 to 1) 0.62 (0.37) 
EQ VAS (0-100) 60.18 (27.26) 
DLQI (0-30) 10.19 (6.46) 
PASI (0-72) 12.94 (8.28) 
PGA VAS (0 –100 mm) 34.66 (22.63) 
Self-assessed disease severity VAS (0–100 mm) 53.60 (26.72) 
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Figure 15 Proportion of the patients reporting problem in EQ-5D domains 
 
 
 
HRQOL and disease severity results of subgroups are presented in Table 22. No significant 
HRQOL difference was noted between males and females. Amongst clinical types, chronic 
plaque psoriasis patients showed the best or the second best general health state measured 
with any instrument; however this difference was not statistically significant. Nail psoriasis 
was associated with the highest HRQOL impairment in EQ-5D, EQ VAS and DLQI scores, 
neither this was significant. Besides, scalp psoriasis patients indicated significantly higher 
disease severity compared to the other clinical types (PASI=16.27, p<0.05). HRQOL was 
found significantly worse in those who had more body sites affected assessed by any outcome 
measure. To focus on localization of psoriatic lesions, patients with neck/décolletage 
involvement showed significantly higher HRQOL reduction in either instruments. Also 
psoriasis on feet/legs was related to fairly low EQ-5D and high PASI scores (0.46 and 16.54).  
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Comparing patients based on their treatment applied in the last 12 months, those who 
received only topical therapy reported better HRQOL, although this difference was proven 
significance only regarding PASI scores (Table 23). 
Table 23 Subgroup analysis of EQ-5D, EQ VAS, DLQI and PASI scores 
 
Variables 
Mean (SD) 
EQ-5D EQ VAS DLQI PASI 
Sex 
Female 0.71(0.22) 57.07(26.56) 8.07(4.65) 11.47(5.97) 
Male 0.60(0.40) 61.20(27.69) 10.87(6.84) 13.40(8.90) 
Clinical types 
Chronic plaque psoriasis 0.66(0.36) 61.49(26.67) 10.37(5.92) 13.57(8.10) 
Inverse psoriasis  0.55(0.33) 55.31(29.52) 11.87(6.59) 15.36(10.24) 
Guttate psoriasis 0.59(0.37) 46.36(27.67) 12.17(7.59) 16.13(8.09) 
Nail psoriasis 0.47(0.38) 54.09(25.38) 13.00(7.48) 14.25(8.33) 
Palmoplantar psoriasis 0.52(0.43) 72.19(21.05)* 11.29(7.49) 13.35(5.95) 
Scalp psoriasis 0.57(0.36) 57.14(29.01) 11.82(7.97) 16.27(8.16)* 
Number of body sites affected 
1-2 0.77(0.24)* 69.3(24.02)* 7.52(4.75)* 9.17(6.43)* 
3-4 0.60(0.41)* 57.89(27.86)* 9.75(6.20)* 14.89(9.10)* 
5-7 0.38(0.40)* 46.43(28.45)* 15.64(6.74)* 18.11(6.83)* 
Localization of the lesions 
Ankles 0.61(0.40) 58.33(29.91) 11.08(7.38) 15.01(7.54) 
Armpits 0.54(0.43) 45.91(27.82) 14.00(8.15) 15.93(6.84) 
Elbows 0.64(0.33) 54.79(27.92) 10.50(5.92) 15.41(8.31) 
Face/forehead 0.53(0.42) 55.59(28.61) 11.65(6.45) 15.33(9.91) 
Feet/legs 0.46(0.44)* 53.95(28.51) 12.10(7.59) 16.54(10.17)* 
Forearms 0.57(0.42) 51.57(31.73) 12.14(7.55) 16.47(8.03)* 
Groin 0.75(0.25) 63.64(24.50) 7.36(4.86) 10.86(5.57) 
Hands/palms 0.54(0.52) 64.64(26.05) 12.73(8.19) 15.01(8.90) 
Knees 0.52(0.39) 59.33(30.45) 10.81(6.23) 13.26(7.17) 
Neck/décolletage  0.36 (0.49)* 45.00(30.57)* 16.21(7.17)* 18.65(9.65)* 
Treatment in the last 12 months 
Topical 0.73 (0.23) 62.37 (25.13) 9.03 (4.81) 10.82 (6.62)* 
Systemic non-biological 0.46 (0.47) 56.30 (30.50) 12.83 (7.96) 16.77 (9.58)* 
*Mann-Whitney U test or Kruskal-Wallis test p <0.05. For DLQI and PASI ‘0’ and for all 
other measures, the highest value is the best possible outcome.  
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Correlations between EQ-VAS, DLQI, PASI, PGA VAS and self-assessed disease severity 
VAS are described in Table 24.  
Both EQ-5D and EQ VAS showed a moderate negative correlation with DLQI (rs = -0.44 for 
both, p < 0.001), and PGA VAS as well as self-assessed disease severity VAS (rs = -0.35 for 
both, p < 0.01). Only EQ VAS was significantly associated with PASI (rs = -0.31, p < 0.01), 
however no significant association was reported with EQ-5D. Moderate positive correlations 
were found between DLQI, PASI, PGA VAS, and self-assessed disease severity VAS, This 
relationship was shown to be stronger compared to those with either EQ-5D or EQ VAS.  
 
Table 24 Spearman’s correlations between the outcome measures 
 
 
EQ-5D 
score (-0.59-
1) 
EQ 
VAS 
(0-100) 
DLQI PASI 
PGA 
VAS 
EQ VAS (0-100) 0.41* - -0.44* -0.31* 
-
0.51* 
DLQI (0-30) -0.44* -0.44* - 0.58* 0.61* 
PASI (0-72) -0.12 -0.31* 0.58* - 0.58* 
PGA VAS (0–100 mm) -0.35* -0.51* 0.55* 0.58* - 
Self-assessed disease 
severity VAS (0–100 mm) 
-0.35* -0.54* 0.48* 0.48* 0.55* 
*Spearman’s rho significant p< 0.05. For EQ-5D and EQ-VAS the lowest value, whereas for 
all other measures the highest value is the worst possible outcome. 
 
6.4.3 Comparison of HRQOL in psoriasis patients to the Iranian general 
population 
One of the main advantages of the EQ-5D questionnaire is that being a generic measure of 
HRQOL results of patients can be compared to those of the general population in countries 
where population norms are available. In Iran, Karyani et al. published an EQ-5D-3L 
population norm in 2016. (Karyani et al., 2016) They surveyed overall 600 members of the 
general population who had health insurance in Tehran, Iran.  
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The comparison of the health status by EQ-5D dimensions between psoriasis patients and the 
age-matched general population (40-49 years) is presented in Figure 16. 
Figure 16 Comparison of the proportion of problems across the five domains of the EQ-
5D-3L in psoriasis patients and the age-matched general population 
 
 
Source: (Karyani et al., 2016) 
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In the mobility dimension the rate of reporting problems was approximately equal among 
psoriasis patients and the general public (18% vs 22%). In the other four dimensions, 
considerably more problems occurred among psoriasis patients. Whereas few members of 
the general population reported severe problems in any dimension, psoriasis patients more 
often had such problems; for example, 16% in anxiety depression and 13% in pain 
discomfort. 
6.4.4 Mapping EQ-5D utilities 
A simple linear regression with EQ-5D as a function of the total DLQI score was performed 
(Fig. 4). Figure 17 shows a scatter plot of EQ-5D as a function of DLQI. 
The black diagonal line in Figure 17 is the regression line and consists of the predicted score 
on EQ-5D for each possible value of DLQI. The distance between the points and the 
regression line represents the errors of predication. As it shows there are many points that are 
near the regression line; that shows the error of prediction for those points are small. Linear 
relationship of DLQI onto both EQ-5D and EQ-VAS was estimated: EQ-5D= 0.88 – 
0.02*DLQI (adjusted r2=0.213, ANOVA p< 0.001), EQ-VAS= 80.14 – 1.98 * DLQI 
(adjusted r2=0.206, ANOVA p< 0.001). Thus, 1 point increase in the DLQI results in 0.02 
point decrease in the EQ-5D and 1.98 points decrease in EQ VAS. The DLQI score explained 
22.6% of variance of EQ-5D and 22 % of the variance of EQ-VAS (Figure 17 and Figure 
18). 
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Figure 17 Scatterplot and a linear relationship between EQ-5D and DLQI 
 
 
Figure 18 Scatterplot and a linear relationship between EQ-VAS and DLQI  
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6.4.5 Resource utilization in Iranian psoriasis 
Table 25 presents the data on healthcare utilization of the patient population. Out of the 62 
psoriasis patients, 16 (26%) used GP visit and 44 (71%) outpatient dermatologist visit. 
Overall 20 patients (34%) were hospitalized due to psoriasis in the past 12 months.  
Table 25 Healthcare resource utilization in psoriasis patients 
 
Cost categories N  Utilization 
(mean, SD) 
Utilization 
(median) 
Direct medical costs     
GP visit (occasions/1 month) 16 0.42 (0.92) 0 
Outpatient dermatologist visit (occasions/3 months) 44 1.27 (1.36) 1 
Hospitalisation (occasions / year) 20 1.05 (1.90) 0 
Direct non-medical costs    
Informal care (hours/week) 18 2.11 (4.74) 0 
Indirect costs (productivity loss)    
Absenteeism (hours/week) 8 3.6 (11.26) 0 
Presenteeism (hours/week) 22 7.75 (14.57) 0 
 
Eighteen patients (29%) used informal care. A mean of 2.11 (SD 4.74) hours of informal care 
were utilized weekly (Figure 19). The maximum hours of informal care used was 25 hours a 
week. 
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Figure 19 Informal care utilization in psoriasis patients (hours/week) 
 
 
Overall 8 patients (18%) missed from work due to psoriasis. The mean weekly working hours 
missed were 3.6 (SD 11.26) (Figure 20). 
Figure 20 Absenteeism in psoriasis patients (hours/week) 
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Overall 22 patients (35%) were bothered by their disease at work. The mean weekly working 
hours lost due to presenteeism were 7.75 (SD 14.57) (Figure 21). 
Figure 21 Presenteeism in psoriasis patients (hours/week) 
 
 
 
6.4.6 Cost-of-illness of psoriasis in Iran 
Total annual per patient cost of psoriasis in Iran in 2016 was 141,664,957 Rial, which equates 
to €3,373 (SD €4,757). Mean per patient annual costs in Rial are presented in Table 26, while 
in EUR in Table 27. 
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Table 26 Annual costs of psoriasis in Iran in IRR (2016) 
 
Health care utilisation and 
costs 
Mean annual 
costs (SD) 
Median Minimum Maximum 
TOTAL COSTS 141,664,957 
(199,792,454) 
63,042,872 0 817,432,16
4 
Direct medical costs 33,131,694 
(53,765,564) 
5,670,000 0 237,820,00
0 
GP visit  1,107,097 
(2,416,216) 
0 0 10,560,000 
Outpatient dermatologist visit 1,758,387 
(1,872,746) 
0 0 8,280,000 
Hospitalisation 28,327,419 
(51,413,111) 
0 0 216,160,00
0 
Drugs and ointments 1,919,032 
(3,169,851) 
180,000 0 17,580,000 
Spa 2,097 0 0 70,000 
Neuropath visit 6,129 (31,485) 0 0 240,000 
Other 11,532 (26,820) 0 0 100,000 
Direct non-medical costs 15,774,285 
(35,409,141) 
0 0 171,710,91
6 
Informal care 15,774,285 
(35,409,141) 
0 0 171,710,91
6 
Indirect costs (productivity 
loss) 
92,758,978 
(170,200,439) 
0 0 808,972,16
4 
Absenteeism 29,390,810 
(91,967,982) 
0 0 490,286,16
0 
Presenteeism 63,368,168 
(119,095,947) 
0 0 416,743 
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Table 27 Annual costs of psoriasis in Iran in EUR (2016) 
 
  Mean annual costs 
(SD) 
Median Minimu
m 
Maximum 
TOTAL COSTS 3372.98 (4756.96) 1501.01 0 19,462 
Direct medical costs 788.85 (1280.13) 135.00 0 5662.38 
GP visit  26.36 (57.53) 0 0 251.43 
Outpatient dermatologist 
visit 
41.87 (44.59) 0 
0 
197.14 
Hospitalization 674.46 (1224.12) 0 0 5146.67 
Drugs and ointments 45.69 (75.47) 4.29 0 418.57 
Spa 0.05 (0.26) 0 0 1.67 
Neuropath visit 0.15 (0.75) 0 0 5.71 
Other 0.27 (0.64) 0 0 2.38 
Direct non-medical costs 375.58 (843.07) 0 0 4088.36 
Informal care 375.58 (843.07) 0 0 4088.36 
Indirect costs (productivity 
loss) 
2208.55 (4052.39) 0 0 19,261.24 
Absenteeism 699.78 (2189,71) 0 0 11673.48 
Presenteeism 1508.77 (2835.61) 0 0 9922.46 
 
Direct medical, direct non-medical and indirect costs were €789, €376 and €2209, 
representing 23%, 11% and 65% of the total costs, respectively. Hospitalizations were 
responsible for the majority of direct medical costs (€674; 85%), which accounted for about 
one-fifth of the total per patient costs of psoriasis. Costs of drugs and ointments were about 
€46 annually, which takes less than 6% of direct medical costs. Per patient annual costs of 
outpatient visits and GP visits were €42 and €26, respectively. Other costs including spa and 
neuropath visits were negligible (Table 27). Overall, €376 was attributable to informal care, 
which represented 11% of the total costs. The highest costs were related to productivity loss. 
Total indirect costs amounted to €2209, with a share of €700 (32%) and €1509 (68%) 
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between absenteeism and presenteeism, respectively. Absenteeism and presenteeism were 
responsible for 21% and 45% of the total per patient annual cost of psoriasis in Iran (Figure 
22). 
Figure 22 Distribution of cost across cost categories in psoriasis in Iran 
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 Discussion 
 
6.5.1 Comparison with previous studies on HRQOL from Iran 
To our knowledge, this is the first study from Iran that measured HRQOL with EQ-5D and 
EQ VAS. Considerable general HRQOL impairment experienced by psoriasis patients was 
observed expressed either in EQ-5D (0.62) or in EQ VAS (60.18). Previous studies from Iran 
have mainly used non-preference-based outcome measures; nevertheless, these instruments 
except for SF-36 are not feasible to calculate utilities that can be used in economic 
evaluations. In a survey by Ghajarzadeh et al. involving 100 psoriasis patients with mean age 
of 36.2 years reported SF-36 and DLQI scores of 59.8 (SD 19.8) and 12.8 (SD 6.1), 
respectively. (Ghajarzadeh et al., 2012) Ansar et al. reported mean SF-36 score 65.05 (SD 
15.51) of 100 psoriasis patients with mean age of 40.45 years. (Ansar et al., 2013) (However, 
none of these two studies calculated utilities from SF-36 scores. Aghaei et al. described 
HRQOL of mean 28 (SD 10.66), 10.3 (SD 5.2), and 11.35 (SD 6.00) scores on PDI2, DLQI, 
and PASI, respectively in 125 chronic plaque psoriasis patients. (Aghaei et al., 2009) In a 
study of Zandi et al. 97 psoriasis patients with mean age of 35.3 years were characterized by 
mean HRQOL of 14.1 on DLQI and 18.6 scores on PASI, respectively. (Zandi et al., 2011)  
Amongst the 5 dimensions beyond the EQ-5D score, 62.9% patients reported having some 
or severe problems in anxiety/depression and pain/discomfort (Figure 15). This seems 
consistent with earlier evidences that suggested prevalence of clinical depression about 
69.4% amongst Iranian psoriasis patients. (Layegh et al., 2010) This is also supported by 
findings of Ghajarzadeh et al. where average BDI3 score of psoriasis patients was observed 
17.1 (SD 12.3) which approximates the upper borderline between mild and moderate 
depression. (Ghajarzadeh et al., 2012) 
Interestingly, psoriasis on the face and/or forehead was not accompanied by significantly 
worse HRQOL compared to other body sites measured with any instrument including PASI. 
                                                 
2 ranges from 0 to 45, where higher score refer to worse HRQOL 
3 ranges from 0 to 63, where higher score refers to worse depression state 
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This finding contradicts to results of a recent Iranian research where authors argued that facial 
psoriasis patients had significantly higher PASI scores compared to those without facial 
involvement. (Keshavarz et al., 2013) In an earlier Iranian study conducted by Zandi et al. 
erythrodermic and pustular types of psoriasis were predictors of the greatest HRQOL 
impairment measured by DLQI (22.3 and 20.8 scores); nonetheless the comparison of our 
results with these evidences is hampered by the very small patient number in these subgroups 
of our study. (Zandi et al., 2011) 
Females of our survey showed better HRQOL measured with EQ-5D, DLQI or PASI but not 
significantly. In contrast, a recently published study from Iran pointed out that female patients 
reported significantly lower scores in SF-36 than males. (Ansar et al., 2013) 
Analyzing the correlations between the outcome measures revealed moderate correlation 
between the general measure of EQ-5D and EQ VAS and disease-specific DLQI and PASI. 
Not unexpectedly, disease-specific tools (DLQI, PASI, PGA VAS, self-assessed disease 
severity VAS) correlated with each other stronger than with EQ-5D or EQ VAS. The 
relationship of DLQI and PASI in psoriasis was discussed in a prior study from Iran and 
found lower DLQI related higher PASI scores (p<0.001) but authors did not report 
correlation coefficient between these two measures. (Zandi et al., 2011) 
 It is notable that average PGA VAS was found significantly lower than self-assessed disease 
severity VAS (34.66 vs 53.60, p<0.001) and suggests an immense discrepancy in disease 
perception between patients and their physician. Thus, more attention should be paid on 
assessment of patients’ HRQOL that might also support finding the optimal treatment 
choices.  
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6.5.2 Comparison of HRQOL findings between the findings of Iranian and the 
Hungarian study 
A very similar questionnaire to this survey was used to assess HRQOL and costs of 
Hungarian moderate-to-severe psoriasis patients by Herédi et al. and Balogh et al. (Heredi et 
al., 2014, Balogh et al., 2014); therefore we can compare some main findings of these two 
studies.  
A comparison between the findings of Iranian and Hungarian studies are summarized in 
Table 28, Table 29, Table 30 and Table 31. (Balogh et al., 2014, Heredi et al., 2014, Moradi 
et al., 2015) 
Mostly the same cross-sectional questionnaire survey was carried out in two countries, Iran 
and Hungary. Details of the questionnaire and little difference between the questionnaires 
explained in study design part (6.2.1). Altogether 200 adult psoriasis patients enrolled from 
two Hungarian university clinics and 62 from an Iranian clinic. Besides HRQOL assessment, 
data on demographics, applied treatments, affected body sites and clinical types were 
collected. Mean age of the Hungarian and Iranian patients were 51.2 ±12.9 years with 69% 
males, and 40.4±17.5 years with 76% males, respectively. (Table 28) 
Table 28 Characteristics of the Hungarian and Iranian patients  
 
 Hungary Iran 
N 200 62 
Age (mean, SD) 51.2 (12.9) 40.4 (17.5) 
Males % 69% 76% 
BMI (mean, SD) 29.89 (5.44) 25.66 (3.29) 
Disease duration 
(mean, SD) 
21.96 (11.67) 13.60 (11.37) 
 
First of all, it should be highlighted, that more than half of the Hungarian patients used 
systemic biological therapy in the last 12 months but none in the Iranian study. Amongst the 
Hungarian patients 18% used none or only topical therapy in the last 12 months, 31% 
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systemic non-biological treatment and 52% biologicals, whereas in Iran 48% of the patients 
applied only topicals and 39% treated with non-biological systematic therapy.  
Mean EQ-5D, DLQI and PASI of the Hungarian and the Iranian sample were 0.69±0.3, 
6.29±7.3, 8.01±10, and 0.62±0.37, 10±6.5, 13±8.3, respectively (Table 29). In both 
researches, psoriatic lesions on the neck/décolletage were associated with the highest 
HRQOL impairment (p<0.05). In this current study a very likely explanation for this is that 
out of the 17 patients with neck/décolletage involvement, 10 reported skin lesions on 5-7 
body sites. Regarding clinical types, in Hungary the palmoplantar involvement while in Iran 
nail psoriasis patients reported the worst general HRQOL (mean EQ-5D scores: 0.36±0.3 
and 0.47±0.4). In Iran patients received only topical therapy in the last 12 months reported 
better HRQOL, compared to those on systemic non-biological treatment while in Hungary, 
patients on biologicals reported the best HRQOL. (Heredi et al., 2014)  
Table 29 Health-related quality of life and disease severity of Hungarian and Iranian 
patients 
 
 Hungary Iran 
Health-related quality of life and disease severity (mean, SD) 
EQ-5D 0.69 (0.3) 0.62 (0.37) 
DLQI 6.29 (7.3) 10 (6.5) 
PASI 8.1 (10) 13 (8.3) 
Treatment (during the last 12 months)  
None or topical therapy 18% 48% 
Systematic non-biological 31% 39% 
Biological 51% 0% 
 
Correlation between EQ-5D and DLQI was found very similar across the two countries (rs=-
0.43- and -0.44, p<0.001), but EQ-5D showed significant correlation with PASI (rs=-0.43, 
p<0.001) only in Hungary. (Table 29) Strong positive correlation was identified between 
DLQI and PASI in both countries but only in those patients who received systemic therapy: 
Iran (rs=0.72, p<0.001) and Hungary (systemic non-biological: rs=0.65, p<0.001, biological: 
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rs=0.76, p<0.001). Correlation between EQ-5D and DLQI was found very similar across the 
two countries (rs=-0.43- and -0.44, p<0.001), but EQ-5D showed significant correlation with 
PASI (rs=-0.43, p<0.001) only in Hungary (Table 29).  
A strong positive correlation was identified between DLQI and PASI in both countries but 
only in those patients who received systemic therapy: Iran (rs=0.72, p<0.001) and Hungary 
(systemic non-biological: rs=0.65, p<0.001, biological: rs=0.76, p<0.001). (Table 30) 
Table 30 Spearman’s correlations between the outcome measures in Iran and 
Hungary 
 
Countries IRAN HUNGARY 
Measures 
EQ-5D 
score 
(-0.59-1) 
DLQ
I 
PASI 
EQ-5D 
score 
(-0.59-1) 
DLQI PASI 
EQ VAS (0-
100) 
0.41* 
-
0.44* 
-
0.31* 
0,56* -0,43 
-
0,42* 
DLQI (0-30) -0.44* - 0.58* -0,48* - 0,81* 
PASI (0-72) -0.12 0.58* - -0,43* 0,81* - 
*Significant p<0.05. For DLQI and PASI ‘0’ and for all other measures the highest value is 
the best possible outcome. 
Results of the comparison suggest that disease severity, treatments, and culture or country-
specific differences might lead to variations in the relationship between the outcomes 
measures used in psoriasis. Per patient annual costs of psoriasis in Iran and Hungary are 
compared in Table 33 by relevant cost categories. 
6.5.3 International comparison of HRQOL results 
We compared our findings to results of earlier cross-sectional studies regarding the 
relationships between the investigated HRQOL measures (Table 31). 
We noticed weak correlation between EQ-5D and PASI similarly to a paper of Norlin et al. 
from Sweden and of Blome et al. from Germany. (Norlin et al., 2012, Blome et al., 2013) EQ 
VAS correlated stronger with PASI likewise according to Blome et al. (Blome et al., 2013) 
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In the line with all of the previous studies, we identified similar moderate correlation between 
DLQI and both EQ-5D and EQ VAS. DLQI and PASI were moderately correlated with the 
value of rs=0.58 and also, Norlin et al. found similar result in Sweden. (Norlin et al., 2012) 
In a study from Iran, mean age of the patients was 40.4, however in the other studies the 
mean age of the patients were more than 50. 
EQ-5D has a greatest value in Hjortsberg et al. from Sweden and Finland (0.75) and in 
Moradi et al. from Iran has the lowest value (0.62). DLQI has the greatest value in Moradi et 
al. (10.19) and then in Blome et al. (8.6 and 7.5), Hjortsberg et al. (6.8) and the lowest value 
in from Herédi et al. (6.29). Therefore, psoriasis has more effect on Iranian patients and also 
Iranian patients have the lowest quality of life compare to the other studied countries.  
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Table 31 Comparison of the relationship between EQ-5D, DLQI and PASI with 
previous studies 
 
Author, 
year 
Country 
N (mean 
age) 
HRQOL 
and 
disease 
severity 
(mean) 
Correlations 
EQ-5D 
& 
PASI 
EQ  V
AS & 
PASI 
EQ-
5D & 
DLQI 
EQ VA
S & 
DLQI 
PASI & 
DLQI 
This 
study, 
2014 
Iran 
62 (40.4 
years) 
EQ-5D= 
0.62 
EQ 
VAS=60.1
8  
DLQI=10.1
9  
PASI=12.9
4  
-0.12 -0.31* -0.44* -0.44* 0.58* 
(Heredi 
et al., 
2014)** 
Hungary 
200 (51.2 
years) 
EQ-
5D=0.69 
EQ-
VAS=64.4
3  
DLQI=6.29  
PASI=8.01  
-0.43* -0.42* -0.48* -0.43* 0.81* 
(Blome et 
al., 2013) 
Germanyi 
Develop-
ment 
database: 
1,511 
(50.5 
years) 
EQ-
5D=77.1 
EQ 
VAS=64.4 
DLQI=8.6 
PASI=11.4 
-0.17* -0.24* - - - 
Cross-
validation 
database: 
2,009 
(51,5 
years) 
EQ-
5D=n.a. 
EQ-
VAS=64.5 
DLQI=7.5  
PASI=10.1  
(Norlin et 
al., 2012) 
Sweden 
2,450 (54 
years§) 
EQ-
5D=0.77§ 
DLQI=4§ 
PASI=4.7§ 
-0.25* - -0.55*  0.51* 
(Hjortsbe
rg et al., 
2011) 
Sweden 
163 (51 
years) 
EQ-
5D=0.75  
DLQI=6.8  
- - -0.52* -0.50* - 
Finland 
110 (53 
years) 
* indicates a statistical significance of p<0.05  
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6.5.4 Comparison with other EQ-5D studies in Iran  
A research conducted on 28 March 2017 on US National Library of Medicine, National 
Institutes of Health (Pubmed database, https://www.ncbi.nlm.nih.gov/pubmed/) to identify 
previous studies using the EQ-5D in Iran. The research detail was “eq-5d[All Fields] AND 
("iran"[MeSH Terms] OR "Iran"[All Fields])”.  
Sixteen studies were found. Five numbers of studies were not related to Iran and Iranian, so 
as a result only 11 of them remained (Table 32). 
The earliest study was published in year 2012, 2 studies in 2013, one study in 2014, 2 studies 
in 2015 and 5 studies in 2016. Our psoriasis study was among the 11 studies that were 
identified. (Moradi et al., 2015) 
One study used EQ-5D and demographic questionnaire in their study on haemodialysis 
patients (Saffari et al., 2013). The other 10 studies used EQ-5D along with other kinds of 
methods or questionnaires, such as socio-demographic questionnaires, SF-36, TTO, VAS, 
DLQI, PASI, Type 2 Diabetes and Health Promotion Scale (T2DHPS). (Seyedifar et al., 
2016, Karyani et al., 2016, Yousefi et al., 2016, Goudarzi et al., 2016, Assadi&Afshari, 2016, 
Javanbakht et al., 2015, Moradi et al., 2015, Saffari et al., 2015, Hosseini Nejhad et al., 2013, 
Javanbakht et al., 2012) 
A cross-sectional analytical study was conducted by Karyani et al. to measure HRQOL in B-
thalassemia patients using ED-5D along with information about participants' demographic, 
socioeconomic, and health status was gathered. (Karyani et al., 2016) Another study also 
used ED-5D with information about participants' demographic in order to conduct their 
survey on patients with type 2 diabetes. (Saffari et al., 2015) 
Six studies used Visual Analogue Scale (VAS) along with ED-5D including the paper we 
published. (Seyedifar et al., 2016, Goudarzi et al., 2016, Hosseini Nejhad et al., 2013, 
Javanbakht et al., 2012, Moradi et al., 2015, Assadi&Afshari, 2016) 
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Table 32 EQ-5D studies in Iran 
 Author, 
year 
Method used Population 
studied 
Sampl
e size 
Mean 
EQ-5D 
score 
Mean EQ 
VAS score 
1 (Seyedifar et 
al., 2016) 
EQ-5D-3L Beta 
Thalassemia 
528  0.85  
(SD 
0.01) 
72.5  
(SD 0.81) 
2 (Karyani et 
al., 2016)  
EQ-5D-3L General 
population 
600 0.74 
(SD 
0.16) 
N/A 
 
3 (Yousefi et 
al., 2016) 
EQ-5D-5L, SF-6D Breast cancer 163 0.685 
(0.216) 
N/A 
4 (Goudarzi et 
al., 2016) 
EQ-5D-3L, VAS General 
population 
869  N/A 79.58 (SE 
0.54) 
5 (Assadi& 
Afshari, 
2016) 
TTO, VAS, EQ-
5D-3L, EQ VAS 
Acute 
poisoning 
82 N/A 45-81   
6 (Javanbakht 
et al., 2015) 
EQ-5D-3L, EQ 
VAS, SF-36 
Beta 
Thalassemia 
196 0.86 
(95% 
CI: 0.83-
0.89) 
71.85 (95% 
CI: 69.13-
74.58) 
 
7 (Moradi et 
al., 2015) 
EQ-5D-3L, EQ 
VAS, DLQI, PASI 
Psoriasis 62 0.62 
(0.37) 
60.18 
(27.26) 
8 (Saffari et 
al., 2015) 
Type 2 Diabetes 
and Health 
Promotion Scale 
(T2DHPS), EQ-5D-
3L 
Type 2 
diabetes  
368  N/A N/A 
9 (Hosseini 
Nejhad et al., 
2013) 
EQ-5D-3L, VAS Type 2 
diabetes 
3472  N/A N/A 
10 (Saffari et 
al., 2013) 
EQ-5D-3L Haemodialysi
s 
362 Males: 
0.71 (SD 
0.33), 
Females: 
0.59 (SD 
0.45)  
Males: 
64.01 (SD 
16.61) 
Females: 
0.479 
Female 
65.47 (SD 
21.72) 
11 (Javanbakht 
et al., 2012) 
EQ-5D-3L, VAS Type 2 
diabetes 
3472 0.70 
(95% CI 
0.69-
0.71) 
56.8 (95% 
CI 56.15-
57.5) 
N/A: not available - scores were not reported in the study, only psychometric properties, e.g. 
correlations with other HRQOL instruments. 
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The SF-36 measures general health in clinical studies and SF-6D is a classification for 
describing health derived from a section of SF-36. Yousefi and et al. compared the 
performance of the EQ-5D and the SF-6D in different state of breast cancer. (Yousefi et al., 
2016) Another cross-sectional study, gathered data by using a socio-demographic 
questionnaire, EQ-5D, and SF-36 instruments on patients with β-thalassemia. (Javanbakht et 
al., 2015) 
Mean EQ-5D-3L index score in psoriasis patients was 0.62, which is lower than experienced 
by patients with type 2 diabetes (0.70), breast cancer (0.69) and beta thalassemia (0.86) 
patients In Iran (Table 32). 
6.5.5 Comparison of cost-of-illness in psoriasis patients in Iran and Hungary 
Comparison of annual per patient costs of psoriasis in Iran and Hungary are presented in 
Table 33. 
Table 33 Comparison of annual cost in psoriasis in Iran and Hungary 
 
  Mean EUR (SD) 
Iran (2016) 
Hungary (2012)  
(Balogh et al., 2014) 
 N=62 N=200 
TOTAL COSTS 3,373 9,254 
Direct medical costs 789 (23%) 7,595 (82%) 
GP visit  26 (0.8%) 22 (0.2%) 
Outpatient dermatologist visit 42 (1%) 36 (0.4%) 
Hospitalizations 674 (20%) 136 (1%) 
Topical and systemic non-biological therapy 46 (1%) 256 (3%) 
Biological therapy - 7,339 (79%) 
Spa 0.05 (0.001%) - 
Other 0.36 (0.01%) 60 (0.7%) 
Direct non-medical costs 376 (11%) 148 (2%) 
Informal care 376 (11%) 117 (1%) 
Transportation N/A 31 (0.3%) 
Indirect costs (productivity loss) 2,209 (65%) 1,255 (14%) 
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Total per patient costs of psoriasis were almost three-fold in Hungary compared to Iran 
(€9,254 vs. €3,373). The large difference in costs is attributable to the application of 
biological therapy in approximately 50% of the Hungarian sample. The major driver of costs 
in Iran was productivity loss (65%), while biological therapy in Hungary (79%). However, 
in Hungary the second largest cost item after biological therapy was productivity loss, 
accounting for 14% of the total costs. As opposed to Hungary, where biologics represented 
the largest part of direct medical costs, in Iran hospitalizations were responsible for 85% of 
the direct medical costs and 20% of the total costs. Costs of hospitalizations were almost 5 
times higher in Iran (€674) compared to Hungary (€136). Interestingly, in Iran costs of 
informal care (€376) also accounted for over times of that in Hungary (€117). (Mean annual 
cost of informal caregiving was €3.0 in Hungary and €3.42 in Iran. (Balogh et al., 2014) The 
comparison between the two countries clearly demonstrates how biological therapy has 
changed the management of psoriasis patients over the past decade. Biological therapy is 
very costly, nevertheless it reduces the number of hospitalizations, and therefore decrease the 
productivity loss in these patients; moreover less is spent on informal caregiving. 
6.5.6 Comparison of cost-of illness of psoriasis and other diseases in Iran 
Results of the most recent cost-of-illness studies from Iran in other diseases are summarized 
in Table 34. It seems that per patient annual costs of psoriasis are similar to that of chronic 
hepatitis B infection, but reasonably less than liver cirrhosis, hepatocellular carcinoma, breast 
cancer, gastric cancer, common variable immunodeficiency or thalassemia major. However, 
many chronic diseases such as diabetes, irritable bowel syndrome, gastro-oesophageal reflux 
(GERD) and dyspepsia account for significantly lower per patient annual costs in comparison 
with psoriasis. It can be expected, nevertheless that annual per patient costs in a sample of 
psoriasis patients with high rate of biological therapy would double or triple the costs 
observed in our study.  
A more precise and detailed comparison of other studies in Table 34 and our findings in 
psoriasis are hampered by the different perspectives of analysis, cost categories considered. 
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Table 34 Recent cost-of-illness studies in Iran 
 
Author, year Disease 
Cost categories 
included (direct 
medical, direct 
non-medical, 
indirect) 
Year 
of 
costs 
Timeframe 
Per patient 
costs 
(Kavosi et al., 
2014) 
Chronic hepatitis B 
infection Direct and indirect 2012 
 3095 USD 
Liver cirrhosis 1 year 17,483 USD 
Hepatocellular carcinoma 32,958 USD 
(Esmaeilzadeh 
et al., 2016) 
Thalassemia Major 
 
Direct medical 
costs, direct non-
medical costs, 
indirect costs 
2015 1 year 8322 USD  
(Izadi et al., 
2016) 
Gastric cancer Direct costs 2015 1 year 74,705,158 IRR 
(60,141,384 IRR 
by the insurance 
and 14,563,774 
by patients) 
(Zare et al., 
2016) 
Chronic hepatitis C  Direct costs 2015 1 year 1,626 USD 
(PPP) Liver cirrhosis 6,117 USD 
(PPP) Hepatocellular carcinoma 
(HCC)  
11,044 USD 
(PPP) 
(Sadeghi et al., 
2015) 
Common variable 
immunodeficiency 
Direct, indirect and 
intangible costs 
2015 1 year  274,200 USD 
(Moghimi-
Dehkordi et 
al., 2011b) 
 
Irritable bowel syndrome 
(IBS) 
Direct and indirect 
costs 
2006-
2007 
6 months 160 USD (PPP) 
Functional constipation 
(FC) 
147 USD (PPP) 
 Unspecified-FBD (U-
FBD) 
103 USD (PPP) 
Functional abdominal 
bloating (FAB)  
96 USD (PPP) 
Functional diarrhea (FD) 42 USD (PPP) 
(Moghimi-
Dehkordi et 
al., 2011a) 
Gastro-oesophageal reflux 
(GERD)  
Direct and 
indirect cost 
2006-
2007 
 6 months 98+14 USD 
(PPP) 
Dyspepsia 108+12 USD 
(PPP) GERD and dyspepsia 101+33 USD 
(PPP) (Esteghamati 
et al., 2009) 
Diabetes Direct and indirect 
costs 
2004 1 year 152 USD 
(Davari et al., 
2013) 
Breast Cancer  Direct medical 
costs 
2010 5 years 10,905 USD 
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6.5.7 Limitations  
Some limitations of this study should be noted. At first, sample size was quite small, however 
this study was a part of a larger study including a total of 262 psoriasis patients (200 psoriasis 
patients from Hungary and 62 from Iran). Most patients were presented with chronic plaque 
psoriasis and only a few patients involved with rare clinical types, e.g., pustular and 
erythrodermic psoriasis. All the patients treated by a single physician at a clinic in Shiraz, 
Iran. In the Iranian study, there were no inclusion criteria specified to this survey and hence, 
every patient regardless of disease severity was allowed to participate, while in the Hungarian 
study only patients with moderate-to-severe psoriasis were recruited. The cost analysis also 
has some important limitations. First, due to the retrospective study design patients might 
have had difficulties to recall all treatments and health care services they utilized. Secondly, 
no data were collected about travelling to physician’s visits or to the hospital, thus this cost 
item was not included in the cost analysis. Finally, none of the patients of this study received 
biological therapies; however, infliximab, etanercept, and adalimumab have legal license for 
distribution in Iran. As biologicals have very high costs compared to any other treatments 
applied in psoriasis, the average per patient annual costs in this study are relevant only for a 
subgroup of patients, but not the entire psoriasis patient population of the country.  
6.5.8 Conclusions 
In conclusion, this is the first study from Iran that assesses HRQOL of psoriasis patients with 
EQ-5D and EQ VAS and the first cost-of-illness study in psoriasis patients. HRQOL 
impairment measured with either EQ-5D or EQ VAS is considerable; some or severe 
problems were most frequently emerged in anxiety/depression and pain/discomfort 
dimensions. Psoriasis patients have significantly decreased HRQOL measured by the EQ-5D 
compared to the general public in Iran. Moreover, EQ-5D scores evaluated in this study 
provide country-specific data for cost-utility analyses. Annual total costs of psoriasis in Iran 
exceeds €3,000 per patient, which is considerably higher than that of diabetes, 
gastroesophageal reflux disease or irritable bowel syndrome. The major cost drivers were 
productivity loss, hospitalizations and informal care. Further researches are suggested to 
measure HRQOL and cost-of-illness in a larger sample and explore more variables that 
influence HRQOL and costs of Iranian psoriasis patients. 
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7 SUMMARY 
 
 
Specific points related to the topics of this thesis were discussed in details at the end of each 
chapter. Therefore, here I provide a brief summary of the main findings and highlight some 
points that are specifically relevant to Iran and point out some health economic and policy 
implications of the studies. 
Technological innovation has brought a remarkable development to the health care sector 
over the past decades. In recent years, breakthroughs in various clinical fields have 
contributed greatly to the quality improvements in health care and the patient's condition. 
However, due to the high costs of the new technologies, it became increasingly important to 
assess the health economic aspects of their introduction.  
The process of priority setting and its criteria in Iran's health care system is not so transparent 
and explicit like in many developing countries. Health Technology Assessment (HTA) has 
been established in the healthcare system of Iran but what is needed is a clear political will 
to push HTA objectives forward. Health system in Iran has gone through several reforms in 
the past thirty years with many challenges and successes. Generally, health-sector reforms 
should include sustainable and purposeful changes to improve efficiency, equity, and 
effectiveness, otherwise change could be harmful rather than useful. 
This thesis focused on HRQOL a key outcome in both clinical care and health economic 
analyses. HRQOL assessments rely on patients’ reports, how they perceive their life affected 
by a disease. In health economic evaluations, however, societal perspective is used to 
evaluate different health states, therefore, it is important to understand how lay people value 
different aspects of health. In our first study (Chapter 5 An empirical investigation into the 
concept of health), therefore, we investigated the notion of health among the general 
population. Results suggest that people attach high importance both to emotional and 
physical factors (e.g., positive emotional feeling, optimism, fitness) and social aspects (e.g. 
goal and harmony, love). The study revealed some further aspects that are outside the narrow 
definition of health, i.e. people reported (among other factors) security, education, social 
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responsibility, motivation, loving animals as relevant factors for health. This experimental 
study highlights how broad the concept of health can be across individuals and points out the 
importance of involving patients in medical decision-making by exploring their thoughts, 
perspective and needs regarding their health and treatment. More importantly, these findings 
open a nice avenue for further research by raising the question whether the health state 
evaluations (e.g. the EQ-5D questionnaire) used for health economic analyses sufficiently 
represent and cover all the important aspects that the society considers highly relevant for 
health. 
Concept of health and the importance people attach to different attributes of it, how people 
perceive health, is highly influenced by cultural factors. These factors also can affect peoples’ 
health related lifestyle, their decisions on participation in health care and acceptance of 
treatments. Therefore, subjective reports on health, the HRQOL results found in one 
jurisdiction are not necessarily applicable in other countries. Hence, the second empirical 
study (Chapter 6 Health-related quality of life and cost-of-illness of psoriasis patients in Iran) 
of this thesis aimed to adapt a Hungarian disease burden survey to Iran, in order to assess the 
HRQOL of Iranian patients with psoriasis and compare with the Hungarian results. Psoriasis 
is a lifelong dermatological chronic disease. Biological drugs have been developed in the 
past decades for the treatment of psoriasis and revolutionized psoriasis care being more 
effective than traditional treatments. However, biological drugs have put economic pressure 
on the societies due to their high costs. Availability and financing of these agents highly 
varies between countries, thus the benefits also bring challenges and concerns about the value 
for money. Nevertheless, there is very little information on the HRQOL and economic impact 
of the disease in the international literature, and practically none in Iran. Little is known on 
how people in Iran perceive psoriasis, how it affects their health, including their 
beauty/attractiveness perception, whether the disease has stigma effects and/or deterioration 
in sociability – aspects that can vary substantially between cultures and societies and thus 
cannot be directly transferred from one country to another. Moreover, there is a lack of 
HRQOL and cost data that hampers cost-effectiveness analyses based on country-specific 
inputs. 
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Our findings revealed that the negative impact on patients’ HRQOL was higher for men than 
women. In addition, the impact on HRQOL increased with the number of body areas involved 
by the disease. The highest negative impact on HRQOL was observed when the skin of the 
neck/décolletage region or hands were involved, and the lowest when the groin was affected. 
Comparison between the findings of Iranian and Hungarian study revealed that, disease 
severity, treatments, and culture or country-specific differences might lead to variations in 
the relationship between the outcome measures used in psoriasis. Furthermore, the study 
provided the first cost results in psoriasis in Iran. Average annual per patient costs of psoriasis 
exceed €3,300 with the main cost drivers are productivity loss, hospitalizations and informal 
care. With the widespread use of biologics to treat psoriasis in Iran, the costs are expected to 
soar, whereas based on experiences from other countries less hospitalizations, better HRQOL 
outcomes and less missed work hours can be expected. 
This research has various economic and health policy implications for Iran. Although 
biological drugs brought the potential to dramatically change the management of patients 
with psoriasis, in Iran, access to biological drug treatment is limited. Due to the high cost of 
biological drugs, most of the patients cannot have access to the biologic therapies. Lack of 
insurance coverage of the biological drugs can lead to economic problems for the patient in 
obtaining them. Private companies (not related to the state) import these kinds of medicines 
and due to the frequent change of the currency value, the price of imported drugs are unstable. 
I believe that our findings can contribute to the improvement of psoriasis care by highlighting 
that this chronic skin disease imposes high burden on the individuals and has significant 
economic impact to the society. Moreover, our study provides reliable input data for cost-
effectiveness analyses of biological drugs that can support sustainable financing decisions 
and long-term health planning. Our experiences with adapting a disease burden survey from 
another country to Iran can serve as a useful experience for other clinical fields with lack of 
HRQOL and disease burden data. 
  
  143 
8 PUBLICATIONS RELATED TO THE THESIS 
 
 
Published papers 
MORADI, M., RENCZ, F.: GULÁCSI, L., MORADI, A., BROSZKY, V. (2015): Health 
status and quality of life in patients with psoriasis: Iranian cross-sectional survey. Arch Iran 
Med. 18(3), pp. 153-9. doi: 0151803/AIM.004. IF 0.931 
MAGYARI-BECK I., MORADI M. (2014): Creative Techniques in the Framework of 
Market and Evolution. Society and Economy 36:(4) pp. 565-577. doi: 
10.1556/SocEc.36.2014.4.7 
MORADI, M., KOVÁCS, Á. (2017): Az egészségügyi forrás allokáció aktuális kérdései 
Iránban; egészségügyi technológiaelemzés. Köz-gazdaság. [accepted for publication] 
 
Other publications 
Poster presentations 
MORADI, M. (2013): Pricing and reimbursement of pharmaceuticals in Iran. Value in 
Health, 16(7), pp. A474-A475., Presented at: International Society for Pharmacoeconomics 
and Outcomes Research (ISPOR) 16th Annual European Congress, 2-6 November 2013, 
Dublin, Ireland 
 
BRODSZKY, V., MORADI, M., GULÁCSI, L., BAJI, P., BALOGH, O., PÉNTEK, M. 
(2013): Indirect comparison of the biologics in patients with psoriasis; a meta-analysis of 
randomized, double blind clinical trials in bayesian framework. Value in Health 16(7), pp. 
A501-A502.  
Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 
16th Annual European Congress, 2-6 November 2013, Dublin, Ireland 
  144 
MORADI, M., RENCZ, F. (2014): A comparative cross-sectional study on health-related 
quality of life in psoriasis from Hungary and Iran. Value in Health, 17(7), p. A612., Presented 
at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th 
Annual European Congress, 8-12 November 2014, Amsterdam, The Netherlands 
Conference papers 
MORADI, M. (2013): Health system in Iran. PhD student conference at Corvinus University 
of Budapest, 30 May 2013 
MORADI, M. (2014): Evaluation of the quality of life in patients with psoriasis; cross 
sectional study from Iran. Corvinus Health Policy and Health Economics Conference Series 
2014/2, at Corvinus University of Budapest, 31 March 2014 
MAGYARI-BECK I., MORADI M. (2014): An empirical investigation into the concept of 
health. [Гигиена Культуры.Здоровье культуры – культура здоровья]. Working paper 
presented at the Russian Conference. Budapest, 2014. 10. 14 – 19. Location: Russian Cultural 
Centre.  
  145 
9 REFERENCES 
 
 
ABBASI, M. (2012): Ethics in health technology assessment. Bioethics Journal, 2, pp. 101-
116. 
AGHAEI, S., MORADI, A. & ARDEKANI, G. S. (2009): Impact of psoriasis on quality of 
life in Iran. Indian J Dermatol Venereol Leprol, 75, p. 220. 
AKAY, A., PEKCANLAR, A., BOZDAG, K. E., ALTINTAS, L. & KARAMAN, A. (2002): 
Assessment of depression in subjects with psoriasis vulgaris and lichen planus. J Eur 
Acad Dermatol Venereol, 16, pp. 347-352. 
AKOBUNDU, E., JU, J., BLATT, L. & MULLINS, C. D. (2006): Cost-of-illness studies: a 
review of current methods. Pharmacoeconomics, 24, pp. 869-890. 
AKSOY, B., ALTAYKAN-HAPA, A., EGEMEN, D. & ATAKAN, N. (2011): Indicators of 
health quality in 154 Turkish patients with psoriasis. J Dermatol, 38, pp. 600-603. 
AL-MAZEEDI, K., EL-SHAZLY, M. & AL-AJMI, H. S. (2006): Impact of psoriasis on 
quality of life in Kuwait. Int J Dermatol, 45, pp. 418-424. 
AL ROBAEE, A. A. & ALZOLIBANI, A. A. (2011): Narrowband ultraviolet B phototherapy 
improves the quality of life in patients with psoriasis. Saudi Med J, 32, pp. 603-606. 
ALI, F. M. & CUEVA, A. C. (2017): A systematic review of the use of quality-of-life 
instruments in randomized controlled trials for psoriasis. Br J Dermatol, 176, pp. 577-
593. 
ALTUNAY, I. K., ATIS, G., ESEN, K. & KUCUKUNAL, A. (2014): Impact of functional 
pruritus compared with mild psoriasis on quality of life: a cross-sectional 
questionnaire study in Turkey. Am J Clin Dermatol, 15, pp. 365-370. 
AMMAR-KHODJA, A., BENKAIDALI, I., BOUADJAR, B., SERRADJ, A., TITI, A., 
BENCHIKHI, H., et al. (2015): EPIMAG: International Cross-Sectional 
Epidemiological Psoriasis Study in the Maghreb. Dermatology, 231, pp. 134-144. 
ANSAR, A., JAHANGARD, L., PAHLEVANI, P., RASOULI, B., TORABIAN, S. & 
RASOULI, S. (2013): Quality of life in patients with psoriasis vulgaris: A case-
control study. Dermatology and Cosmetic, 4, pp. 113-119. 
ANSARIPOUR, A., UYL-DE GROOT, C., STEENHOEK, A. & REDEKOP, W. (2014): 
The Drug Reimbursement Decision-Making System in Iran. Value in Health 
Regional Issues, 3C, pp. 174-181. 
ARAB-ZOZANI, M., HABIB JALILIAN, H., OSKOUEI, M., DEHGHANIAN, M. & 
AGHBALAGHI, Z. (2017): Implementing health technology assessment in Iran: a 
stakeholder analysis. BMJ Open 7, pp. A1–A78. 
ARNESEN, T. M. & NORHEIM, O. F. (2003): Quantifying quality of life for economic 
analysis: time out for time tradeoff. Med Humanit, 29, pp. 81-86. 
ARYANKHESAL, A., SHELDON, T. A. & MANNION, R. (2013): Role of pay-for-
performance in a hospital performance measurement system: a multiple case study in 
Iran. Health Policy Plan, 28, pp. 206-214. 
  146 
ASSADI, R. & AFSHARI, R. (2016): Suicidal Attempt With Intentional Poisoning Seems a 
Comorbid Illness With an Increased Burden. Int J High Risk Behav Addict, 5, p. 
e24380. 
ATAKAN, N., YAZICI, A. C., OZARMAGAN, G., INALOZ, H. S., GURER, M. A., 
SABUNCU, I., et al. (2016): TUR-PSO: A cross-sectional, study investigating 
quality of life and treatment status of psoriasis patients in Turkey. J Dermatol, 43, pp. 
298-304. 
BAGHESTANI, S., ZARE, S. & MAHBOOBI, A.-A. (2005): Skin disease patterns in 
Hormozgan, Iran. International Journal of Dermatology, 44, pp. 641-645. 
BAHADORI, M., RAVANGARD, R., ALIMOHAMMADZADEH, K. & HOSSEINI, S. M. 
(2015): Plan and road map for health reform in Iran. Bmj, 351, p. h4407. 
BALCI, D. D., INANDI, T., DOGRAMACI, C. A. & CELIK, E. (2009): DLQI scores in 
patients with keloids and hypertrophic scars: a prospective case control study. J Dtsch 
Dermatol Ges, 7, pp. 688-692. 
BALOGH, O., BRODSZKY, V., GULACSI, L., HEREDI, E., HERSZENYI, K., JOKAI, 
H., et al. (2014): Cost-of-illness in patients with moderate to severe psoriasis: a cross-
sectional survey in Hungarian dermatological centres. Eur J Health Econ, 15(Suppl 
1), pp. S101-109. 
BALTA, I., KARADAG, A. S., SELEK, S., ONDER, S., KANBAY, A. & BURAKGAZI-
YILMAZ, H. (2016): General psychiatric symptoms, quality of sleep, and coping 
strategies in patients with psoriasis vulgaris. Int J Dermatol, 55, pp. 60-64. 
BARADARAN-SEYED, Z. & MAJDZADEH, R. (2012): Evidence-Based Health Care, Past 
Deeds at a Glance, Challenges and the Future Prospects in Iran. Iranian J Publ Health, 
41, pp. 1-7. 
BARAN, R. (2010): The burden of nail psoriasis: an introduction. Dermatology, 221(Suppl 
1), pp. 1-5. 
BARATI MARNANI, A., TEYMOURZADEH, E., BAHADORI, M., RAVANGARD, R. & 
SAEID POUR, J. (2012): Challenges of a large health insurance organization in iran-
A qualitative study. International Journal of Collaborative Research on Internal 
Medicine & Public Health  
BASAKHA, M., YAVARI, K., SADEGHI, H. & NASERI, A. (2014): Health care cost 
disease as a threat to Iranian aging society. J Res Health Sci, 14, pp. 152-156. 
BASAVARAJ, K. H., NAVYA, M. A. & RASHMI, R. (2011): Stress and quality of life in 
psoriasis: an update. Int J Dermatol, 50, pp. 783-792. 
BASRA, M. K., FENECH, R., GATT, R. M., SALEK, M. S. & FINLAY, A. Y. (2008): The 
Dermatology Life Quality Index 1994-2007: a comprehensive review of validation 
data and clinical results. Br J Dermatol, 159, pp. 997-1035. 
BEHESHTIAN, M., KHOSRAVI, A., OLYAEEMANESH, A., MALEKAFZALI, H., 
BONAKDAR ESFAHANI, S., HOSSEINY GHAVAMABAD, L., et al. (2015): 
Developing a household survey tool for health equity: A practical guide in Islamic 
Republic of Iran. Med J Islam Repub Iran, 29, p. 305. 
BELLIENI, C. (2014): Sport, Disability and an Original Definition of Health. Zenit 
BERGER, K., EHLKEN, B., KUGLAND, B. & AUGUSTIN, M. (2005): Cost-of-illness in 
patients with moderate and severe chronic psoriasis vulgaris in Germany. J Dtsch 
Dermatol Ges, 3, pp. 511-518. 
BEYER, V. & WOLVERTON, S. E. (2010): Recent trends in systemic psoriasis treatment 
costs. Arch Dermatol, 146, pp. 46-54. 
  147 
BHOSLE, M. J., KULKARNI, A., FELDMAN, S. R. & BALKRISHNAN, R. (2006): 
Quality of life in patients with psoriasis. Health and Quality of Life Outcomes, 4, pp. 
35-35. 
BILAC, C., ERMERTCAN, A. T., BILAC, D. B., DEVECI, A. & HORASAN, G. D. (2009): 
The relationship between symptoms and patient characteristics among psoriasis 
patients. Indian J Dermatol Venereol Leprol, 75, pp. 551. 
BILGIC, A., BILGIC, O., AKIS, H. K., ESKIOGLU, F. & KILIC, E. Z. (2010): Psychiatric 
symptoms and health-related quality of life in children and adolescents with psoriasis. 
Pediatr Dermatol, 27, pp. 614-617. 
BLAXTER, M. Health. (2010), Polity. Cambridge. 
BLOME, C., BEIKERT, F. C., RUSTENBACH, S. J. & AUGUSTIN, M. (2013): Mapping 
DLQI on EQ-5D in psoriasis: transformation of skin-specific health-related quality 
of life into utilities. Arch Dermatol Res, 305, pp. 197-204. 
BOCCUZZI, S. J. (2003): Indirect Health Care Costs. In: WEINTRAUB, W. S. (ed.) 
Cardiovascular Health Care Economics. Humana Press. Totowa, NJ: 
BOEHNCKE, W. H. & SCHON, M. P. (2015): Psoriasis. Lancet, 386, pp. 983-994. 
BORMAN, P., TOY, G. G., BABAOGLU, S., BODUR, H., CILIZ, D. & ALLI, N. (2007): 
A comparative evaluation of quality of life and life satisfaction in patients with 
psoriatic and rheumatoid arthritis. Clin Rheumatol, 26, pp. 330-334. 
BRAAKMAN-JANSEN, L., TAAL, E., KUPER, I. & VAN DE LAAR, M. (2012): 
Productivity loss due to absenteeism and presenteeism by different instruments in 
patients with RA and subjects without RA. Rheumatology (Oxford) 51, pp. 354-361. 
BRAZIER, J. E., YANG, Y., TSUCHIYA, A. & ROWEN, D. L. (2010): A review of studies 
mapping (or cross walking) non-preference based measures of health to generic 
preference-based measures. Eur J Health Econ, 11, pp. 215-225. 
BRODSZKY, V., BAJI, P., BALOGH, O. & PENTEK, M. (2014): Budget impact analysis 
of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six 
Central and Eastern European countries. Eur J Health Econ, 15(Suppl 1), pp. S65-71. 
BRODSZKY, V., RENCZ, F., PENTEK, M., BAJI, P., LAKATOS, P. L. & GULACSI, L. 
(2016): A budget impact model for biosimilar infliximab in Crohn's disease in 
Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia. Expert Rev 
Pharmacoecon Outcomes Res, 16, pp. 119-125. 
BRONSARD, V., PAUL, C., PREY, S., PUZENAT, E., GOURRAUD, P. A., ARACTINGI, 
S., et al. (2010): What are the best outcome measures for assessing quality of life in 
plaque type psoriasis? A systematic review of the literature. J Eur Acad Dermatol 
Venereol, 24(Suppl 2), pp. 17-22. 
BYFORD, S., TORGERSON, D. J. & RAFTERY, J. (2000): Cost of illness studies. BMJ : 
British Medical Journal, 320, pp. 1335-1335. 
CAKMUR, H. & DERVIS, E. (2015): The relationship between quality of life and the 
severity of psoriasis in Turkey. Eur J Dermatol, 25, pp. 169-176. 
CARRASCOSA, J. M., PUJOL, R., DAUDEN, E., HERNANZ-HERMOSA, J. M., 
BORDAS, X., SMANDIA, J. A., et al. (2006): A prospective evaluation of the cost 
of psoriasis in Spain (EPIDERMA project: phase II). J Eur Acad Dermatol Venereol, 
20, pp. 840-845. 
CHAN, B., HALES, B., SHEAR, N., HO, V., LYNDE, C., POULIN, Y., et al. (2009): Work-
related lost productivity and its economic impact on Canadian patients with moderate 
to severe psoriasis. J Cutan Med Surg, 13, pp. 192-197. 
  148 
CHANDRAN, V. & RAYCHAUDHURI, S. P. (2010): Geoepidemiology and environmental 
factors of psoriasis and psoriatic arthritis. J Autoimmun, 34, pp. J314-321. 
CHERAGHALI, A. (2006): Iran pharmaceutical market. Iran J. Pharm. Res, pp. 1-7. 
CHERAGHALI, A. (2016): Newly Defined Role of Pharmacoeconomics in Iran National 
Medicine Policy. Shiraz E-Med J, 17, p. e35258. 
CHERAGHALI, A. M. (2013): Impacts of international sanctions on Iranian pharmaceutical 
market. Daru, 21, pp. 64. 
CHERAGHALI, A. M. (2017): Trends in Iran Pharmaceutical Market. Iran J Pharm Res, 16, 
pp. 1-7. 
CHUANG, L. H. & WHITEHEAD, S. J. (2012): Mapping for economic evaluation. Br Med 
Bull, 101, pp. 1-15. 
CLEVERLEY, W. O. & CAMERON, A. E. Essentials of Health Care Finance. (2007), Jones 
& Bartlett Learning. Sudbury, Massachusetts. 
COLOMBO, G. L., ALTOMARE, G. F., PERIS, K., MARTINI, P., QUARTA, G., 
CONGEDO, M., et al. (2008): Moderate and severe plaque psoriasis: cost-of-illness 
study in Italy. Therapeutics and Clinical Risk Management, 4, pp. 559-568. 
Constitution of the Islamic Republic of Iran. (1979). 
COOPER, B. S. & RICE, D. P. (1976): The economic cost of illness revisited. Soc Secur 
Bull, 39, pp. 21-36. 
CURRIE, C. J. & CONWAY, P. (2007): PSK11 evaluation of the association between EQ5D 
utility and dermatology life quality index (DLQI) score in patients with psoriasis. 
Value in Health, 10, pp. A470-A471. 
CZIMBALMOS, Á., NAGY, Z., VARGA, Z. & HUSZTIK, P. (1999): Páciens 
megelégedettségi vizsgálat. Népegészségügy, LXXX, pp. 4-19. 
CSÍKSZENTMIHÁLYI, M. Flow The psychology of optimal experience (1990), 
Harperprennial. New York.  
DAKIN, H. (2013): Review of studies mapping from quality of life or clinical measures to 
EQ-5D: an online database. Health Qual Life Outcomes, 11, pp. 151. 
DALIENTO, L., MAPELLI, D. & VOLPE, B. (2006): Measurement of cognitive outcome 
and quality of life in congenital heart disease. Heart, 92, pp. 569-574. 
DAVARI, M., HAYCOX, A. & WALLEY, T. (2012): The Iranian health insurance system; 
past experiences, present challenges and future strategies. Iran J Public Health, 41, 
pp. 1-9. 
DAVARI, M., YAZDANPANAH, F., ASLANI, A., HOSSEINI, M., NAZARI, A. R. & 
MOKARIAN, F. (2013): The Direct Medical Costs of Breast Cancer in Iran: 
Analyzing the Patient's Level Data from a Cancer Specific Hospital in Isfahan. Int J 
Prev Med, 4, pp. 748-754. 
DE KORTE, J., SPRANGERS, M. A., MOMBERS, F. M. & BOS, J. D. (2004): Quality of 
life in patients with psoriasis: a systematic literature review. J Investig Dermatol 
Symp Proc, 9, pp. 140-147. 
DEHNAVIEH, R., NOORI HEKMAT, S., SEPEHRIAN, R., GHORBANI NIA, R. & 
SHARIFI, T. (2015): Systematic review of prioritization criteria for topics of HTA 
projects: suggestions for Iran Journal of Novel Applied Sciences, 4, pp. 940-946. 
DEMIREL, R., GENC, A., UCOK, K., KACAR, S. D., OZUGUZ, P., TOKTAS, M., et al. 
(2013): Do patients with mild to moderate psoriasis really have a sedentary lifestyle? 
Int J Dermatol, 52, pp. 1129-1134. 
  149 
DEVRIMCI-OZGUVEN, H., KUNDAKCI, T. N., KUMBASAR, H. & BOYVAT, A. 
(2000): The depression, anxiety, life satisfaction and affective expression levels in 
psoriasis patients. J Eur Acad Dermatol Venereol, 14, pp. 267-271. 
DINARVAND, R. (2009): New National Drug Policy in Iran leading to Expanded 
Pharmaceutical Market and Extended Access of Public to Medicines. Iranian Journal 
Public health, 38, pp. 158-161. 
DOAEE, S., OLIYAEEMANESH, A., NEJATI, M., MOBINIZADEH, M., ABOEE, P. & 
EMAMI RAZAVI, S. H. (2012): Establishment of health technology assessment in 
Iran Journal of Family and Reproductive Health 6, pp. 73-78. 
DOLAN, P. (1997): Modeling valuations for EuroQol health states. Med Care, 35, pp. 1095-
1108. 
DONG, J. & GOLDENBERG, G. (2017): New biologics in psoriasis: an update on IL-23 
and IL-17 inhibitors. Cutis, 99, pp. 123-127. 
DORMAN, P. J., WADDELL, F., SLATTERY, J., DENNIS, M. & SANDERCOCK, P. 
(1997): Is the EuroQol a Valid Measure of Health-Related Quality of Life After 
Stroke? Stroke, 28, pp. 1876-1882. 
DOSHMANGIR, L., RASHIDIAN, A., JAFARI, M., TAKIAN, A. & RAVAGHI, H. (2015): 
Opening the Black Box: The Experiences and Lessons From the Public Hospitals 
Autonomy Policy in Iran. Arch Iran Med, 18, pp. 416-424. 
DRIESSEN, R. J., BISSCHOPS, L. A., ADANG, E. M., EVERS, A. W., VAN DE 
KERKHOF, P. C. & DE JONG, E. M. (2010): The economic impact of high-need 
psoriasis in daily clinical practice before and after the introduction of biologics. Br J 
Dermatol, 162, pp. 1324-1329. 
EDLUND, M. J. So What's Your Definition of Health? (2012) Available from: 
https://www.psychologytoday.com/blog/getting-healthy-now/201205/so-whats-
your-definition-health [Last accessed: 04/23/2017]. 
EL-DAROUTI, M. A., GAWDAT, H. I., HEGAZY, R. A., TAWDY, A. M., FAWZY, M. 
M. & ABDEL HALIM, D. M. (2015): Crude Coal Tar and Ultraviolet (UV) A 
radiation (Modified Goeckerman Technique) in Treatment of Psoriasis. Acta 
Dermatovenerol Croat, 23, pp. 165-170.  
Emergency Medical Services: Tariffs and Mandates for Private Ambulance Centers. (2017a) 
Available from: http://fouriyat.ir/ [Last accessed: 22/08/2017]. 
ESKIN, M., SAVK, E., USLU, M. & KUCUKAYDOGAN, N. (2014): Social problem-
solving, perceived stress, negative life events, depression and life satisfaction in 
psoriasis. J Eur Acad Dermatol Venereol, 28, pp. 1553-1559. 
ESMAEILI, R., HADIAN, M., RASHIDIAN, A., SHARIATI, M. & GHADERI, H. (2014): 
Family medicine in Iran: facing the health system challenges. Glob J Health Sci, 7, 
pp. 260-266. 
ESMAEILZADEH, F., AZARKEIVAN, A., EMAMGHOLIPOUR, S., AKBARI SARI, A., 
YASERI, M., AHMADI, B., et al. (2016): Economic Burden of Thalassemia Major 
in Iran, 2015. J Res Health Sci, 16, pp. 111-115. 
ESMAIL, E. S., ASAL, F. H., YUSSIF, M. & ELFERT, A. A. (2015): Low dose ribavirin 
has been effective in the treatment of incapacitating muco-cutaneous extrahepatic 
manifestations in patients with hepatitis C with contraindication or no access for 
approved antiviral treatment. Arab J Gastroenterol, 16, pp. 125-128. 
  150 
ESTEGHAMATI, A., KHALILZADEH, O., ANVARI, M., MEYSAMIE, A., ABBASI, M., 
FOROUZANFAR, M., et al. (2009): The economic costs of diabetes: a population-
based study in Tehran, Iran. Diabetologia, 52, pp. 1520-1527. 
European Medicines Agency Evaluation of Medicines for Human Use. Guideline on clinical 
investigation of medicinal products indicated for the treatment of psoriasis (2004) 
Available from: 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/200
9/09/WC500003329.pdf [Last accessed: 23/04/2017]. 
EUROQOLGROUP. (1990): EuroQol--a new facility for the measurement of health-related 
quality of life. Health Policy, 16, pp. 199-208. 
FACEY, K. (2006): Health Technology Assessment (HTA) Glossary In: TOPFER, L.A., 
CHAN, L. (eds.) Health Technology Assessment. INAHTA Secretariat. Stockholm. 
FAZAELI, S., AHMADI, M., RASHIDIAN, A. & SADOUGHI, F. (2014): A framework of 
a health system responsiveness assessment information system for iran. Iran Red 
Crescent Med J, 16, p. e17820. 
FELDMAN, B. M., GRUNDLAND, B., MCCULLOUGH, L. & WRIGHT, V. (2000): 
Distinction of quality of life, health related quality of life, and health status in children 
referred for rheumatologic care. J Rheumatol, 27, pp. 226-233. 
FELDMAN, S. R. (2000): Advances in Psoriasis Treatment. Dermatology Online Journal, 6, 
p. 4. 
FERRANS, C. E., ZERWIC, J. J., WILBUR, J. E. & LARSON, J. L. (2005): Conceptual 
model of health-related quality of life. J Nurs Scholarsh, 37, pp. 336-342. 
FERREIRA, B. I., ABREU, J. L., REIS, J. P. & FIGUEIREDO, A. M. (2016): Psoriasis and 
Associated Psychiatric Disorders: A Systematic Review on Etiopathogenesis and 
Clinical Correlation. J Clin Aesthet Dermatol, 9, pp. 36-43. 
FINLAY, A. Y. (2005): Current severe psoriasis and the rule of tens. Br J Dermatol, 152, pp. 
861-867. 
FINLAY, A. Y. & KHAN, G. K. (1994): Dermatology Life Quality Index (DLQI)--a simple 
practical measure for routine clinical use. Clin Exp Dermatol, 19, pp. 210-216. 
FONIA, A., JACKSON, K., LEREUN, C., GRANT, D. M., BARKER, J. N. & SMITH, C. 
H. (2010): A retrospective cohort study of the impact of biologic therapy initiation 
on medical resource use and costs in patients with moderate to severe psoriasis. Br J 
Dermatol, 163, pp. 807-816. 
FOURNIER, M. F. (2012): Knowledge mobilization in the context of health technology 
assessment: an exploratory case study. Health Res Policy Syst, 10, p. 10. 
FREDRIKSSON, T. & PETTERSSON, U. (1978): Severe psoriasis--oral therapy with a new 
retinoid. Dermatologica, 157, pp. 238-244. 
GARRIDO, M. V., ORGANIZATION, W. H., SYSTEMS, E. O. O. H. & POLICIES. Health 
Technology Assessment and Health Policy-making in Europe: Current Status, 
Challenges and Potential. (2008), World Health Organization. 
GBD Mortality and Causes of Death Collaborators (2016): Global, regional, and national life 
expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 
1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. 
Lancet, 388, pp. 1459-1544. 
Georgetown University. National Center for Cultural Competence. Definitions of Health, 
Illness and Sickness. (2017b) Available from: 
  151 
https://nccc.georgetown.edu/body_mind_spirit/definitions_health_sickness.html 
[Last accessed: 23/04/2017]. 
GHAJARZADEH, M., GHIASI, M. & KHEIRKHAH, S. (2012): Associations between skin 
diseases and quality of life: a comparison of psoriasis, vitiligo, and alopecia areata. 
Acta Med Iran, 50, pp. 511-515. 
GHASSEMI, S. & DEHNAVIEH, R. (2016): Applying the results of Health Technology 
Assessment reports in developing countries, the pale face of coin. Technol Health 
Care, 24, pp. 781-782. 
GHATNEKAR, O., LJUNGBERG, A., WIRESTRAND, L. E. & SVENSSON, A. (2012): 
Costs and quality of life for psoriatic patients at different degrees of severity in 
southern Sweden - a cross-sectional study. Eur J Dermatol, 22, pp. 238-245. 
GINSBURG, I. H. & LINK, B. G. (1989): Feelings of stigmatization in patients with 
psoriasis. J Am Acad Dermatol, 20, pp. 53-63. 
GLADMAN, D. D., ANTONI, C., MEASE, P., CLEGG, D. O. & NASH, P. (2005): Psoriatic 
arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis, 
64(Suppl 2), pp. 14-17. 
GODLEE, F. (2011): What is health? BMJ, 343, p. d4817. 
GOKDEMIR, G., ARI, S. & KOSLU, A. (2008): Adherence to treatment in patients with 
psoriasis vulgaris: Turkish experience. J Eur Acad Dermatol Venereol, 22, pp. 330-
335. 
GOLICKI, D., NIEWADA, M., HOUT, B. V., JANSSEN, M. F. & PICKARD, A. S. (2014): 
Interim EQ-5D-5L Value Set for Poland: First Crosswalk Value Set in Central and 
Eastern Europe. Value in Health Regional Issues, 4, pp. 19-23. 
GONZALEZ, J., CUNNINGHAM, K., PERLMUTTER, J. & GOTTLIEB, A. (2016): 
Systematic Review of Health-Related Quality of Life in Adolescents with Psoriasis. 
Dermatology, 232, pp. 541-549. 
GOODMAN, C. S. HTA 101: Introduction to Health Technology Assessment. (2004), 
publisher not identified. 
GOUDARZI, R., ZERAATI, H., AKBARI SARI, A., RASHIDIAN, A. & MOHAMMAD, 
K. (2016): Population-Based Preference Weights for the EQ-5D Health States Using 
the Visual Analogue Scale (VAS) in Iran. Iran Red Crescent Med J, 18, p. e21584. 
GRAD, F. P. (2002): The Preamble of the Constitution of the World Health Organization. 
Bulletin of the World Health Organization, 80, pp. 981-981. 
GROSS, P. R., LEVITT, N. & LEWIS, M. W. The Flight from Science and Reason. (1996), 
New York Academy of Sciences. New York. 
GULACSI, L., BONCZ, I. & DRUMMOND, M. (2004): Issues for countries considering 
introducing the "fourth hurdle": the case of Hungary. Int J Technol Assess Health 
Care, 20, pp. 337-341. 
GULÁCSI, L., BRODSZKY, V., BAJI, P., RENCZ, F. & PÉNTEK, M. (2017): The 
Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact 
Analysis in 28 European Countries. Adv Ther (Advances in Therapy), 34, pp. 1128-
1144. 
GULER, S., TEKATAS, A., ARICAN, O., KAPLAN, O. S. & DOGRU, Y. (2015): Restless 
legs syndrome and insomnia frequency in patients with psoriasis. Ideggyogy Sz, 68, 
pp. 331-336. 
GUPTA, M. A., GUPTA, A. K. & HABERMAN, H. F. (1987): Psoriasis and psychiatry: an 
update. Gen Hosp Psychiatry, 9, pp. 157-166. 
  152 
GUSI, N., OLIVARES, P. R. & RAJENDRAM, R. (2010): The EQ-5D Health-Related 
Quality of Life Questionnaire. In: PREEDY, V. R. & WATSON, R. R. (eds.) 
Handbook of Disease Burdens and Quality of Life Measures. Springer. New York. 
GUTKNECHT, M., KRENSEL, M. & AUGUSTIN, M. (2016): Health economic analyses 
of psoriasis management: a systematic literature search. Arch Dermatol Res, 308, pp. 
601-616. 
HAIDER, S., WAHID, Z., NAJAM US, S. & RIAZ, F. (2014): Efficacy of Methotrexate in 
patients with plaque type psoriasis. Pakistan Journal of Medical Sciences, 30, pp. 
1050-1053. 
HAJIZADEH, M. & NGHIEM, H. S. (2011): Out-of-pocket expenditures for hospital care 
in Iran: who is at risk of incurring catastrophic payments? Int J Health Care Finance 
Econ, 11, pp. 267-285. 
HENSHALL, C., OORTWIJN, W., STEVENS, A., GRANADOS, A. & BANTA, D. (1997): 
Priority setting for health technology assessment. Theoretical considerations and 
practical approaches. Priority setting Subgroup of the EUR-ASSESS Project. Int J 
Technol Assess Health Care, 13, pp. 144-185. 
HERDMAN, M., GUDEX, C., LLOYD, A., JANSSEN, M. F., KIND, P., PARKIN, D., et 
al. (2011): Development and preliminary testing of the new five-level version of EQ-
5D (EQ-5D-5L). Quality of Life Research, 20, pp. 1727-1736. 
HEREDI, E., RENCZ, F., BALOGH, O., GULACSI, L., HERSZENYI, K., HOLLO, P., et 
al. (2014): Exploring the relationship between EQ-5D, DLQI and PASI, and mapping 
EQ-5D utilities: a cross-sectional study in psoriasis from Hungary. Eur J Health Econ, 
15(Suppl 1), pp. S111-119. 
HJORTSBERG, C., BERGMAN, A., BJARNASON, A., HEIKKILA, H., HJELMGREN, J., 
SVENSSON, A., et al. (2011): Are treatment satisfaction, quality of life, and self-
assessed disease severity relevant parameters for patient registries? Experiences from 
Finnish and Swedish patients with psoriasis. Acta Derm Venereol, 91, pp. 409-414 
HODGSON, T. A. & MEINERS, M. R. (1982): Cost-of-Illness Methodology: A Guide to 
Current Practices and Procedures. The Milbank Memorial Fund Quarterly. Health 
and Society, 60, pp. 429-462. 
HONGBO, Y., THOMAS, C. L., HARRISON, M. A., SALEK, M. S. & FINLAY, A. Y. 
(2005): Translating the science of quality of life into practice: What do dermatology 
life quality index scores mean? J Invest Dermatol, 125, pp. 659-664. 
HOSSEINI NEJHAD, Z., MOLAVI VARDANJANI, H., ABOLHASANI, F., HADIPOUR, 
M. & SHEIKHZADEH, K. (2013): Relative effect of socio-economic status on the 
health-related quality of life in type 2 diabetic patients in Iran. Diabetes Metab Syndr, 
7, pp. 187-190. 
HUBER, M., KNOTTNERUS, J. A., GREEN, L., VAN DER HORST, H., JADAD, A. R., 
KROMHOUT, D., et al. (2011): How should we define health? BMJ, 343, pp. d4163. 
HURST, N. P., JOBANPUTRA, P., HUNTER, M., LAMBERT, M., LOCHHEAD, A. & 
BROWN, H. (1994): Validity of EuroQol—a generic health status instrument—in 
patients with rheumatoid arthritiseconomic and health outcomes research group. 
Rheumatology, 33, pp. 655-662. 
HYLAND, M. E. (1997): Quality-of-life measures as providers of information on value-for-
money of health interventions. Comparison and recommendations for practice. 
Pharmacoeconomics, 11, pp. 19-31. 
  153 
ILLYÉS, G. Kháron ladikján (In Charon’s Boat). (1976), Szépirodalmi könyvkiadó. 
Budapest, Hungary. 
INANIR, I., AYDEMIR, O., GUNDUZ, K., DANACI, A. E. & TUREL, A. (2006): 
Developing a quality of life instrument in patients with psoriasis: the Psoriasis Quality 
of Life Questionnaire (PQLQ). Int J Dermatol, 45, pp. 234-238. 
IndexMundi (2017a): Age structure: Iran Available from: 
http://www.indexmundi.com/iran/age_structure.html [Last accessed: 22/08/2017]. 
IndexMundi (2017b): Iran GDP per capita (PPP) Available from: 
http://www.indexmundi.com/iran/gdp_per_capita_(ppp).html [Last accessed: 
22/08/2017]. 
Institute for Health Metrics and Evaluation. (2017c) Available from: 
http://www.healthdata.org/results/country-profiles [Last accessed: 22/08/2017]. 
Institute for Health Metrics and Evaluation: Hungary. (2017d) Available from: 
http://www.healthdata.org/hungary [Last accessed: 22/08/2017]. 
Institute for Health Metrics and Evaluation: Iran. (2017e) Available from: 
http://www.healthdata.org/iran; [Last accessed: 22/08/2017].  
IR Currency. (2017f) Available from: http://www.ircurrency.com/ [Last accessed: 
22/08/2017]. 
ISKANDAR, I. Y., ASHCROFT, D. M., WARREN, R. B., LUNT, M., MCELHONE, K., 
SMITH, C. H., et al. (2017): Comparative effectiveness of biologic therapies on 
improvements in quality of life in patients with psoriasis. Journal. 
Islamic Republic of Iran Health Sector Review-Volume II: Background Sections. (2008). 
WorldBank. 
IZADI, A., SIRIZI, M. J., ESMAEELPOUR, S. & BAROUNI, M. (2016): Evaluating Direct 
Costs of Gastric Cancer Treatment in Iran - Case Study in Kerman City in 2015. Asian 
Pac J Cancer Prev, 17, pp. 3007-3013. 
JAMSHIDI, H. R., FOROUTAN, N. & SALAMZADEH, J. (2014): "Budget impact 
analyses": a practical policy making tool for drug reimbursement decisions. Iran J 
Pharm Res, 13, pp. 1105-1109. 
JAVANBAKHT, M., ABOLHASANI, F., MASHAYEKHI, A., BARADARAN, H. R. & 
JAHANGIRI NOUDEH, Y. (2012): Health related quality of life in patients with type 
2 diabetes mellitus in Iran: a national survey. PLoS One, 7, p. e44526. 
JAVANBAKHT, M., KESHTKARAN, A., SHABANINEJAD, H., KARAMI, H., 
ZAKERINIA, M. & DELAVARI, S. (2015): Comparison of Blood Transfusion Plus 
Chelation Therapy and Bone Marrow Transplantation in Patients with beta-
Thalassemia: Application of SF-36, EQ-5D, and Visual Analogue Scale Measures. 
Int J Health Policy Manag, 4, pp. 733-740. 
JEFFERSON, T., DEMICHELI, V. & MUGFORD, M. Elementary Economic Evaluation in 
Health Care. (2000), BMJ Books. London. 
JO, C. (2014): Cost-of-illness studies: concepts, scopes, and methods. Clinical and Molecular 
Hepatology, 20, pp. 327-337. 
JOEL E, S. (2006): Cost-of-Illness Studies—A Primer. RTI-UNC Center of Excellence in 
Health Promotion Economics, pp. 1-39. 
KARACA, S., FIDAN, F., ERKAN, F., NURAL, S., PINARCI, T., GUNAY, E., et al. 
(2013): Might psoriasis be a risk factor for obstructive sleep apnea syndrome? Sleep 
Breath, 17, pp. 275-280. 
  154 
KARYANI, A., RASHIDIAN, A., SEFIDDASHTI, S. & SARI, A. (2016): Self-reported 
health-related quality of life (HRQOL) and factors affecting HRQOL among 
individuals with health insurance in Iran. Epidemiol Health. 38, p. e2016046. 
KAVOSI, Z., ZARE, F., JAFARI, A. & FATTAHI, M. R. (2014): Economic burden of 
hepatitis B virus infection in different stages of disease; a report from southern iran. 
Middle East J Dig Dis, 6, pp. 156-161. 
KEBRIAEEZADEH, A., KOOPAEI, N. N., ABDOLLAHIASL, A., NIKFAR, S. & 
MOHAMADI, N. (2013): Trend analysis of the pharmaceutical market in Iran; 1997-
2010; policy implications for developing countries. Daru, 21, pp. 52. 
KESHAVARZ, E., ROKNSHARI, S., SHIRALI MOHAMMADPOUR, R. & 
ROKNSHARI, M. (2013): Clinical Features and Severity of Psoriasis: A Comparison 
of Facial and Nonfacial Involvement in Iran. Arch Iran Med, 16, pp. 25 –28. 
KESHAVARZIAN, M. & MOFIDIAN, S. (2014): An Overview on Iran Health Care 
Financing System: Challenges and Solutions. Journal of Health Policy and 
Sustainable Health, 1, pp. 131-136. 
KHAMMARNIA, M., KESHTKARAN, A., KAVOSI, Z. & HAYATI, R. (2014): The 
Household Health Spending and Impoverishment: Findings from the Households 
Survey in Shiraz, Iran. Bangladesh Med Res Counc Bull, 40, pp. 58-62. 
KHANGAH, H., JANNATI, A., IMANI, A., SALIMLAR, S., DERAKHSHANI, N. & 
RAEF, B. (2017): Comparing the Health Care System of Iran with Various Countries. 
Journal, 6, p. e34459. 
KIMBALL, A. B., GUERIN, A., TSANEVA, M., YU, A. P., WU, E. Q., GUPTA, S. R., et 
al. (2011): Economic burden of comorbidities in patients with psoriasis is substantial. 
J Eur Acad Dermatol Venereol, 25, pp. 157-163. 
LAJEVARDI, V., HALLAJI, Z., DAKLAN, S., ABEDINI, R., GOODARZI, A. & 
ABDOLREZA, M. (2015): The efficacy of methotrexate plus pioglitazone vs. 
methotrexate alone in the management of patients with plaque-type psoriasis: a 
single-blinded randomized controlled trial. Int J Dermatol, 54, pp. 95-101. 
LANKARANI, K., ALAVIAN, S. & PEYMANI, P. (2013): Health in the Islamic Republic 
of Iran, challenges and progresses. Medical Journal of Islamic Republic of Iran, 27, 
pp. 42-49. 
LARG, A. & MOSS, J. R. (2011): Cost-of-illness studies: a guide to critical evaluation. 
Pharmacoeconomics, 29, pp. 653-671. 
LARSEN, C. G., ANDERSEN, P. H., LORENTZEN, H., ZACHARIAE, C., HULDT-
NYSTROM, T., DOTTERUD, L. K., et al. (2013): Clinical and economic impact of 
etanercept in real-life: a prospective, non-interventional study of etanercept in the 
treatment of patients with moderate to severe plaque psoriasis in private 
dermatologist settings (ESTHER). Eur J Dermatol, 23, pp. 774-781. 
LAYEGH, P., ARSHADI, H., SHAHRIARI, S., PEZESHKPOUR, F. & NAHIDI, Y. (2010): 
A Comparative Study on the Prevalence of Depression and Suicidal Ideation in 
Dermatology Patients Suffering from Psoriasis, Acne, Alopecia Areata and Vitiligo. 
Iranian Journal of Dermatology pp. 106-111. 
LE MOIGNE, M., SOMMET, A., LAPEYRE-MESTRE, M., BOURREL, R., MOLINIER, 
L., PAUL, C., et al. (2014): Healthcare cost impact of biological drugs compared with 
traditional systemic treatments in psoriasis: a cohort analysis in the French insurance 
database. J Eur Acad Dermatol Venereol, 28, pp. 1235-1244. 
  155 
LEBWOHL, M. (2005): A clinician's paradigm in the treatment of psoriasis. J Am Acad 
Dermatol, 53, pp. S59-69. 
LEMAN, J. A. & BURDEN, A. D. (2008): Treatment of severe psoriasis with infliximab. 
Therapeutics and Clinical Risk Management, 4, pp. 1165-1176. 
LEVY, A. R., DAVIE, A. M., BRAZIER, N. C., JIVRAJ, F., ALBRECHT, L. E., 
GRATTON, D., et al. (2012): Economic burden of moderate to severe plaque 
psoriasis in Canada. Int J Dermatol, 51, pp. 1432-1440. 
LEWIS, V. & FINLAY, A. Y. (2004): 10 years experience of the Dermatology Life Quality 
Index (DLQI). J Investig Dermatol Symp Proc, 9, pp. 169-180. 
LIPSCOMB, J., GOTAY, C. C. & SNYDER, C. Outcomes Assessment in Cancer: Measures, 
Methods and Applications. (2004), Cambridge University Press. Cambridge. 
LØNNBERG, A. S., ZACHARIAE, C. & SKOV, L. (2014): Targeting of interleukin-17 in 
the treatment of psoriasis. Clinical, Cosmetic and Investigational Dermatology, 7, pp. 
251-259. 
LOTFI, F., GORJI, H., MAHDAVI, G. & HADIAN, M. (2015): Asymmetric Information in 
Iranian’s Health Insurance Market: Testing of Adverse Selection and Moral Hazard. 
Global Journal of Health Science, 7, pp. 146-155. 
LOUDEN, B. A., PEARCE, D. J., LANG, W. & FELDMAN, S. R. (2004): A Simplified 
Psoriasis Area Severity Index (SPASI) for rating psoriasis severity in clinic patients. 
Dermatol Online J, 10, p. 7. 
LU, G., BRAZIER, J. E. & ADES, A. E. (2013): Mapping from disease-specific to generic 
health-related quality-of-life scales: a common factor model. Value Health, 16, pp. 
177-184. 
MAUSKOPF, J. A., SULLIVAN, S. D., ANNEMANS, L., CARO, J., MULLINS, C. D., 
NUIJTEN, M., et al. (2007): Principles of good practice for budget impact analysis: 
report of the ISPOR Task Force on good research practices--budget impact analysis. 
Value Health, 10, pp. 336-347. 
MCGREGOR, M. (2003): Cost–utility analysis: Use QALYs only with great caution. CMAJ: 
Canadian Medical Association Journal, 168, pp. 433-434. 
MEASE, P. J. & ARMSTRONG, A. W. (2014): Managing Patients with Psoriatic Disease: 
The Diagnosis and Pharmacologic Treatment of Psoriatic Arthritis in Patients with 
Psoriasis. Drugs, 74, pp. 423-441. 
MEDICINE, I. & TECHNOLOGY, C. H. C. Quality of Life and Technology Assessment. 
(1989), National Academies Press. Washington. 
Medilexicon. (2014a) Available from: http://www.medilexicon.com/ [Last accessed: 
23/04/2017]. 
MEEUWIS, K. A., DE HULLU, J. A., VAN DE NIEUWENHOF, H. P., EVERS, A. W., 
MASSUGER, L. F., VAN DE KERKHOF, P. C., et al. (2011): Quality of life and 
sexual health in patients with genital psoriasis. Br J Dermatol, 164, pp. 1247-1255. 
MEHRDAD, R. (2009): Health System in Iran. JMAJ, 52, pp. 69-73. 
MENTER, A. & GRIFFITHS, C. E. (2007): Current and future management of psoriasis. 
Lancet, 370, pp. 272-284. 
MENTER, A., KORMAN, N. J., ELMETS, C. A., FELDMAN, S. R., GELFAND, J. M., 
GORDON, K. B., et al. (2011): Guidelines of care for the management of psoriasis 
and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and 
psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am 
Acad Dermatol, 65, pp. 137-174. 
  156 
MERCAN, S., ALTUNAY, I. K., DEMIR, B., AKPINAR, A. & KAYAOGLU, S. (2008): 
Sexual dysfunctions in patients with neurodermatitis and psoriasis. J Sex Marital 
Ther, 34, pp. 160-168. 
MERHDAD, R. (2009): Health System in Iran. JMAJ, 52, pp. 69-73.  
Merriam-Webster Collegiate Dictionary. (2014b), Merriam-Webster Inc. USA 
MEYER, N., PAUL, C., FENERON, D., BARDOULAT, I., THIRIET, C., CAMARA, C., et 
al. (2010): Psoriasis: an epidemiological evaluation of disease burden in 590 patients. 
J Eur Acad Dermatol Venereol, 24, pp. 1075-1082. 
MICHALEK, I. M., LORING, B. & JOHN, S. M. (2017): A systematic review of worldwide 
epidemiology of psoriasis. Journal of the European Academy of Dermatology and 
Venereology, 31, pp. 205-212.  
Ministry of Health and Medical Education- Food and Drug administration of Iran. (2017g) 
Available from: http://www.fda.gov.ir/en/ [Last accessed: 23/04/2017]. 
MOBINIZADEH, M., DOAVEE, S., OLYAEEMANESH, A., AZADBAKHT, M., NEJATI, 
M. & ABOEE, P. (2014): Health Technology Assessment of CAD/CAM in Dentistry. Int J 
Travel Med Glob Health, 2, pp. 81-85. 
MOBINIZADEH, M., RAEISSI, P., NASIRIPOUR, A., OLYAEEMANESH, A. & TABIBI, 
S. (2016): A model for priority setting of health technology assessment: the 
experience of AHP-TOPSIS combination approach. Daru  
MOGHIMI-DEHKORDI, B., VAHEDI, M., KHOSHKROOD MANSOORI, B., 
KASAEIAN, A., SAFAEE, A., HABIBI, M., et al. (2011a): Economic burden of 
gastro-oesophageal reflux disease and dyspepsia: A community-based study. Arab J 
Gastroenterol, 12, pp. 86-89. 
MOGHIMI-DEHKORDI, B., VAHEDI, M., POURHOSEINGHOLI, M. A., 
KHOSHKROOD MANSOORI, B., SAFAEE, A., HABIBI, M., et al. (2011b): 
Economic burden attributable to functional bowel disorders in Iran: a cross-sectional 
population-based study. J Dig Dis, 12, pp. 384-392. 
MOHTASHAM, F., YAZDIZADEH, B., ZALI, Z., MAJDZADEH, R. & NEDJAT, S. 
(2016): Health technology assessment in Iran: Barriers and solutions. Med J Islam 
Repub Iran, 30, p. 321. 
MONTAZERI, A., GOSHTASEBI, A., VAHDANINIA, M. & GANDEK, B. (2005): The 
Short Form Health Survey (SF-36): Translation and validation study of the Iranian 
version. Quality of Life Research, 14, pp. 875-882. 
MORADI-LAKEH, M., SHAKERIAN, S. & ESTEGHAMATI, A. (2012): Immunization 
against Haemophilus Influenzae Type b in Iran; Cost-utility and Cost-benefit 
Analyses. Int J Prev Med, 3, pp. 332-340. 
MORADI-LAKEH, M. & VOSOOGH-MOGHADDAM, A. (2015): Health Sector 
Evolution Plan in Iran; Equity and Sustainability Concerns. Int J Health Policy 
Manag, 4, pp. 637-640. 
MORADI, M., RENCZ, F., BRODSZKY, V., MORADI, A., BALOGH, O. & GULACSI, 
L. (2015): Health status and quality of life in patients with psoriasis: an Iranian cross-
sectional survey. Arch Iran Med, 18, pp. 153-159. 
MORK, C., OZEK, M. & WAHL, A. K. (2004): [Psoriasis and psoriatic arthritis--is climate 
therapy a treatment or a leisure activity?]. Tidsskr Nor Laegeforen, 124, pp. 60-62. 
MROWIETZ, U., KRAGBALLE, K., REICH, K., SPULS, P., GRIFFITHS, C. E. M., NAST, 
A., et al. (2011): Definition of treatment goals for moderate to severe psoriasis: a 
European consensus. Archives of Dermatological Research, 303, pp. 1-10. 
  157 
MUMFORD, L. & WINNER, L. Technics and Civilization. (2010), University of Chicago 
Press. Chicago. 
MUSTONEN, A., MATTILA, K., LEINO, M., KOULU, L. & TUOMINEN, R. (2013): The 
Costs of Psoriasis Medications. Dermatology and Therapy, 3, pp. 169-177. 
MUSTONEN, A., MATTILA, K., LEINO, M., KOULU, L. & TUOMINEN, R. (2015): How 
much of the productivity losses among psoriasis patients are due to psoriasis. BMC 
Health Services Research, 15, p. 87. 
NAHVIJOU, A., DAROUDI, R., TAHMASEBI, M., HASHEMI, F., HEMAMI, M., SARI, 
A., et al. (2016): Cost-Effectiveness of Different Cervical Screening Strategies in 
Islamic Republic of Iran: A Middle-Income Country with a Low Incidence Rate of 
Cervical Cancer. PLoS One, 11, p. e0156705. 
NAJAFI, F., KARAMI-MATIN, B., REZAEI, S., RAJABI-GILAN, N. & SOOFI, M. 
(2016): Health system responsiveness after health sector evolution plan (HSEP): An 
inpatient survey in Kermanshah in 2015. Medical Journal of the Islamic Republic of 
Iran, 30, pp. 387-387. 
NAJARIAN, D. J. & GOTTLIEB, A. B. (2003): Connections between psoriasis and Crohn's 
disease. J Am Acad Dermatol, 48, pp. 805-821. 
NAS, K., CAPKIN, E., DAGLI, A. Z., CEVIK, R., KILIC, E., KILIC, G., et al. (2017): 
Gender specific differences in patients with psoriatic arthritis. Mod Rheumatol, 27, 
pp. 345-349. 
NASSERI, K., SADRIZADEH, B., MALEK-AFZALI, H., MOHAMMAD, K., CHAMSA, 
M., CHERAGHCHI-BASHI, M. T., et al. (1991): Primary health care and 
immunisation in Iran. Public Health, 105, pp. 229-238. 
NAST, A., ROSUMECK, S. & SEIDENSCHNUR, K. (2015): Biosimilars: a systematic 
review of published and ongoing clinical trials of antipsoriatics in chronic 
inflammatory diseases. J Dtsch Dermatol Ges, 13, pp. 294-300. 
NAVARINI, A. A., LAFFITTE, E., CONRAD, C., PIFFARETTI, P., BROCK, E., 
RUCKDAESCHEL, S., et al. (2010): Estimation of cost-of-illness in patients with 
psoriasis in Switzerland. Swiss Med Wkly, 140, pp. 85-91. 
NIKBAKHT, A. & KAFI, M. The history of traditional medicine and herbal plants in Iran 
2008. International Society for Horticultural Science (ISHS), Leuven, Belgium, pp. 
255-258. 
NOJOMI, M., MORADI-LAKEH, M., VELAYATI, A., NAGHIBZADEH-TAHAMI, A., 
DADGOSTAR, H., GHORABI, G., et al. (2016): Health technology assessment of 
non-invasive interventions for weight loss and body shape in Iran. Med J Islam Repub 
Iran, pp. 76-83. 
NOORBALA, M. T. & KAFAIE, P. (2010): Pattern of skin diseases in the Central Iran Yazd. 
Journal of Pakistan Association of Dermatologists 20, pp. 137-141. 
NORLIN, J. M., STEEN CARLSSON, K., PERSSON, U. & SCHMITT-EGENOLF, M. 
(2012): Analysis of three outcome measures in moderate to severe psoriasis: a 
registry-based study of 2450 patients. Br J Dermatol, 166, pp. 797-802. 
NOURAEI MOTLAGH, S., ABOLGHASEM GORJI, H., MAHDAVI, G. & GHADERI, H. 
(2015): Main Determinants of Supplementary Health Insurance Demand: (Case of 
Iran). Glob J Health Sci, 7, pp. 285-294. 
NOVIN, I. (2016): Iranian Pharmaceuticals Industry Analysis Report Journal. 
Nursing Organization Of Islamic Republic Iran. (2017h) Available from: 
http://ino.ir/tabid/4076/ID/42746/ [Last accessed: 22/08/2017]. 
  158 
OLYAEEMANESH, A., DOAEE, S., MOBINIZADEH, M., NEDJATI, M., ABOEE, P. & 
EMAMI-RAZAVI, S. (2014): Health technology assessment in Iran: challenges and 
views. Med J Islam Repub Iran 
OLYAEEMANESH, A. & MAJDZADEH, R. (2016): Health technology assessment: A 
necessity in post-sanctions Iran while implementing the health transformation plan. 
Med J Islam Repub Iran 
ORLEWSKA, E. & GULACSI, L. (2009): Budget-impact analyses: a critical review of 
published studies. Pharmacoeconomics, 27, pp. 807-827. 
Oxford Dictionary of English. (2010): NY, USA, Oxford University Press. 
PANDIT, N. Sociology & Health for Physiotherapists. (2009), B.I. Publications Pvt. Limited. 
Delhi. 
PARDASANI, A. G., FELDMAN, S. R. & CLARK, A. R. (2000): Treatment of psoriasis: 
an algorithm-based approach for primary care physicians. Am Fam Physician, 61, pp. 
725-733, 736. 
PATEL, R. V., SHELLING, M. L., PRODANOVICH, S., FEDERMAN, D. G. & KIRSNER, 
R. S. (2011): Psoriasis and vascular disease-risk factors and outcomes: a systematic 
review of the literature. J Gen Intern Med, 26, pp. 1036-1049. 
PATHIRANA, D., ORMEROD, A., SAIAG.P, SMITH, C., SPULS.PI, NAST, A., et al. 
(2009): European S3-Guidelines on the systemic treatment of psoriasis vulgaris. 
JEADV, 23(Suppl 2), pp. 1-70. 
PAUL, C., GOURRAUD, P. A., BRONSARD, V., PREY, S., PUZENAT, E., ARACTINGI, 
S., et al. (2010): Evidence-based recommendations to assess psoriasis severity: 
systematic literature review and expert opinion of a panel of dermatologists. J Eur 
Acad Dermatol Venereol, 24(Suppl 2), pp. 2-9. 
PEARCE, D. J., SINGH, S., BALKRISHNAN, R., KULKARNI, A., FLEISCHER, A. B. & 
FELDMAN, S. R. (2006): The negative impact of psoriasis on the workplace. J 
Dermatolog Treat, 17, pp. 24-28. 
POLANYI, K. The Great Transformation: The Political and Economic Origins of Our Time. 
(1944), Beacon Press. Boston. 
PopulationPyramid.net: Hungary. (2016a) Available from: 
https://www.populationpyramid.net/iran-islamic-republic-of/2016/ [Last accessed 
22/08/2017]. 
PopulationPyramid.net: Iran (Islamic Republic of). (2016b) Available from: 
https://www.populationpyramid.net/iran-islamic-republic-of/2016/ [Last accessed 
22/08/2017]. 
POURAHMAD, J. (2008): History of Medical Sciences in Iran. Iranian Journal of 
Pharmaceutical Research, 7, pp. 93-99. 
POWER, S., GALLAGHER, J. & MEANEY, S. (2009): Quality of life in health care workers 
with latex allergy. Occupational Medicine, 60, pp. 62-65. 
PUNJABI, N. M. (2008): Patient Versus Proxy Ratings of Quality of Life. In: VERSTER, J. 
C., PANDI-PERUMAL, S. R. & STREINER, D. L. (eds.) Sleep and Quality of Life 
in Clinical Medicine. Humana Press. Totowa, NJ. 
PUZENAT, E., BRONSARD, V., PREY, S., GOURRAUD, P. A., ARACTINGI, S., 
BAGOT, M., et al. (2010): What are the best outcome measures for assessing plaque 
psoriasis severity? A systematic review of the literature. J Eur Acad Dermatol 
Venereol, 24(Suppl 2), pp. 10-16. 
  159 
RADTKE, M. A. & AUGUSTIN, M. (2014): Biosimilars in psoriasis: what can we expect? 
J Dtsch Dermatol Ges, 12, pp. 306-312. 
RAHO, G., KOLEVA, D. M., GARATTINI, L. & NALDI, L. (2012): The burden of 
moderate to severe psoriasis: an overview. Pharmacoeconomics, 30, pp. 1005-1013. 
RANDHEALTH. (2017): 36-Item Short Form Survey (SF-36). Available from: 
https://www.rand.org/health/surveys_tools/mos/36-item-short-form.html [Last 
accessed: 22/08/2017]. 
RATSON, G. A. The Meaning of Health: The Experience of a Lifetime. (2003), Trafford 
Publishing. Victoria, Canada. 
REICH, K. (2009): Approach to managing patients with nail psoriasis. J Eur Acad Dermatol 
Venereol, 23(Suppl 1), pp. 15-21. 
REILLY, M. C., ZBROZEK, A. S. & DUKES, E. M. (1993): The validity and reproducibility 
of a work productivity and activity impairment instrument. Pharmacoeconomics, 4, 
pp. 353-365. 
RENCZ, F., KEMENY, L., GAJDACSI, J. Z., OWCZAREK, W., ARENBERGER, P., 
TIPLICA, G. S., et al. (2015): Use of biologics for psoriasis in Central and Eastern 
European countries. J Eur Acad Dermatol Venereol, 29, pp. 2222-2230. 
BMI REPORT (2016a): Iran Pharmaceuticals & Healthcare Report Q3  
IRAN PHARMACEUTICAL AND HEALTHCARE REPORT (2016b): Iran 
Pharmaceuticals & Healthcare Report Q4. Journal. 
BMI RESEARCH,. (2016): Iran Pharmaceuticals & Healthcare Report - Includes 10-Year 
Forcasts To 2025.  
RICE, D. P. (1994): Cost-of-illness studies: fact or fiction? Lancet, 344, pp. 1519-1520. 
RYAN, S. (2008): Psoriasis: characteristics, psychosocial effects and treatment options. Br J 
Nurs, 17, pp. 284-290. 
SAAD, A. A., HYRICH, K. L. & ASHCROFT, D. M. (2011): Drug persistence, effectiveness 
and safety assessment of anti-TNF therapies in psoriatic arthritis. Expert Opin Drug 
Saf, 10, pp. 219-226. 
SADEGHI, B., ABOLHASSANI, H., NASERI, A., REZAEI, N. & AGHAMOHAMMADI, 
A. (2015): Economic burden of common variable immunodeficiency: annual cost of 
disease. Expert Rev Clin Immunol, 11, pp. 681-688. 
SAFDARI, R., SAEEDI, M., VALINEJADI, A., BOURAGHI, H. & SHAHNAVAZI, H. 
(2017): Technology Acceptance Model in health care centers of Iran. IJCSNS 17, p. 
42. 
SAFFARI, M., KARIMI, T., KOENIG, H. G. & AL-ZABEN, F. (2015): Psychometric 
evaluation of the Persian version of the Type 2 Diabetes and Health Promotion Scale 
(T2DHPS): a diabetes-specific measure of lifestyle. Scand J Caring Sci, 29, pp. 603-
612. 
SAFFARI, M., PAKPOUR, A. H., NADERI, M. K., KOENIG, H. G., BALDACCHINO, D. 
R. & PIPER, C. N. (2013): Spiritual coping, religiosity and quality of life: a study on 
Muslim patients undergoing haemodialysis. Nephrology (Carlton), 18, pp. 269-275. 
SAHA, S. & GERDTHAM, U. G. (2013): Cost of illness studies on reproductive, maternal, 
newborn, and child health: a systematic literature review. Health Economics Review, 
3, pp. 24-24. 
SCHÖFFSKI, O., AUGUSTIN, M., PRINZ, J., RAUNER, K., SCHUBERT, E., SOHN, S., 
et al. (2007): Costs and quality of life in patients with moderate to severe plaque-type 
  160 
psoriasis in Germany: A multi-center study. JDDG: Journal der Deutschen 
Dermatologischen Gesellschaft, 5, pp. 209-218. 
SCHRAG, A., SELAI, C., JAHANSHAHI, M. & QUINN, N. P. (2000): The EQ-5D--a 
generic quality of life measure-is a useful instrument to measure quality of life in 
patients with Parkinson's disease. J Neurol Neurosurg Psychiatry, 69, pp. 67-73. 
SCHUESSLER, K. F. & FISHER, G. A. (1985): Quality of Life Research and Sociology. 
Annual Review of Sociology, 11, pp. 129-149. 
SEGEL, J. (2006): Cost of illness studies—A primer: RTI International. RTI-UNC Center of 
Excellence in Health Promotion Economics, 1, pp. 1-39. 
SEYEDIFAR, M., DORKOOSH, F. A., HAMIDIEH, A. A., NADERI, M., KARAMI, H., 
KARIMI, M., et al. (2016): Health-Related Quality of Life and Health Utility Values 
in Beta Thalassemia Major Patients Receiving Different Types of Iron Chelators in 
Iran. Int J Hematol Oncol Stem Cell Res, 10, pp. 224-231. 
SHAHRAZ, S., FOROUZANFAR, M. H., SEPANLOU, S. G., DICKER, D., NAGHAVI, 
P., POURMALEK, F., et al. (2014): Population health and burden of disease profile 
of Iran among 20 countries in the region: from Afghanistan to Qatar and Lebanon. 
Arch Iran Med, 17, pp. 336-342. 
SHAW, J. W., JOHNSON, J. A. & COONS, S. J. (2005): US valuation of the EQ-5D health 
states: development and testing of the D1 valuation model. Med Care, 43, pp. 203-
220. 
SHERMAN, E. J., PFISTER, D. G., RUCHLIN, H. S., RUBIN, D. M., RADZYNER, M. H., 
KELLEHER, G. H., et al. (2001): The collection of indirect and nonmedical direct 
costs (COIN) form. Cancer, 91, pp. 841-853. 
SHIRVANI, A., OLYAEEMANESH, A., RABBANIKHAH, F. & NEJATI, M. (2014): 
Establishment of Clinical Policy Making in Iran. Patient Saf Qual Improv., 2, pp. 101-
105. 
SHIU, A. T. Y., CHOI, K. C., LEE, D. T. F., YU, D. S. F. & MAN NG, W. (2014): 
Application of a health-related quality of life conceptual model in community-
dwelling older Chinese people with diabetes to understand the relationships among 
clinical and psychological outcomes. Journal of Diabetes Investigation, 5, pp. 677-
686. 
SIVAMANI, R. K., GOODARZI, H., GARCIA, M. S., RAYCHAUDHURI, S. P., WEHRLI, 
L. N., ONO, Y., et al. (2013): Biologic therapies in the treatment of psoriasis: a 
comprehensive evidence-based basic science and clinical review and a practical guide 
to tuberculosis monitoring. Clin Rev Allergy Immunol, 44, pp. 121-140. 
SMITH, A. An Inquiry Into the Nature and Causes of the Wealth of Nations. (1776), W. 
Strahan and T. Cadell. London. 
SMITH, K. C. (2000): Systemic therapy of psoriasis using methotrexate. Skin Therapy Lett, 
6, pp. 1-5. 
SMITH, O. & NGUYEN, S. (2013): Getting better: improving health system outcomes in 
Europe and Central Asia. World Bank Publications. 
Statistical Center for Iran. (2017i) Available from: https://www.amar.org.ir/english/ [Last 
accessed: 21/08/2017]. 
STEINKE, S. I. B., PEITSCH, W. K., LUDWIG, A. & GOEBELER, M. (2013): Cost-of-
Illness in Psoriasis: Comparing Inpatient and Outpatient Therapy. PLoS ONE, 8, p. 
e78152. 
  161 
SUKAROVSKA, B. G., LIPOZENCIC, J. & VRZOGIC, P. (2007): Topical corticosteroids 
and corticosteroid sparing therapy in psoriasis management. Acta Med Croatica, 61, 
pp. 375-381. 
SULLIVAN, G. M. & ARTINO, A. R. (2013): Analyzing and Interpreting Data From Likert-
Type Scales. J Grad Med Educ, 5, pp. 541-542. 
TAKESHITA, J., GREWAL, S., LANGAN, S. M., MEHTA, N. N., OGDIE, A., VAN 
VOORHEES, A. S., et al. (2017a): Psoriasis and comorbid diseases: Epidemiology. 
J Am Acad Dermatol, 76, pp. 377-390. 
TAKESHITA, J., GREWAL, S., LANGAN, S. M., MEHTA, N. N., OGDIE, A., VAN 
VOORHEES, A. S., et al. (2017b): Psoriasis and comorbid diseases: Implications for 
management. J Am Acad Dermatol, 76, pp. 393-403. 
TALLI, S., ETCHETO, A., FAUTREL, B., BALANESCU, A., BRAUN, J., CANETE, J. D., 
et al. (2016): Patient global assessment in psoriatic arthritis - what does it mean? An 
analysis of 223 patients from the Psoriatic arthritis impact of disease (PsAID) study. 
Joint Bone Spine, 83, pp. 335-340. 
TANG, M. M., CHANG, C. C., CHAN, L. C. & HENG, A. (2013): Quality of life and cost 
of illness in patients with psoriasis in Malaysia: a multicenter study. Int J Dermatol, 
52, pp. 314-322. 
TARRICONE, R. (2006): Cost-of-illness analysis. Health Policy, 77, pp. 51-63. 
TEZEL, N., YILMAZ TASDELEN, O., BODUR, H., GUL, U., KULCU CAKMAK, S., 
OGUZ, I. D., et al. (2015): Is the health-related quality of life and functional status 
of patients with psoriatic arthritis worse than that of patients with psoriasis alone? Int 
J Rheum Dis, 18, pp. 63-69. 
The World Health Organization Quality of Life assessment (WHOQOL): position paper from 
the World Health Organization. (1995). 
THE WORLDBANK DataBank, Iran, Islamic Republic. (2015) Available from: 
http://data.worldbank.org/country/iran-islamic-rep?view=chart [Last accessed: 
23/04/2017]. 
THE WORLDBANK Mortality rate, infant (per 1,000 live births). (2017) Available from: 
http://data.worldbank.org/indicator/SP.DYN.IMRT.IN [Last accessed: 22/08/2017]. 
TILL, J. E., OSOBA, D., PATER, J. L. & YOUNG, J. R. (1994): Research on health-related 
quality of life: dissemination into practical applications. Qual Life Res, 3, pp. 279-
283. 
TORRANCE, G. W. & FEENY, D. (1989): Utilities and quality-adjusted life years. Int J 
Technol Assess Health Care, 5, pp. 559-575. 
Iran GDP per capita. (2017) Available from: https://tradingeconomics.com/iran/gdp-per-
capita [Last accessed: 21/08/2017]. 
TRISTANI-FIROUZI, P. & KRUEGER, G. G. (1998): Efficacy and safety of treatment 
modalities for psoriasis. Cutis, 61, pp. 11-21. 
TURAN, Y., DURUOZ, M. T. & CERRAHOGLU, L. (2009): Relationship between 
enthesitis, clinical parameters and quality of life in spondyloarthritis. Joint Bone 
Spine, 76, pp. 642-647. 
TUREL ERMERTCAN, A., TEMELTAS, G., DEVECI, A., DINC, G., GULER, H. B. & 
OZTURKCAN, S. (2006): Sexual dysfunction in patients with psoriasis. J Dermatol, 
33, pp. 772-778. 
  162 
ULLBRO, C., CROSSNER, C. G., NEDERFORS, T., ALFADLEY, A. & THESTRUP-
PEDERSEN, K. (2003): Dermatologic and oral findings in a cohort of 47 patients 
with Papillon-Lefevre syndrome. J Am Acad Dermatol, 48, pp. 345-351. 
VAN VOORHEES, A. S. & FRIED, R. (2009): Depression and quality of life in psoriasis. 
Postgrad Med, 121, pp. 154-161. 
VELAYATI, A. (1988): An introduction to the history of medicine in Islam and Iran. Med J 
Islam Repub Iran, 2, pp. 131-136. 
WAGSTAFF, A. & EOZENOU, P.-V. (2016): CATA meets IMPOV: a unified approach to 
measuring financial protection in health. World Bank Policy Research Working 
Paper. 
WAKKEE, M., THIO, H. B., SPULS, P. I., DE JONG, E. M. & NIJSTEN, T. (2008): 
Evaluation of the reimbursement criteria for biological therapies for psoriasis in the 
Netherlands. Br J Dermatol, 158, pp. 1159-1161. 
WARWICK-BOOTH, L., CROSS, R. & LOWCOCK, D. Contemporary Health Studies: An 
Introduction. (2012), Polity. Cambridge.  
WEINSTEIN, M. C., SIEGEL, J. E., GOLD, M. R., KAMLET, M. S. & RUSSELL, L. B. 
(1996): Recommendations of the panel on cost-effectiveness in health and medicine. 
JAMA, 276, pp. 1253-1258. 
WHITEHEAD, S. J. & SHEHZAD, A. (2010): Health outcomes in economic evaluation: the 
QALY and utilities. British Medical Bulletin, 96, pp. 5-21. 
WHO. The Ottawa Charter for Health Promotion. First International Conference on Health 
Promotion. (1986): Ottawa. 
WHO. Report on the First Inter-Country Meeting on HealthTechnology Assessment (HTA): 
A tool for evidence informed decision making in health. (2013). 
WHO. Iran (Islamic Republic of). (2017a) Available from: 
http://www.who.int/countries/irn/en/. 
WHO. Islamic Republic of Iran - Health care financing. (2017b) Available from: 
http://www.emro.who.int/irn/programmes/healthfinancinguniversality.html. 
WIEBE, S., GUYATT, G., WEAVER, B., MATIJEVIC, S. & SIDWELL, C. (2003): 
Comparative responsiveness of generic and specific quality-of-life instruments. J Clin 
Epidemiol, 56, pp. 52-60. 
WILSON, I. B. & CLEARY, P. D. (1995): Linking clinical variables with health-related 
quality of life. A conceptual model of patient outcomes. Jama, 273, pp. 59-65. 
WU, E. Q., MULANI, P., FARRELL, M. H. & SLEEP, D. (2007): Mapping FACT-P and 
EORTC QLQ-C30 to Patient Health Status Measured by EQ-5D in Metastatic 
Hormone-Refractory Prostate Cancer Patients. Value in Health, 10, pp. 408-414. 
YAMAUCHI, K., AKI, H., TOMOTAKE, M., IGA, J., NUMATA, S., MOTOKI, I., et al. 
(2008): Predictors of subjective and objective quality of life in outpatients with 
schizophrenia. Psychiatry Clin Neurosci, 62, pp. 404-411. 
YANG, Y., BRAZIER, J. & LONGWORTH, L. (2015): EQ-5D in skin conditions: an 
assessment of validity and responsiveness. Eur J Health Econ, 16, pp. 927-939. 
YAZDANI, S. & JADIDFARD, M. (2017): Developing a decision support system to link 
health technology assessment (HTA) reports to the health system policies in Iran. 
Health Policy Plan, 32, pp. 504-515. 
YAZDIZADEH, B., SHAHMORADI, S., MAJDZADEH, R., DOAEE, S., BAZYAR, M., 
SOURESRAFIL, A., et al. (2016): Stakeholder involvement in health technology 
  163 
assessment at national level: a study from Iran. Int J Technol Assess Health Care, 32, 
pp. 181-189. 
YOUSEFI, M., NAJAFI, S., GHAFFARI, S., MAHBOUB-AHARI, A. & GHADERI, H. 
(2016): Comparison of SF-6D and EQ-5D Scores in Patients With Breast Cancer. 
Iran Red Crescent Med J, 18, p. e23556. 
YU, A. P., TANG, J., XIE, J., WU, E. Q., GUPTA, S. R., BAO, Y., et al. (2009): Economic 
burden of psoriasis compared to the general population and stratified by disease 
severity. Curr Med Res Opin, 25, p. 2429-2438. 
YUSEFZADEH, H., REZAPOUR, A., LOTFI, F., EBADIFARD AZAR, F., NABILO, B., 
ABOLGHASEM GORJI, H., et al. (2015): A Study of Comparative Advantage and 
Intra-Industry Trade in the Pharmaceutical Industry of Iran. Glob J Health Sci, 7, pp. 
295-307. 
ZANDI, S., SHAMSI MEYMANDI, S., HASHEMINASAB GORJI, S. & SABOURI 
SHAHREBABAK, F. (2011): Evaluation of quality of life in patients with psoriasis. 
Dermatology and Cosmetic, 2, pp. 166-173. 
ZANOLLI, M. (2003): Phototherapy treatment of psoriasis today. J Am Acad Dermatol, 49, 
pp. S78-86. 
ZARE, F., FATTAHI, M. R., SEPEHRIMANESH, M. & SAFARPOUR, A. R. (2016): 
Economic Burden of Hepatitis C Virus Infection in Different Stages of Disease: A 
Report From Southern Iran. Hepat Mon, 16, p. e32654. 
ZARE, H., TRUJILLO, A. J., DRIESSEN, J., GHASEMI, M. & GALLEGO, G. (2014): 
Health inequalities and development plans in Iran; an analysis of the past three 
decades (1984-2010). Int J Equity Health, 13, p. 42. 
ZARGARAN, M., NIKFAR, S. & CHERAGHALI, A. M. (2016): Evaluation of 
prescriptions of medicines not included in Iran medicine list: A cross-sectional study. 
J Res Pharm Pract, 5, pp. 234-237. 
ZENG, J., LUO, S., HUANG, Y. & LU, Q. (2017): Critical role of environmental factors in 
the pathogenesis of psoriasis. J Dermatol March 2017 [Ebub ahead of print] DOI: 
10.1111/1346-8138.13806 
ZGHAL, A., ZEGLAOUI, F., KALLEL, L., KARMOUS, R., BEN AMMAR, H., 
LABBANE, R., et al. (2003): [Quality of life in dermatology: Tunisian version of the 
Skindex-29]. Tunis Med, 81, pp. 34-37. 
ZUG, K. A., LITTENBERG, B., BAUGHMAN, R. D., KNEELAND, T., NEASE, R. F., 
SUMNER, W., et al. (1995): Assessing the preferences of patients with psoriasis. A 
quantitative, utility approach. Arch Dermatol, 131, pp. 561-568. 
 
 
  164 
10  APPENDICES 
 
 
 Appendix 1- Questionnaire  
In your opinion what factors contribute the most to the health of a person in general? 
Degree of Importance in respect of health in general: 
0: Most Irrelevant, 1: Irrelevant, 2: Not at all Relevant, 3: Neutral, 4: Less Relevant, 5: 
Relevant, 6: Most Relevant 
Please do not answer if you do not understand the term.  
 
 
Aspects 
 
Degree of Importance  
0 1 2 3 4 5 6 
1 Self-reproduction         
2 Reproduction of society         
3 Sociability          
4 Well-balanced        
5 Machine-like        
6 Flow        
7 Constructive Programs of Personality        
8 Normal Genes        
9 Identity or Rooted in one’s Culture        
10 Creativity         
11 Longevity        
12 Beauty        
13 Attractiveness        
14 Fitness        
15 Workability        
16 Ability to Relax        
17 Sport        
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18 Goals, Harmony        
19 Religiousness and Belief        
20 Optimism        
21 Realism        
22 Maturity        
23 Playfulness        
24 Discipline        
25 Lack of Illness        
26 Engagement        
27 Inner Freedom        
28 Productivity        
29 Innovativeness        
30 Positive Emotional Feeling        
31 Constructive Hobby        
32       Morality        
33 Love         
34 Responsibility        
 
Please write the names of any factor(s), which you think is/are important in the overall 
well-being of a person. 
……………………………………………………………………………………………….   
………………………………………………………………………………………………
…………………………………. 
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 Appendix 2 – Dermatology life quality index 
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 Appendix 3 – EQ-5D-3L 
 
  168 
 
 
                                                 
